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ABSTRACT 
Fumonisins, mycotoxins produced by the fungus, Fusarium moniliforme, which grows on 
maize, are a major worldwide agricultural problem. Consumption of contaminated maize 
feeds causes a wide variety of toxic effects in animals depending on the species of animal. In 
humans, high concentrations of fumonisins have been shown to correlate with increased 
incidence of oesophageal cancer (OC). Most analyses for fumonisins are done using high 
performance liquid chromatography (HPLC) which requires time-consuming extraction and 
clean-up prior to preparation of a fluorescent derivative. Enz~~~-link~d immunosorbent 
assays (ELISA), which are sensitive and specific, are a viable alternative but commercially 
available antibodies and kits are extremely expensive. 
Polyclonal antibodies against fumonisin B, (FB,) were raised in chickens and rabbits; all 
animals produced antibodies from week 2 onwards, the highest titre was at week 8 from one 
of the chickens. Cross-reactivities with FB, analogues were checked. A sensitive, quantitative 
competitive indirect ELISA (CI-ELISA) was developed and optimised; range 0.2 to 20 ng/ml 
(in buffer), detection limit 0.2 nglml (in buffer), intra-assay coefficient of variation (CV) was 
5.33 % and inter-assay 7.04%. 
This method was adapted to analyse human plasma and urine samples. After removal of 
proteins by boiling, the range of recoveries of FBI were 94.7% toI12.4% at 4 ng/ml; and 
94.6% to 108.7% at 8 ng/ml. Blood and urine samples from patients with OC (40 plasma, 17 
urine), controls (21 plasma, 12 urine) and patients with other forms of cancer (20 plasma, 10 
urine) were collected from hospitals in the Durban Metropolitan area and analysed for 
fumonisins. Detectable levels (>0.4 nglml) were found in 86.9% of plasma samples and 
94.9% of urine samples. Statistical evaluation showed a highly significant difference between 
plasma results for OC and controls (p<0.000 1) but no significant difference between the urine 
results. Comparison of other forms of cancer and controls showed no significant differences 
for either the plasma or the urine samples. However, there was a highly significant difference 
between the OC and other forms of cancer results for both plasma (p<0.005) and urine 
(p<0.05) samples. Some samples (9 plasma, 8 urine) were checked by HPLC. For plasma 
samples there was correlation between the ELISA and HPLC methods (r = 0.656, p<0.005) 
but not for urine samples. 
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1.1 Fumonisin Mycotoxicoses 
Mycotoxins are secondary metabolites produced by filamentous fungi which are harmful to 
animals and humans. Normally, the production of my cot ox ins is restricted to specific species 
(Dutton, 1996) and may occur in the field but more commonly during poor storage of 
commodities (Sydenham et al., 1990B). The ingestion of mycotoxins, usually through food 
and feed, causes mycotoxicoses which manifest with a wide variety of disease symptoms 
(Nelson et al., 1993). Fumonisins are mycotoxins produced by the fungus, Fusarium 
moniliforme Sheldon [recently renamed Fusarium verticillioides (Kriek et at., 1981; Marin 
et at., 1999; Blackwell et al., 1999)] which is a common contaminant of maize and to a 
lesser extent other cereals such as wheat and barley. 
[In overseas publications, the term com is used for maize (Zea mays)]. 
Fumonisins are a major worldwide agricultural problem as the consumption of contaminated 
feeds can cause a wide variety of signs in animals depending on the species of animal, 
concentration of mycotoxin present and the duration of exposure to the contaminated feed. 
Fumonsins have been associated with various syndromes and mycotoxicoses including equine 
leukoencephalomalacia (ELEM) (Kellerman et aI., 1990; Marasas et aI., 1988A); porcine 
pulmonary oedema (PPE) (Haschek et aI., 1992; Riley et al., 1993) and hepatocarcinoma and 
nephrotoxicity in rats (Gelderblom et al., 1991; Voss etal., 1993, 1995A). In humans, high 
concentrations of fumonisins have been shown to correlate with increased incidence of 
oesophageal cancer (OC) in the Transkei (Marasas et aI., 1988B; Sydenham et al., 1990A, 
1990B) and China (Chu & Li, 1994; Yoshizawa et al., 1994). 
1.2 Chemistry 
Chemically the fumonisins are a group of related, polar molecules based on a long 
hydroxylated hydrocarbon chain (pentahydroxyicosane) with attached methyl, amino and 
carboxyl groups (propane-l ,2,3-tricarboxylic acid moieties esterified to two hydroxyl 
groups). The B series have a free amino group; the A series are N-acetyl derivatives. 
1 
The configuration of the fumonisins is a cage-like structure suggesting they might act as 
chelators and may interact with divalent cations (Sauviat et aI. , 1991; Beier et aI. , 1995; 
Beier & Stanker, 1997). 
The major fumonisin is fumonisin B, (FBI) but fumonisin B2 (FB2), fumonisin B3 (FB3) and 
fumonisin B4 (FB4) are also produced by F. moniliforme (Bezuidenhout et aI. , 1988; 
Gelderblom et al., 1988, 1992B). Structurally the fumonisins are similar to the long chain 
bases sphinganine (Sa) and sphingosine (So), components of sphingolipids which play 
important roles in cell regulation including the control of normal growth (DNA synthesis) 
and differentiation; as well as roles in the structure and functions of cell membranes (Merrill 
et al., 1995B, 1996). 
1.3 Mechanisms 
Using primary rat hepatocytes, it was found that FBI is a potent competitive inhibitor of the 
enzyme, ceramide synthase (sphingosine N-acyltransferase) required for formation of 
complex sphingolipids. It is believed that at a molecular level many of the effects of FBI 
toxicity are due to interference with sphingolipid metabolism and an increase in the amount 
of free sphinganine (Sa) (Wang et al., 1991). Animals consuming feed contaminated with 
FB1 showed an increase in free Sa and the ratio of So to Sa in sera and tissues (liver, lung, 
kidney). These changes provide an early marker of exposure to fumonisins since they were 
seen before detectable lesions or elevations of enzymes (Wang et al., 1992; Riley et al., 
1993). 
Experiments done by dosing animals with unlabelled or radiolabelled FB I and FB2, showed 
that they are poorly absorbed from the gut, and are rapidly eliminated mainly via the faeces, 
bile and urine (Shephard et al., 1992A, 1992C, 1994A, 1994B, 1994C). 
1.4 Analysis 
At present most analyses for fumonisins are done using high performance liquid 
chromatography (HPLC) which requires time consuming extraction and clean-up prior to 
formatiod of a fluorescent derivative (Shephard et al., 1990). AlthouJh simpler, thin layer 
chromatography (TLC) also requires prior extraction, clean-up and derivatisation and is not 
as sensitive (Rottinghaus et al., 1992). 
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Shephard et ai. (1992B, 1994A, 1994B, 1995A, 1995B) succeeded in developing HPLC 
methods to measure FBI and FB2 in urine, plasma, bile and faeces; Shetty & Bhat (1998) 
optimised a HPLC method to analyse urine and Chelule et al. (2000) analysed human faecal 
samples for FBI. Other investigations of the absorption and excretion offumonisins in 
animals used the HPLC methods (Shephard et ai., 1992A; Smith & Thakur, 1996) or 
radio labelled FB I and FB2 (Norred et at., 1993; Prelusky et ai., 1994; Shephard et ai., 
1992C, 1994C; Vudathala et ai., 1994). 
Immunoassays, which are sensitive and specific, are a viable alternative to chromatography 
and recent groups have developed assay methods using antibodies to FB1 and an enzyme-
linked immunosorbent assay (ELISA) format. Although antibodies and kits (Veratox ® 
Fumonisin Kit and Fumonisin Agri-Screen) are now commercially available, they are not 
widely used because of high cost (Azcona-Olivera et al., 1992A, 1992B; Usleber et ai., 
1994; Abouzied et ai., 1996). Furthermore, methods that have been developed are primarily 
used for the measurement of fumonisins in maize and other agricultural products (Azcona-
Olivera et ai., 1992A, 1992B; Pestka et ai., 1994; Shelby et ai., 1994; Usleber et ai., 1994; 
Ware et ai., 1994; Schneider et ai., 1995; Abouzied et ai., 1996; Sydenham et al., 1996A, 
1996B; Thompson & Maragos, 1996; Yeung et ai., 1996; Yu & Chu, 1996; Maragos, 1997) 
or milk (Maragos & Richard, 1994; Hammer et al., 1996) or beer (Scott et al., 1997). 
There are no recorded ELISA methods suitable for analysis of physiological fluids for 
fumonisins. 
1.5 Health Risks 
Maize is a staple food for many people in South and Southern Africa. Contamination of 
maize with F. moniliforme and fumonisins is common. By eating this food humans expose 
themselves to the risk of acquiring fumonisin-related mycotoxicoses. The health risk 
associated with exposure to fumonisins is unknown. Safe concentrations of fumonisins for 
human or animal feed have not been determined (Maras as et ai., 1988B; Sydenham et ai., 
1990B; Rheeder et ai., 1992; Thiel et ai., 1992; Badria et ai., 1996; Doko et al., 1996; Rava 
et at., 1996). 
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"Maximum allowable levels of FB1, FB2, and FB3 in maize exported from and imported into 
Africa and in maize-based human foods and animal feeds should be specified. Important 
risk assessment factors in determining these tolerance levels include the following: hazard 
assessment by determining toxic and carcinogenic levels of fumonisins in animal 
experiments and exposure assessment by determining naturally occurring levels of 
fumonisins in human foods and animal feeds. A great deal of research remains to be done 
however, on the risk assessment of the fumonisins for human health in Africa." (Maras as et 
al., 1993). 
1.6 Objectives 
The aims of this study were: 
1. To raise polyclonal antibodies against FBI in chickep.s and rabbits and check these 
for titre and cross-reactivity. 
2. To use the antibodies to develop and optimise a quantitative, sensitive and 
economical ELISA to analyse human blood and urine samples. 
3. To analyse samples from controls, patients with OC and patients with other types of 





Fumonisins are produced by a limited variety of fungi, members of the genus Fusarium in 
the section Liseola; predominantly F moniliforme Sheldon, now called F verticilliodes, and 
F proiiferatum (Kriek et ai., 1981, Thiel et ai., 1991A; Ross et ai., 1990; Marin et ai., 1999; 
Blackwell et ai., 1999). Only the A and D mating populations of F moniliforme that share 
the teleomorph (sexual stage) Gibberella moniliformis, produce fumonisins; and different 
mating populations vary considerably in the amount of fumonisin produced (Leslie, 1996). 
These fungi also produce moniliformin and fusarins (Nelson et ai., 1993). 
Fusarium moniliforme is an endophyte found distributed over the pericarp of maize kernels 
and within the kernel with hyphae found in roots, stems, leaves and cobs. Disease signs are 
found with symptom-inducing strains where hyphae colonise the interior of the kernel 
including the embryo. Of more concern for animal and human health is the symptomless 
infection where the fungus may be located in vegetative parts (e.g. root or shoot) (Bacon & 
Williamson, 1992). Studies on the incidence of seedborne fungi in commercial South 
African maize showed the predominant fungi were F subgiutinans and F moniliforme 
(Rava et al., 1996). 
2.2 OCCURRENCE of FUMONISINS 
Sydenham et al. (1990A) were the first to conclusively report the natural occurrence ofFBt 
in maize (Zea mays) by analysing mouldy home-grown maize collected from the 
Butterworth district in the Transkei. In the1989 and 1990 South African harvests, yellow 
maize had higher levels of F moniliforme but lower levels of fumonisins than white maize. 
In the 1993 harvest fumonisins were found in all samples analysed with levels being higher 
in yellow maize than white (FB 1>FB2>FB3) (Rheeder et al., 1995; Rava et ai., 1996). 
Fumonisin producing strains of F moniliforme have been found in a variety of samples from 
different countries. Strains were isolated from maize seeds from Mexico (Desjardins et ai., 
1994) and poultry feed, maize, soybean, pea and wheat samples from Spain (Castella et ai., 
1996). 
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Samples of maize, wheat, barley, sorghum and mixed feed from Italy, Spain, Poland and 
France had highest levels of FBI in isolates from maize (average 1 259 f,Lg/g) followed by 
wheat (average 769 Ilg/g) and barley (320 Ilg/g) (Visconti & Doko, 1994B). 
Musser & Plattner (1997) examined 22 cultures of Fusaria for total fumonisin composition. 
The major fumonisins in all cultures were FBI, FB2, FB3, fumonisin Al (FAI) and fumonisin 
A2 (FA2); but seven other fumonisins of the A, P and C series were identified at levels <10% 
of the FB I produced. In contrast, Shetty & Bhat (1997 A) tested the ability of different maize 
varieties to support production of FBI by inoculating with F. moniliforme. All varieties 
tested showed good fungal growth with a wide range of concentrations of FBI (159 f,Lg/g to 1 
824 Ilg/g of dried culture material) but there was no correlation between fungal growth and 
the amount of FB I produced. 
Natural co-occurrence offumonisins and other toxins has been reported. Analysing mouldy 
maize samples from the Transkei, Sydenham et al. (1990A, 1990B) found high concentrations 
of FB I and FB2, but also deoxynivalenol, moniliformin, nivalenol and zearalenone. 
In South African maize products for the 1994/1995 season, Rava et al. (1996) and Rava 
(1996), found both fumonisins, deoxynivalenol and nivalenol in maize bran and maize 
screenings; zearalenone and fumonisins in sifted, special and super maize meal for human 
consumption; and ochratoxin A and fumonisins in maize germ meal for animal consumption. 
Highest mean levels offumonisins were found in maize bran (1 788 Ilg/kg) and maize 
screenings (8 878 Ilg/kg); levels in animal feed products were higher (1 993 f,Lg/kg) than in 
yellow commercial maize for humans (865 Ilg/kg). 
In China, co-occurrence offumonisins with type-A trichothecenes (e.g. T-2 toxin) were 
found in mouldy com but levels of aflatoxin were low (Chu & Li, 1994). However, Shetty & 
Bhat (1997B) found both FBI and aflatoxin BI in normal and rain-affected sorghum, maize 
and poultry samples in India. In Italy, fusaproliferin and beauvericin were found associated 
with FBI in 22 samples of pre harvest maize ears infected with Fusarium (Ritieni et al., 
1997). 
In several countries, various maize and maize-based products for human and animal 
consumption have been analysed for fumonisins (Tables 2.1, 2.2 and 2.3). 
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TABLE 2.1 OCCURRENCE OF FUMONISINS IN FOODSfFEEDS IN AFRICA 
Country Type of Sample Fumonisins hu!/k2) Reference 
South Africa White maize FBI: 30 (0 - 5 637) Rava et ai., 1996 
(1993 maize crop) FB2: 55 (0 - 1 430) 
FB3 : 27 (0 - 400) 
YeHow maize FBI: 677 (0 - 11 773) Rava et ai., 1996 
(1993 maize crop) FB2: 220 (0 - 5 690) 
FB1 : 106 (0 - 1 963) 
White maize FBI: 637 (0 - 12963) Rava, 1996 
(199411995 maize crop) FB2: 118 (0 - 4 187) 
FB3: 83 (0-3110) 
Yellow maize FBI: 664 (0 - 5 062) Rava, 1996 
(1994/1995 maize crop) FB2: 148 (0 - 2 000) 
FB3: 54 (0 - 1 431) 
Maize meal FBI: 138 (0 - 475) Sydenham et ai., 
FB2 : 83 (0 - 131) 1991 
Maize-grits FBI:125 (0 - 190) Sydenham et ai., 
FB2: 85iO - 120) 1991 
Botswana Maize meal FBI: 35 - 255 Doko et ai., 1996 
FB2: nd - 85 FB3: nd - 40 
Maize kernels FBI: 350 Doko et ai., 1996 
FB2 : 105 FB3: 70 
Sorghum meal FBI: 20 Doko et ai., 1996 
FB2 and FB3: nd 
Egypt Corn-based human FBI: 2 380 (1 780 - 2 980) Sydenham et ai., 
foodstuffs FB2: 595 (470 -780) 1991 
Kenya Maize kernels FBI: 780 Doko et ai., 1996 
FB2: 275 FB3: 130 
Malawi Maize kernels FBI: nd - 115 Doko et ai., 1996 
FB2 : nd - 30 FB]: nd 
Mozambique Maize kernels FBI: 240 - 295 Doko et ai., 1996 
FB2 : 75 - 110 FB]: 25 - 50 
Tanzania Maize kernels FBI: nd - 165 Doko et ai., 1996 
FB2: nd - 60 FB3: nd 
Uganda Maize kernels FB l : 605 Doko et al., 1996 
FB2: 155 FB3: 85 
Zambia Maize meal FBI: 740 Doko et ai., 1996 
FB2 : 380 FB3: 85 
Zimbabwe Maize meal FBI: 55 - 1 910 Doko et ai., 1996 
FB2: nd - 620 
FB3: nd - 205 
Maize kernels FB l : nd - 125 Doko et ai., 1996 
FB2: nd - 40 FB3: nd .. 
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TABLE 2.2 OCCURRENCE OF FUMONISINS IN FOODSIFEEDS IN EUROPE and ASIA 
Country Tvpe of Sample Fumonisins (J121k2) Reference 
EUROPE 
Italy Maize FBI:upto5310 Doko & Visconti, 
FB2: 1 480 1994 
Puffed corn FBI: up to 6100 Doko & Visconti, 
FB1 : 520 1994 
Corn-grits/ cornflour FBI: 420 - 3760 Doko & Visconti, 
/polenta FB2: 80 - 910 1994 
Sweetcorn FBI: 60 - 790 Doko & Visconti, 
FB2: nd 1994 
Popcorn FBI: up to 60 Doko & Visconti, 
FB2: up to 20 1994 
Tortilla chips FBI: up to 60 Doko & Visconti, 
FB1 : up to 10 1994 
Corn flakes FB1: 10 Doko & Visconti, 
1994 
Sardinia Infected maize ear FBI: up to 250 000 Bottalico et ai., 1995 
kernels 
Switzerland Maize-based food for FBI: 55 - 790 Pittet et ai., 1992 
humans FB2: 50 - 160 
Poultry feed FBI: 235 Pittet et ai., 1992 
United Kingdom Corn snacks FBI: 11 - 220 Patel et ai. 1997 
Breakfast cereals FBI: 11 - 194 Patel et ai., 1997 
Popping corn & FBI: 14 - 784 Patel et ai., 1997 
microwaveable 
popcorn 
Polenta FBI: 16 - 2 124 Patel et ai. 1997 
ASIA 
China Maize kernel FB1: 6 800 (5 300 - 8 400) Ueno et ai., 1993 
FB2: 3 300 (2 300 - 4 300) 
Maize flour FB1: 100 (60 - 200) Ueno et ai., 1993 
FB2: nd 
India Sorghum (rain affected FB1: 480 (70 - 8 000) Shetty & Bhat 1997B 
Sorghum (normal) FB1: 270 (150 - 510) Shetty & Bhat 1997B 
Maize (rain affected) FB1 : 1 170 (40 - 65000) Shetty & Bhat 1997B 
Maize (normal) FB1: 620 (10 - 5000) Shetty & Bhat 1997B 
Poultry feed FB1: 100 (20 - 260) Shetty & Bhat 1997B 
Japan Corn-grits FB1: 500 (200 - 2 600) Ueno et ai., 1993 
FB2 : 1 000 (300 - 2 800) 
Korea Maize kernels FB1: 53 - 1 327 Ung-Soo et ai., 1994 
FB2: 69 - 680 
Nepal Maize kernel FB1: 600 (50 - 4600) Ueno et ai., 1993 
FB2 : 1 600 (100 - 5 500) 
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Of maize-based food samples analysed in the United Kingdom, none were detected in food 
product samples from commercial maize processing although fumonisins were found in the 
original maize. Fumonisins were also not found in samples of barley, wheat, soya, oats, rice, 
com syrup or oil, corn-on-the-cob, com-fed chicken or wheat flour tortilla. Yet fumonisins 
(chiefly FBI) were detected in 26% (76/291) of retail samples with highest levels being in 
samples of polenta (16 to 2 124 Jlg/kg); popping com and microwaveable popcorn (14 - 784 
Jlglkg); com snacks samples (11 - 220 Jlglkg); and breakfast cereals (11 - 194 Jlg/kg) (Patel 
et al., 1997) (Table 2.2). 
In India, FBI was found in rain-affected maize (0.04 - 65 mg/kg) and sorghum (0.07 - 8 
mglkg) samples. However, FBI was also found in 5/14 poultry feed samples; 26/35 normal 
maize samples (0.01 - 5 mg/kg); and 2/43 normal sorghum samples (0.15 - 0.51 mg/kg) 
(Shetty & Bhat, 1997 A, 1997B) (Table 2.2). 
In samples from the 1988-1991 maize crops from Iowa, Wisconsin & Illinois (USA), 
Murphy et al. (1993) found levels offumonisins to be about 10 times higher in maize 
screenings as compared to maize. In Columbia, a higher number of positive FBI samples 
(75%) were found in maize and maize-based products for animal intake than for human 
consumption (55%). The actual levels of FBI were also higher; average 694 Jlglkg for 
animals as opposed to 218 Jlg/kg for humans. Percentage positive samples and levels of FB2 
were lower (58.3%, average 283 Jlg/kg and 35%, average 118 Jlg/kg for animal and human 
consumption respectively) (Perilla & Diaz, 1998) (Table 2.3). 
The first report ofFB3 and hydrolysed fumonisin BI (HFB I) in human foods (in the USA) was 
by Hopmans & Murphy (1993) who analysed yellow and white maize meal, canned com, masa 
and tortilla chips; FB3 was detected in 10/13 foods and HFBI in canned yellow maize, masa and 
tortilla chips. Fumonisins B I , B2 and B3 were also found in dry dog and cat foods, and rat chow. 
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TABLE 2.3 OCCURRENCE OF FUMONISINS IN FOODSIFEEDS IN AMERICA 
Country Type of SamJ!le Fumonisins (Jl!dk2) Reference 
Georgia, USA Maize FB1: 870 Chamberlain et al., 
1993 
Iowa, Wisconsin & Maize (1988) FB1: 0 -14 900 Murphy et al., 1993 
FB2: 700 
FB3: 200 
Illinois Maize (1989) FB1: 37900 Murphy et al., 1993 
FB2: 800 
FB~: 200 
Maize (1990) FB1: 0 - 19 100 Murphy et al., 1993 
FB2: 900 
FB3: 300 
Maize (1991) FB1: 0 - 15 800 Murphy et al., 1993 
FB2: 800 
FB~: 400 
Columbia Maize/maize-based FB1: 218 (24 - 2170) Perilla & Diaz, 1998 
products for humans FB2: 118 (21 - 833) 
Maize/maize-based FB1: 694 (32 - 2 964) Perilla & Diaz, 1998 
products for animals FB2: 283 (44 - 9871 
Hominy feed FB1: 86 - 2964 Perilla & Diaz, 1998 
FB2: 57 - 987 
Costa Rica Maize FB1: Viquez et ai., 1996 
Brunca 2500 
Huetar Norte 3580 
Huetar Atlantica 1 810 
Argentina Maize FB1: 1110-6695 Sydenham et al., 1993 
FB2 : 325 - 2680 
FB3: 130 - 855 
Peru Maize meal (human) FB1: 660 (0 - 660) Sydenham et al., 1991 
FB2: 135JO - 135) 
Canada Maize meal (human) FB1: 50 (0 - 50) Sydenham et al., 1991 
FB2: 0 
USA Maize meal (human) FB1: 1 048 (0 - 2790) Sydenham et al., 1991 
FB2: 298 (0 - 920) 
Corn-grits (human) FB1: 601 (105 - 2545) Sydenham et al., 1991 
FB2: 375 (0 - 1 065) 
USA Maize-based mixed FB1: 1 300 - 16800 Sydenham et al., 1992 
feeds FB2: 100 - 6500 
FB3: 0-2650 
USA Canned & frozen FB1: 0 - 82 Trucksess et al., 1995 
sweetcorn (235:111 
350: 1111 
Data in Tables 2.1, 2.2 and 2.3 show that the presence of fumonisins in food and feeds for 
both human and animal consumption is a worldwide problem. "Thus, contamination of 
maize with the foodbome carcinogenic mycotoxins, the fumonisins, is a Pan-African, as well 
as a global problem" (Marasas et al., 1993). 
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2.3 CHEMISTRY 
Fumonisins wefl~ first isolated from F moniliforme MRC 826, a toxigenic ~train isolated 
from mouldy com in the Tnmskei by extraction with ethyl acetate and methanol and purified 
using chromatographic methods (Kriek et al. , 1981; Gelderblom et al., 1988). 
The structures were elucidated using liquid secondary ion mass spectrometry and nuclear 
magnetic resonance spectrometry. The backbone for the B series is 2-amino-12,16,dimethyl-
3,5,IO,14,15-pentahydroxyicosane joined in diester linkage with propane-l,2,3,-tricarboxylic 
acid [tricarballylic acid (TCA)] via hydroxyl groups at C-14 and C-15; and the terminal 
carboxyl group of TCA (Figure 2.1). The presence of a free amino group and four free 
carboxyl groups means the fumonisins are strongly polar and water soluble. They are also 
soluble in methanol and acetonitrile/water but are not soluble in non-polar solvents (Scott & 
Lawrence, 1992). Both the fumonisins and AAL toxin show structural similarities with 
sphingosine (Figure 2.1). 
FUMONISINS 
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fA. OH OH 
FA, H OH 
FB. OH OH 
FB, H OH 
FBI OH H 

















CH, OH CHi OH NH~ 
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NH .. 
FIGURE 2.1 CHEMICAL STRUCTURES OF FUMONISINS, SPHINGOSINE AND 
AALTOXIN (Norred, 1993) 
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The predominant fumonisin is FBI whereas FB2, the C-I0 deoxy analogue of FBI is less 
common. The B series have a free amino group which distinguishes them from the A series 
(F AI and F A2) that are the N-acetyl derivatives (Bezuidenhout et al., 1988; Gelderblom et 
al., 1988). Fumonisin B3 and fumonisin B4 (FB4) (Figure 2.1), were later identified by 
Gelderblom et al. (1992B). Branham & Plattner (1993A) isolated a new fumonisin, 
fumonisin CI(FCI), from liquid cultures of F. moniliforme which differs from FBI in that it 
lacks the amino-end terminal-methyl group. In the P series (FPI-3), 3-hydroxypyridinium 
replaces the amine at C-2; these new fumonisins can occur in amounts approximately one-
third of the B series (Musser et al., 1996). Recently, MacKenzie et al. (1998) reported the 
discovery of iso-fumonisin BI which has a hydroxyl group at C-4 instead of C-5. 
Other chemical forms of the fumonisins can be prepared. Treatment with calcium hydroxide, 
i.e. hydrolysis, results in the sequential formation of a partially hydrolysed (removal of one 
of the two tricarballylic acid groups) and then a fully hydrolysed (removal of both groups) 
molecule or aminopentol [e.g. FBI to HFBI or aminopentol (API)]. Partially hydrolysed FBI 
(PHI) exists as an equilibrium mixture of the two possible mono esters, HFBI and hydrolysed 
FB2 (HFB2), which retain biological activity (Sydenham et al. , 1995B; Badria et al., 1995). 
2.3.1 Extraction and Purification 
Extraction and purification of fumonisins from culture material is necessary so they may be 
used as standards; and for other analytical and toxicity experiments. Gelderblom et al. 
(1988) used ethyl acetate and aqueous methanol for extraction followed by XAD-2 
adsorption chromatography, Sephadex LH-20 fractionation and a reverse phase CIS column 
for final clean-up to give a 92% recovery of two amorphous solids, pure FBI and pure FB2. 
Cawood et al., (1991) successfully purified fumonisins B 1-4 and their N-acetyl derivatives 
from com cultures by extracting with methanol:water (3:1), purification on an Amberlite 
XAD-2 column, then two silica gel columns and finally a reversed phase CIS column but the 
yield was low (40%). If methanol is used for extraction, mono- and dimethylesters are 
produced which interfere with the purification of individual fumonisins. 
Using solid com or rice cultures inoculated with F. proliferatum strain M5591, Dantzer et 
al. (1996) obtained 85% pure FBI. Liquid cultures of the same strain gave better results-
>95% purity and 37% recovery. Purification was by XAD-16 adsorption liquid 
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chromatography, Cs partition liquid chromatography, DEAE-Sepharose (ion exchange liquid 
chromatography) and finally gradient CIS partition liquid chromatography. 
Poling & Plattner (1996) working with an unusual strain of F. moniliforme (KSU 819) 
which mainly produces FB3 and FB4, obtained 95% recovery using solid phase C IS- and 
propyl amine (NH2)- bonded phases. 
Liquid culture has made possible production of radiolabelled fumonisin by adding 14C_ 
acetate or L-[methyl-14C] methionine to the medium to produce 14C labelled FBI with the 
isotope at C-21 and C-22. These studies also showed that in the biosynthesis offumonisins, 
methionine, glutarate and serine or alanine are added to the hydrocarbon backbone (Branham 
& Plattner, 1993B; Alberts et at., 1993; Blackwell et at., 1994). 
2.3.2 Stereochemistry 
Studies of the stereochemistry using molecular modelling techniques show the fumonisin 
molecules (FB I-4) have a unique folded globular structure, similar to a peptide with internal 
H-bonding, and a predominantly hydrophobic surface. The folding of the amine backbone 
with the two esterified tricarballylic side chains forms a three-dimensional cage-like 
structure suggesting the molecules may act as chelators. Furthermore, there appears to be an 
internal space beginning on the electrophilic end, transversing the molecule, bifurcating and 
opening into two locations to either side of the lipophilic end (Beier et ai., 1995; Beier & 
Stanker, 1997). The authors suggest that, "These spaces may change in size as a result of 
changing hydrogen bond patterns. If the lipophilic end of FBI were imbedded into a 
membrane with the electrophilic portion protruding; the membrane may become leaky due to 
these spaces or holes within the fumonisin structure." This hypothesis seems likely in view 
of work done by Sauviat et at., (1991) on frog heart muscle where they found FBI interacted 
with the calcium channel inhibiting conductance. 
2.3.3 Stability 
Several workers have investigated the heat stability of fumonisins in aqueous solution. 
Processing for 60 minutes at 125, 150 and 175°C resulted in loss of <27%, 18 - 90% and 
>90% of 5 ppm FBI respectively. Fumonisin BI was most stable at pH 7, then pH 10 and 
least stable at pH 4 (Jackson et at., 1996A). Similar results were obtained for FB2 (Jackson et 
at., 1996B). 
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In a 6 week storage experiment at four storage temperatures (-18, 4, 25, 40°C), FBI and FB2 
were found to be most stable in acetonitrile:water (1: 1) but decomposition and/or formation 
of fumonisin methyl esters occurred if stored in methanol. Extending the storage time to 6 
months confirmed the stability of fumonisins in acetonitrile:water (Visconti et al., 1994A). 
2.4 ANALYSIS 
2.4.1 Thin Layer Chromatography 
This is a simple method but requires initial sample extraction. Rapid methods have been 
developed for FBI. FB2 and FB3 in corn (Ackermann, 1991; Cawood et al., 1991) and rice 
samples (Dawlatana et al., 1995). After extraction with acetonitrile:water (1: 1) and 
separation on normal phase silica with chloroform:methanol:acetic acid as the mobile phase, 
acidic anisaldehyde was used as the visualisation reagent. Alternatively CI8 columns were 
used for further clean-up prior to separation on reverse phase CI8 plates using methanol:4% 
aqueous potassium chloride as the developing solvent. Visualisation was achieved by 
spraying successively with O.IM sodium borate buffer, fluorescamine and O.OIM boric acid. 
Examination under longwave ultraviolet light (UV) showed FBI (RfO.5) and FB2 (RfO.l) as 
bright yellowish-green fluorescent bands (Rottinghaus et al., 1992). Stockenstrom et al. 
(1994), found less interferences if strong anion exchange (SAX) columns were used instead 
OfC I8. 
Thin layer chromatography is a suitable method, particularly for analysing large numbers of 
samples, as it is faster and cheaper than HPLC; but results are not as accurate. Comparison 
of HPLC and a rapid TLC method (similar to the above) in maize samples showed good 
agreement (r = 0.953; p<0.0005) (Schaafsma et al., 1998). 
2.4.2 High Performance Liquid Chromatography - FluorometriclUV detection 
High performance liquid chromatography is the most frequently used method of analysis for 
fumonisins. However, fumonisins do not absorb UV light nor do they fluoresce so formation 
of a fluorescent derivative is essential; and to overcome matrix interferences, prior extraction 
and clean-up is required. Extractions have been done using methanol:water (3:1) or 
acetonitrile:water (1 : 1) followed by further purification using SAX or C 18 columns. The 
SAX columns were washed with methanol:water (1:3 or 3: 1) and pure methanol; elution was 
with methanol:water (3: 1); or 5%, 1 % or 0.5% acetic acid in methanol (Sydenham et al., 
1990A; Shephard et al., 1990; Akiyama et al., 1995; Vehizquez et ai., 1995). 
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The CIS columns were washed with acetonitrile:water (1 :4) and the eluant was 
acetonitrile:water (1:1 or 7:3) (Hopmans & Murphy, 1993). Bennett & Richard (1994) found 
SAX columns to be efficient in isolating fumonisins from crude extracts but for partial 
purification of hydrolysis products CIS columns were needed, because hydrolysed 
fumonisins are not retained by SAX columns (Stockenstrom et al., 1994). 
Alternatives to SAX and CIS columns are immunoaffinity columns (Fumonitest TM); elution 
is with methanol: buffer. These have been successfully applied to corn, milk, and canned and 
frozen sweetcorn (Scott et al., 1994; Ware et ai., 1994; Trucksess et at., 1995; Duncan et at., 
1998). However, they have a small capacity (1 Ilg FBI) so are not suitable iflarge amounts 
of fumonisins are present, yet may be useful for measurements in tissues or plasma (Bennett 
& Richard, 1994). 
Eluates from the extraction/clean-up procedure were evaporated to dryness at 60°C under 
nitrogen and redissolved prior to the formation of a fluorescent derivative and analysis by 
HPLC. Sydenham et ai. (1990A) made a maleyl (UV absorbing) and a fluorescamine 
(fluorescent) derivative. Unfortunately, the maleyl derivative did not have the desired 
specificity or sensitivity. Successful HPLC for FBI and FB2 was done with an 0-
phthaldialdehyde (OPA) derivative using a CIS reversed phase column and methanol:O.l M 
sodium dihydrogen phosphate (PH 3.3) (80:20) as the mobile phase. The acidic pH is 
required to prevent ionisation of the TCA groups (Shephard et al., 1990). 
Since OPA derivatives are unstable and fluorescamine derivatives give two peaks, other 
methods were developed viz. 4-fluoro-7-nitrobenzofurazan (NBD-F) or naphthalene-2,3-
dicarboxaldehyde- potassium cyanide (NDA-KCN) (Scott & Lawrence, 1992; Scott et at., 
1994). Other derivatising chemicals used were 9-fluorenylmethyl chloroformate (FMOC) 
(Holcomb et al., 1993); naphthalene dicarboxaldehyde (NDA) (Bennett & Richard, 1994); 4-
(N,N-dimethyl-aminosulphonyl)-7 -fluoro-2, 1 ,3-benzoxadiazole (DBD-F) (Akiyama et ai., 
1995); 6-amino-quinolyl N-hydroxy-succinimidylcarbamate (Velasquez et aI., 1995) and 
fluorescein isothiocyanate (FITC) (Maragos, 1995). 
Of all the derivatising agents, OP A is now the one used most often (Shephard et al., 1990; 
Sydenham et al., 1992; Scott et al., 1994; Trucksess et ai., 1995; Thakur & Smith, 1996; 
Rava et al., 1996, Rava, 1996; Duncan et al., 1998). It reacts with all free primary amines 
15 
(hence extensive clean-up is needed) and since the fluorescence intensity decays with time, 
timing between addition of the reagent and injection on to the column must be constant and 
accurately reproduced for each sample - usually one minute (Shephard et al., 1990; 
Sydenham et al., 1992; Thakur & Smith, 1996). 
A Cl8 column was used for separation with a mobile phase ofmethanol:0.05M sodium 
dihydrogen phosphate buffer (PH 3.5) alone or with acetonitrile:water (Scott et al., 1994); or 
various proportions of acetonitrile:water:acetic acid (Trucksess et at., 1995; Thakur & Smith, 
1996). Sydenham et at. (1992) used a C8 column and a mobile phase of methanol: 
0.1M sodium dihydrogen phosphate (PH 3.35) to simultaneously analyse FBI, FB2, and FB3. 
TABLE 2.4 IDGH PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS OF 
FUMONISINS 
Sam me Recovery Detection Limits Reference 
Maize 99.5% (FB1) 50 ng/g FB1 Shephard et al., 1990 
85.9% (FB2) 100 ng/g FB2 
Maize 66.3% 10 Jlg/g Sydenham et al., 
(FB 1 at 100 Ug/g) 1990A 
Maize 94% (FB1) 100 ng/g Scott & Lawrence, 
80% (FB2) Range (125 - 5 000 1992) 
ng/g) 
Maize 96.8%(FB3) 50 ng/g Sydenham et al., 
1992 
Rodent feed 83% (FB1 at 2-20 ppm) 200 ng/g Holcomb et al. 1993 
Maize 116% , 119%, 110% 25 ng/ml FB1 standard Hopmans & Murphy, 
{FBI at 250 500, 1 000 ng/g) 50 ng/ml FB2 standard 1993 
Milk 87 - 109% 3 ng/ml (FB1 and FB2) Scott et al., 1994 
(FBI at 5 - 50 ng/ml) 20 - 25 ng/ml (API) 
69 - 83% 
(API at 50 - 100 ng/ml) 
Maize 85.4% (FB1) 10 ng/g FB1 Ware et al., 1994 
87.1 % (FB2 ) 4 ng/g FB2 
Maize 92% (FB1) 0.01 ,...g/g Akiyama et al., 1995 
90% (FB2) 
(0.5 ug/g) 
Canned & frozen 76 - 88% (FB1) 4ng/g Trucksess et al., 
sweetcorn (50 - 200 ng/g) 1995 
Maize no data 0.26 Jlg/g Velazquez et at., 
1995 
Maize 80 - 85% 20 Ilg/kg (FB1' FB2, Rava et at., 1996, 
FB3) Rav/h 1996 
Maize 83% 0.016 Jlg/g Duncan et al., 1998 
Range 0 - 1 0 j.l.g! g 
Successful HPLC analysis was done on a variety of samples - maize and maize-based 
products but also on milk and rodent feed (Table 2.4). 
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Recoveries varied from 66.3%to 119% and detection limits for FBI from 4 to 260 ng/g (in 
maize); and for FB2 from 3 ng/ml (in milk) to 100 ~g/g (in maize). 
An International Union of Pure and Applied Chemistry (IUP AC) inter-laboratory 
comparative study analysing maize samples by a specified method gave intra-laboratory 
relative standard deviations (RSD) of 7.7 to 25.5% for FBI (200 to 2 000 ng/g) and 12.5 to 
36.8% for FB2 (70 to 740 ng/g). Inter-laboratory RSD's were 18.0 to 26.7% for FBI and 28.0 
to 45.6% for FB2. Statistical comparisons (using the ratio of the actual inter-laboratory RSD 
with that predicted from the known concentration) to evaluate the method showed that the 
results were acceptable and the method is suitable for adoption as an official method (Thiel 
et al., 1993). 
In a European study intra-laboratory RSD's were 15% for FBI and FB2, while intet-
laboratory RSD's were 11 % (FBI) and 13% (FB2) (Visconti et al., 1996A). These results 
confirm the role of HPLC as a viable, reproducible and widely used method for analysis of 
fumonisins (Shephard, 1998). 
2.4.3 Other Methods 
Liquid chromatography used with mass spectrometry (MS) and no derivatisation gave 
detection limits of 0.01 Ilg/g for both FBI and FB2 (Akiyama et al., 1998). 
Both positive and negative electrospray ionisation mass spectrometry (ESI-MS) and liquid 
chromatography /electrospray ionisation mass spectrometry (LC-ESI-MS) have been 
successful in analysis of FBI, FB2 and FB3 in com-grit, maize meal, rodent feed and forage 
grass (Mirocha et al., 1992; Caldas et al., 1995; Lukacs et al., 1996; Josephs, 1996; 
Churchwell et al., 1997). 
Thermospray mass spectrometry and capillary liquid chromatography-fast atom 
bombardment mass spectrometry have been used to analyse HFBJ, HFB2 and PHFBI and 
F A2 (Thakur & Smith, 1996; Xie et al., 1997). 
A capillary gas chromatography - mass spectrometry method identified the TCA moieties 
after acid hydrolysis and esterification of FBI (Sydenham et at., 1990A). 
Supercritical fluid ( carbon dioxide) extraction (SFE) of maize, maize dust and F. 
moniliforme culture samples followed by HPLC analysis gave a sensitive, fast and 
reproducible method for analysing FBI in low concentrations (Selim et al., 1996). 
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Using fluorescein isothiocyanate (FIT C) derivatives of FBI, FB2 and HFB 1, Maragos (1995) 
achieved good correlation when comparing capillary zone electrophoresis (CZE) and HPLC. 
The most sensitive method was high-performance liquid chromatography - electrospray-
ionisation, tandem mass spectrometry (HPLC-ESI-MS-MS) with a detection limit of 0.8 
ng/g in maize (Lukacs et at., 1996); the least sensitive (with detection limits of 0.25 Jlglg for 
both), were fluorometry for maize (Duncan et at., 1998) and high-performance thin-layer 
chromatography (HPTLC) for rice (Dawlatana et at., 1995) (Appendix 1, Table 2.5). 
2.4.4 Immunoassay 
Because ofits sensitivity and specificity, use ofimmunoassays particularly ELISA's for 
analysis of mycotoxins is an obvious choice. Several workers have developed methods using 
both polycIonal and monoclonal antibodies raised in various animals (rabbits, mice, hens, 
ascites fluid) to analyse for different mycotoxins (zearalenone, aflatoxin BI, aflatoxin MI, 
ochratoxin A, citrinin, T -2 toxin, cyclopiazonic acid, roridin A) in a variety of samples 
(maize, maize meal, wheat, barley, cereals, peanuts, Job's tears, animal and human serum 
and urine, pig feed, chicken meat, milk, dairy products) (Table 2.6). 
Since fumonisins are of low molecular weight, they must first be conjugated to a protein to 
form an immunogenic molecule. The most common method is by linking the C-2 amine of 
FBI to a glutaraldehyde activated protein and stabilising the linkage with sodium 
borohydride (Chu, 1996). The carrier proteins used have included cholera toxin (CT) 
(Azcona-Olivera et at., 1992A, 1992B; Yeung et at., 1996); keyhole limpet hemocyanin 
(KLH) (Usleber et at., 1994; Fukuda et at., 1994; Yu & Chu, 1996; Abouzied et al., 1996); 
bovine serum albumin (BSA) (Yu & Chu, 1996; Hammer et at., 1996); human serum 
albumin (HSA) (Yeung et at., 1996) and ovalbumin (OVA) (Fukuda et at., 1994). 
By protecting the amino group prior to carbodiimide coupling of FBI to HSA and then 
deprotecting before immunisation, Yeung et al. (1996) managed to produce high affinity and 
avidity antibodies. 
The initial step in the assay is to coat microwell plates with FBI and for this another 
conjugate was made e.g. FBI-ovalbumin (FBJ-OVA)(Azcona-Olivera et at., 1992A, 1992B; 
Yu & Chu, 1996; Abouzied et at., 1996; Yeung et al., 1996) or FBI-bovine serum albumin 
(FBI-BSA) (Fukuda et at., 1994). 
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TABLE 2.6 IMMUNOASSAYS OF VARIOUS MYCOTOXINS 






































EZ-Screen test kit 
Methodology Substance analysed 
CI-ELISA Porcine urine 
CD-ELISA Milk 
Line immunoblot Maize 
. assay 
CD-ELISA Maize, wheat, pig feed 
CI-ELISA Barley, Job's tears 
CI-ELISA Serum (blood donors) 
CD-ELISA Maize, peanuts 
RIA Human sera 
CD-ELISA Urine (human and animal) 
Line immunoblot Maize 
assay 
Fiber-optic Peanuts and maize meal 
biosensor 
CD-ELISA Dairy products 
CI-ELISA Chicken meat, wheat flour, 
porcine plasma, bovine 
serum 
RIA Human sera 
CI-ELISA Swine finisher diets 
CD-ELISA Cereals 
CI-ELISA Wheat flour 
Dipstick CD- Wheat 
ELISA 
Sandwich ELISA Fungal mycelia and cheese 




competitive indirect ELISA 
competitive direct ELISA 
radio-immunoassay 
Reference 
MacDougald et al., 
1990 
Azcona et al. 1990 
Abouzied & Pestka, 
1994 
Bennett & Nelsen, 
1994 
Tanaka et at., 1995 
Wilkinson et al. 1988 
Park et al. 1989 
Fukal & Reisnerova, 
1990 
Stubblefield et al., 
1991 
Abouzied & Pestka, 
1994 
Carter et al., 1997 
Fremy & Chu, 1984 
Kawamura et al., 1989 
Fukal & Reisnerova, 
1990 
Clarke et al. 1993 
B arn a-Vetra et al., 
1996 
Abramson et al., 1995 
de Saeger & van 
Peteghem 1996 
Hahnau & Weiler, 
1993 
Yu & Chu, 1998 
Martlbauer et al. 1988 
aflatoxin test kit (Environmental Diagnostics Inc., Burlington, NC) 
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Both polyclonal (PAb) and monoclonal (mAb) antibodies against fumonisins (usually FBI) 
have been raised in a variety of animals and both competitive direct ELISA (CD-ELISA) and 
competitive indirect ELISA (CI-ELISA) methods developed. Monoclonal antibodies were 
IgGI kappa (Azcona-Olivera et al., 1992B; Fukuda et al., 1994). 
The enzyme used most often was horseradish peroxidase (HRPO) either attached to the 
second antibody (CI-ELISA) (Yu & Chu, 1996); or to FBI (CD-ELISA) (Azcona-Olivera et 
al., 1992B; Usleber et al., 1994; Abouzied et al., 1996; Yu & Chu, 1996). 
Different antibodies/methods have different detection limits, ranges and cross-reactivities 
with FBI, FB2, FB), HFBI and TCA (Table 2.7). 
TABLE 2.7 ELISA METHODS FOR FUMONISINS 
Antibody / Detection limit IDso Range Cross- Reference 
ELISA Method (buffer) (nl!l'ml) (nwml) reactivity 
pAb; BALB/c 100 ng/ml FB. - 260 no data FB2 - 87% Azcona-
mice; ascites fluid; FB2 - 300 FB3 - 40% Olivera et ai., 
CI-ELISA FB3 - 650 TCA-O% 1992A 
mAb;BALB/c 50 ng/ml FB.- 630 50 to 5 000 FB2 - 38% Azcona-
mice; CD-ELISA FB2 - 1 800 FB3 - 33% Olivera et al., 
FB3 -2 300 TCA-O% 1992B 
HFBt-O% 
mAb;mice; FB. - 144 10 to 1 000 FB2- 290% Fukuda et al., 
CI-ELISA FB2 - 56 to 5 000 1994 
pAb; rabbits; FBt - 167 pg/ml FB1 - 0.623 0.02 to 20 FB2 - 24% Usleber et al., 
CD-ELISA FB2 - 1 200 pg/ml FB3 - 55% 1994 
FB3 - 460 pg/ml 
pAb; sheep; <0.1 ng/ml FB. - 5.5 0.1 to 30 FB2 - 24% Abouzied et 
CD-ELISA FB2 - 23 ng/ml FB3 - 30% al., 1996 
FB3-18 
pAb; rabbits; 0.05 ng/ml FB. - 0.66 0.05 to 0.75 FB2- 62% Yeung et al., 
CI-ELISA FB3 - 14% 1996 
HFB I -ll% 
HFB2- 3% 
pAb; rabbits; no data FBt - 0.45 0.01 to FB2 - 62% Yu&Chu, 
CD-ELISA FB2 - 0.72 1000 FB3 - 1.8% 1996 
FB3 - 25 
pAb; rabbits; no data FBt - 1.33 0.01 to FB2 - 80% Yu&Chu, 
CI-ELISA FB2 - 1.66 1000 FB3 -4.8% 1996 
FB3 - 28 
Cross-reactivities with FBI (Table 2.7) were 100% in each case. Studies of the cross-
reactivities suggest that the epitope lies in the C-11 to C-20 region of FBI (Azeona-Olivera et 
al., 1992A, 1992B) or antibodies may recognise a completely different region (Fukuda et ai., 
1994). 
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The IDso is the concentration of mycotoxin required for 50% inhibition of antibody binding 
and is an indication of affinity; the lower the value the greater the affinity. High affinity 
antibodies give better sensitivity in immunoassays (Yu & Chu, 1996). Detection limits in 
buffer varied from 0.05 ng/ml to 100 ng/ml (Table 2.7). 
The monoclonal antibodies raised by Azcona-Olivera et al.(1992B) were used to develop the 
Fumonisin Agri-Screen kits (Neogen); and Abouzied et al., (1996) used their polyclonal 
antibodies to develop the Veratox ® Fumonisin Kit (Neogen). 
To improve sensitivity and specificity, it was found necessary to perform some 
cleanup/extraction before application to a microwell plate as different matrices caused 
interference (Table 2.8). 
TABLE 2.8 EXTRACTION AND RECOVERY IN ELISA METHODS FOR FUMONISIN 
BI 
Method Sample Extraction Detection Recovery Reference 
limit 
CD-ELISA Maize 50% acetonitrile and 5 ).lglg 103% Azcona-
dilution of Olivera et al., 
supernatant 1992B 
CD-ELISA Milk None 100 - 300 no data Maragos & 
(Agri-Screen ng/ml Richard, 
kit) 1994 
CD-ELISA Maize Methanol:water 10 ng/g 59.7% (50 ng/g) Usleber et al., 
(75:25) 73.2% (500 ng/g) 1994 
CD-ELISA Maize Methanol: water 0.1 nglml 74 - 91% Abouzied et 
(Veratox® 70% (v/v); filtration, al.,1996 
kit) dilution 
CI-ELISA Maize Methanol: water 5ng/g 75.5% - 90.3% Yeung et al., 
75% (v/v); filtration, 1996 
dilution 
CD-ELISA Maize Acetonitrile:water 10-50 85.9% (no clean- Yu&Chu, 
(1: 1) and dilution in ng/g up) 1996 
buffer or CIS column 70.5% (with c1ean-
clean-up up) 
CD-ELISA Beer None 0.1 ng/ml 98.7 - 102.8% Scott et al., 
1997 
Recoveries ranged from 59.7% to 103% and detection limits from 0.1 nglml (beer and 
maize) to 500 nglg (maize) (Table 2.8). Recoveries are similar to those for HPLC but ELISA 
methods are more sensitive (Table 2.4 and 2.8). 
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In comparing TLC and competitive ELISA for screening of large numbers of samples, the 
ELISA method gave higher values which was attributed to lack of specificity of the 
antibodies, or loss of sample during the more extensive clean-up done prior to TLC (Shelby 
et al., (1994). 
Comparison of results obtained from ELISA and HPLC methods showed higher values for 
the ELISA methods but generally good correlation, r = 0.967, p<O.OOI (Sydenham et al., 
1996B). Better correlation in analysing maize and wheat-based food products is found 
between gas chromatography - mass spectrometry (GC-MS) and HPLC (r = 0.946, p<0.01) 
than between ELISA and HPLC (r = 0.512, p<0.05) (Pestka et al., 1994). 
When analysing maize samples, Yu & Chu (1996) surprisingly found better correlation 
between ELISA and HPLC for samples without clean-up (r = 0.955, p<0.001) than for 
samples with clean-up (r = 0.811, p<O.Ol). Similarly, for beer samples, Scott et al. (1997) 
found better correlation between liquid chromatography (LC) and ELISA at low levels of 
FBI (0 -10 ng/ml) for samples with no clean-up compared to those extracted on an 
immunoaffinity column. In contrast to other workers, they found ELISA results were lower 
than HPLC. Using an in-house immunoaffinity column prior to analysis of maize samples by 
both immunoassay and HPLC, Maragos (1997) found good agreement between 
immunoassay and HPLC results at low levels offumonisins « 2 Ilg/g) but at higher levels 
the HPLC results were lower. 
Several possible explanations for these differences have been proposed including differences 
in extraction procedures and lower recoveries from samples prepared for HPLC; interference 
(inhibition) in the ELISA methods by components in the sample (matrix differences, 
possibly lipid based); completely different methodology principles; and precursors or 
metabolites produced by F. moniliforme that cross-react with the antibodies or interfere in 
the immunoassay (Pestka et at., 1994; Usleber et al., 1994; Schneider et at., 1995; Tejada-
Simon et al., 1995; Abouzied et at., 1996; Sydenham et al., 1996A, 1996B; Yu & Chu, 
1996). Most antibodies (including monoclonal antibodies) are not specific for FBI but rather 
measure total fumonisins (Table 2.7). 
Usleber et al. (1994) suggested differences in the ratio of the open chain and cyclic forms of 
the TCA side chains may have affected results as this ratio is pH dependent and different 
extraction procedures gave different pH values of the extracts. 
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The TCA groups are believed to be important for antibody binding (Azcona-Olivera et al., 
1992A, 1992B). Use of higher d:lutions for samples with high concentrations offumonisins 
can overcome the matrix effect (Usleber et al. , 1994; Sydenham et al., 1996A). 
In addition to ELISA's, immunoassays with different formats have been developed mainly to 
provide rapid visual screening tests suitable for use in the field. These include a line 
immunoblot assay using monoclonal antibodies, detection limit 500 ng/ml (Abouzied et al. , 
1994); dipstick immunoassay using polyclonal antibodies, detection limits 40 - 60 ng/g in 
maize samples (Schneider et aI., 1995); fiber-optic immunosensor with fluorescence 
detection using monoclonal antibodies, detection limit 3.2 J.1g/g in spiked maize from diluted 
methanolic extracts and 0.4 J.1g/g from affinity column purified extracts (Thompson & 
Maragos,1996; Maragos, 1997) and a surface plasmon resonance immunosensor using 
polyclonal antibodies, detection limit 50 ng/ml in buffer (Mullett et al., 1998). None of these 
methods areas sensitive as ELISA assays. 
2.4.5 Analysis of Physiological Samples 
Most of the methods of analysis have been applied to maize and maize-based products and 
very little work has been done on analysis of fumonisins in physiological samples. Shephard 
et al., (1992, 1995B) developed methods for analysing FBI and FB2 in physiological samples 
from rats injected intraperitoneally with FBI . Urine samples were diluted in distilled water, 
extracted with methanol, cleaned up on a SAX column, and measured as OP A derivatives on 
reverse phase HPLC (as for maize samples). Plasma samples for FBI were de-proteinised by 
addition of methanol, centrifuged and the supernatant applied to a SAX column and analysed 
as for urine. For FB2, acetonitrile was used for deproteinisation of plasma samples and 
acetonitrile and acetonitrile/water (1: 1) for washing the SAX columns; elution and analysis 
was as for FBI. Recoveries were 91% and 94% (FBI in urine); 86% and 87% (FBI in 
plasma); 101.5% (FB2 in urine) and 90.3% (FB2 in plasma). Detection limits were about 50 
ng/ml and relative standard deviations <5%. 
Freeze-dried faecal samples were ground to a powder and fumonisins extracted nine times 
with O.IM ethylenediaminetetraacetic acid (EDTA) (PH 5.2):methanol (4:1). Supernatants 
were combined, acidified to pH 3.1 and an aliquot applied to a CIS cartridge conditioned 
with methanol and then water. After washing with water, methanol:water (1 :3) and (1: 1), 
samples were eluted with methanol. The dried residue was redissolved in methanol prior to 
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derivatisation and HPLC. Extraction recoveries were 90% for FBI and 86.4% for FB2 
(Shephard et al. , 1994A, 1995B). Using this method, Chelule et al. (2000) analysed human 
faecal samples and found FBI in 35% of samples from rural dwellers and in 9% of samples 
from urban dwellers; concentrations ranged from 790 to 19560 ng/g of freeze-dried faeces . 
To improve sensitivity and remove interfering solutes in human urine samples, Shetty & 
Bhat (1998) used an Amberlite XAD-2 non-ionic polymeric resin column prior to the SAX 
column. For 100 ml spiked samples, 10 to 500 ng/ml FBI, recoveries were 93.6% to 94.4%, 
RSD <5% and detection limit <8 ng/ml. Using a commercial immunoaffinity column for 
clean-up, horse serum spiked with FBI was derivatised with FITC and analysed by CZE. 
Recoveries at 100 ng/ml were 76% (range 67.0-85.6%; CV 10.6%) but levels below 100 
ng/ml could not be quantitated because of interference by a component in the unspiked 
serum which had a similar migration time to FB I (Maragos, 1995). 
2.5 TOXIC EFFECTS OF FUMONISINS IN HUMANS 
2.5.1 Oesophageal Cancer 
Maize and maize products are vitally important in the daily diet of humans in Southern 
Africa (Rava et at., 1996). However, fungal infection of maize with production of 
mycotoxins is associated with the risk of oesophageal cancer (OC). Common factors in 
regions with high incidence of OC are mineral poor soil with excessive alkalinity and low 
annual rainfall resulting in stressed plants susceptible to heavy fungal contamination 
(including F moniliforme) with the production of potentially carcinogenic mycotoxins. Also, 
the diet of people living in high risk areas is based on maize or wheat whereas, in low risk 
areas, more nutritious staples like sorghum, millet, cassava and peanuts are consumed (Rose, 
1982; van Rensburg, 1985). 
As early as 1957, in a study done on 104 OC cases from the local Bantu population attending 
the out-patients department of Frere Hospital, East London, it was concluded that the most 
likely reason for the high prevalence of OC was consumption ofthe local brew (cidiviki) 
which was shown to contain both cancer initiators and cancer promoters. Possibly, the rural 
Xhosa in the past had intuitive knowledge of possible deleterious effects of drinking 
home brewed beer. "There is mounting evidence that even the 'raw', rural Xhosa has an 
insight into umhlaza wombiza, 'a sore inside the gullet which never heals'. 
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This affliction is attributed to having drunk, at a stranger's kraal, kaffir-beer which was 
'poisoned' by someone intent upon avenging an old score." (Burrell, 1957). 
In a case-control study of the urban black population of So we to where several risk factors 
were considered, the major possible causes of OC were identified as smoking pipe tobacco 
and consumption of traditional beer brewed from malted sorghum and maize, alcohol 
content about 3%. The risk with drinking large quantities of beer may derive from its poor 
nutritional qualities (decreased B group vitamins) and cancer promoting effects of alcohol 
rather than a direct carcinogen (Segal et ai. , 1988). Dietary deficiencies of zinc, 
molybdenum, selenium, magnesium, riboflavin and nicotinic acid are believed to increase 
susceptibility to carcinogens (van Rensburg, 1985). Deficiencies in molybdenum, zinc, iron, 
copper, and magnesium were found in the soil of areas with a high rate of OC in the 
Transkei (Rose, 1982). 
The strong link between OC and fumonisins is due to the work done at the Programme on 
Mycotoxins and Experimental Carcinogenesis (PROMEC) group studying low (Bizana and 
Lusikisiki) and high (Butterworth and Kentani ) risk areas in the Transkei. Over a period of 
15 years, for people aged 0 to 70 years, the incidence rate was 33 .58/100 000 for males and 
females in Kentani and 2.52/100 000 in Bizana (Rose, 1982; Jaskiewicz et ai., 1987B). 
During 1985 and1986, using brush biopsy capsules, cytological examinations were done on 
adults in 12 households in a low, intermediate and high OC rate area. Mild and advanced 
cellular changes occurred more frequently in occupants of high OC rate households. 
Analysis of samples of both good and mouldy homegrown maize from the same households 
showed a significantly higher prevalence of F. moniliforme (p<0.001) in households whose 
members showed cytological abnormalities (Maras as et ai., 1988B; Rheeder et ai., 1992). 
Significantly higher levels ofFB\ and FB2 were found in healthy maize samples from the 
high OC rate area compared with the low rate area; including some of the highest recorded 
levels from naturally infected maize viz. 117520 ng/g FBI and 22960 ng/g FB2 (Sydenham 
et ai., 1990B; Rheeder et ai., 1992). 
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In China, too, a higher incidence of contamination with fumonisins was found in maize from 
households in a high risk area for human OC compared with a low risk area (Y oshizawa et 
ai., 1994). Strains of F. moniliforme, isolated from mouldy maize from OC regions in China, 
produced various nitrosamines in addition to fumonisins which, with other mycotoxins, are 
probably factors in carcinogenesis (Chu & Li, 1994; Mingxin et ai., 1980). 
A survey of animal epidemiology in high and low risk OC areas in China revealed that the 
incidence of pharyngeal and OC in chickens paralleled the human cancer rate; rats were also 
found with hyperplastic lesions but they are short-lived compared to hens. Attempts to 
induce OC in domestic fowls by nitrosamines were unsuccessful and the conclusion was that 
other factors in both the human and animals' diet were responsible. Could these be the 
fumonisins ? (Mingxin et ai., 1980). Lim et ai. (1996) induced oesophageal cell proliferation 
in rats after a single injection of FBI but no tissue injury. In contrast, Gelderblom et ai. 
(1991) found oesophageal basal cell hyperplasia in rats after feeding them culture material of 
F. moniliforme but administering pure FBI did not cause any oesophageal lesions. 
TABLE 2.9 AVERAGE LEVELS OF FUMONISINS IN MAIZE FROM LOW AND 
IDGH RISK AREAS FOR OESOPHAGEAL CANCER 
Country Area RiskforOC FBI (ng/e) FB2 (ng/e) Reference 
South Butterworth; High 1600 610 Rheeder et al., 
Africa Kentani (good maize) 1992 
High 23900 7550 Rheeder et al., 
.(mouldy maize) 1992 
Bizana; Low 375 83 Rheeder et al., 
Lusikisiki (good maize) 1992 
Low 6520 2500 Rheeder et al., 
(mouldy maize) 1992 
China Cixian; Linxian High 35300 Chu & Li, 1994 
(good maize) 
High 74000 Chu & Li, 1994 
(mouldy maize) 
China Linxian High 872 448 Y oshizawa et al., 
1994 
-0 
Shanqui Low 890 330 Y oshizawa et al., 
1994 




In India in 1995, there was an outbreak of a foodbome disease later traced to being caused 
by consumption of rain affected mouldy sorghum and maize samples infested with F. 
moniliforme and producing FB1. The characteristics of the disease were abdominal pain, 
borborygmi and diarrhoea; the diarrhoea was reproduced in day old cockerels fed 
contaminated grains from affected households. Levels of FB I in affected households were 
0.14 -7.8 mg/kg (sorghum) and 0.25 - 64.7 mg/kg (maize) and in unaffected households 
were 0.07 - 0.36 mg/kg (sorghum) and 0.05 - 0.24 mglkg (maize). The disease was self 
limiting and symptoms ceased when non-mouldy grain was eaten. Thus, fumonisins can 
cause gastrointestinal effects in humans as well as their association with OC (Bhat et ai., 
1997). 
2.6 TOXIC EFFECTS OF FUMONISINS IN ANIMALS AND PLANTS 
2.6.1 Rodents 
Marasas et ai., (1984) fed freeze- or oven-dried culture material of F. moniliforme MRC 826 
to male BD IX rats in a life-long feeding experiment. Hepatotoxicity and 100% mortality 
occurred at a level of 8%; levels of 4% (later reduced to 2%) caused hepatocellular and 
ductular liver carcinomas - the incidence of carcinomas increased with time. 
Using a short-term cancer initiation-promotion bioassay in rats as the monitoring system, the 
cancer-promoting compounds were isolated viz. the fumonisin mycotoxins. The bioassay 
was checked using purified FBI (0.1 %) which caused a marked reduction in weight gain, 
induction of y-glutamyl transferase (GGT) positive foci and toxic hepatitis (Gelderblom et 
ai., 1988). Elevated serum enzyme activities [alanine transaminase (ALT), aspartate 
transaminase (AST), alkaline phosphatase (ALP)] and microscopic liver lesions (indicating 
liver damage) were found after feeding rats aqueous and chloroform! methanol extracts of F 
moniliforme MRC 826. Toxic diets had concentrations of93 - 139 ppm (FB}) and 82 - 147 
ppm (FB2); non-toxic ~ 22 ppm (FBI) and ~ 65 ppm (FB2) (Voss et ai., 1990). 
After the development of methods to purify fumonisins, several authors administered the 
mycotoxins themselves rather than culture material extracts either in the rats' diets or by 
injection which rapidly induces hepato-and nephrotoxicity (Bondy et ai., 1995). 
A variety of symptoms of fumonisin toxicity in rats have been recorded (Table 2.10). 
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TABLE 2.10 LEVELS OF FUMONISINS FED TO RATS AND TOXIC EFFECTS 
Fumonisin BL Toxic Effect Reference 
50 mg/kg diet t AST, GGT, creatinine, conjugated bilirubin Gelderblom et 
for 26 months macro- and micro nodular cirrhosis, al., 1991 
cholangiofibrosis, hepatic carcinoma 
chronic interstitial nephritis 
0, 15, 50, 150 ppm ().tg/g or t ALT, ALP, triglycerides, cholesterol Voss et al., 
mg/kg) diet for 4 weeks t sphingolipids, free Sa 1993 
NOEL < 15 ppm -l-kidney weight Riley et ai., 
microscopic liver lesions 1994 
nephrosis Voss et ai., 
1995A 
7.5 or 10 mg/kg injected -l- body, kidney, liver, spleen, thymus weights, Bondy et ai., 
intraperitoneally for 4 days food consumption 1995 
-l- glucose, amylase 
t urine volume, relative brain weights, ALT, 
AST, cholesterol, calcium, total protein, albumin, 
globulins, urea, erythrocytes, haemoglobin 
Lesions in liver kidney, thymus 
7.5 or 10 mg/kg injected -l- food intake, body weight, absolute kidney Suzuki et al., 
peritoneally for 4 days weight, urine osmolality 1995 
t urine volume, urine proteins, urine GGT, LDH, 
NAG 
0, 1,3,9,27,81 ppm diet for -l- kidney weight Voss et al., 
13 weeks t serum creatinine 1995B 
NOEL 3 ppm (mice 27 ppm) microscopic kidney lesions 
0, 1.25 mglkg injected t cholesterol, urea -l- glutathione (hepatic and Lim et ai., 
intravenously renal) 1996 
Cell proliferation, apoptosis and necrosis in 
kidney outer medulla 
Cell~oliferation in liver and oeso~ha~us 
0, 15,50, 150 ppm diet for t serum creatinine, free Sa and Sa/So ratio in liver Voss et ai., 
28 days and kidney 1996B 
NOEL for hepatotoxicity in -l- kidney wt., tC02 
rats is 163 ppm (F); 
234 ppm (M) 
Kidney lesions (liver lesions only at 150 ppm) 
0, 1, 10,55 ppm diet for 18 t ALT, AST, ALP, urea, creatinine, bilirubin, Voss et al., 
weeks cholesterol 1996C 
-l- tC02, body weight gain, liver and kidney 
weights 
Mild renal lesions 
50, 100,250 mg/kg diet for t cholesterol (liver & serum), Gelderblom et 
21 days phosphatidylethanolamine (liver) al., 1997 
-l- sphingomyelin Jliveu 
1, 10,25 mglkg diet fed for 2 t phosphatidylethanolamine (liver) Gelderblom et 
years al., 1997 
69.3 ).tmol/kg diet fed for 4 t cholesterol, ALT, prostaglandins (PGF2o. , Lu et al., 1997 
weeks PGE2) 
GGT- and PGST- positive hepatic foci 
-l- NK cell activity, body weight 
(Key to Table 2.10 is on the next page). 
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Key to Table 2.10 
i increase 
LDH lactate dehydrogenase 
NK natural killer 
PGST placental glutathione S-transferase 
t decrease 
NAG N-acetyl-(3-D-glucosaminidase 
NOEL no observed effect level 
tC02 total serum carbon dioxide 
Decreased food intake and body weight gain, decreased organ weights (absolute/relative), 
increased free Sa and Sa/So ratio in urine, serum, liver and kidney indicate exposure to 
fumonisins (Voss et al., 1993, 1995A, 1996B; Riley et al., 1994). Increased bilirubin, AST, 
ALT, GGT, cholesterol, triglycerides, and microscopic liver lesions to cirrhosis, carcinoma 
indicate hepatotoxicity (Gelderblom et al., 1991; Voss et al., 1993). Increased excretion of 
high molecular weight proteins, enzymuria [GGT, lactate dehydrogenase (LDH), N-acetyl-~­
D-glucosaminidase (NAG)], increased creatinine and urea, increased urine volume and 
decreased osmolality, nephrosis, microscopic kidney lesions, apoptosis and necrosis in outer 
medulla indicate nephrotoxic effects (Suzuki et al., 1995; Bondy et aI., 1995; Voss et al., 
1995B, 1996B, 1996C; Lim et al., 1996; Lu et al., 1997). 
Nephrotoxic effects in rats occur at lower concentrations of FBI than hepatotoxic effects. 
(Lim et al., 1996; Voss et al., 1996B). There was also a sex-related difference; no observed 
effect level (NOEL) for nephrotoxicity was 27 ppm for female rats but 3 ppm for males; 
hepatotoxicity 163 ppm for females but 234 ppm for males (Voss et al., 1995B, 1996B). 
Fumonisin BI causes alterations in the phospholipids (sphingomyelin, phosphatidylcholine, 
phosphatidyl-ethanolamine) and their fatty acid components in the blood and liver of rats. 
The actual effects depend on the level and duration of treatment with FBI; changes in lipid 
biosynthesis may be mediators of hepatic effects offumonisin BI (Gelderblom et al., 1997). 
Mice are less sensitive to FBI than rats. Feeding various concentrations of FBI to both rats and 
mice, Voss et al. (1995B, 1996B) found significant interspecies differences in that mice showed 
mild hepatic injury while rats showed minimal to mild nephrosis. After feeding mice 1 to 75 mg 
FBJ/kg body weight /day for14 days, Bondy et al. (1997) found increased serum cholesterol 
and AL T, single cell necrosis, mitosis and anisokaryosis in the liver and minor 
histopathological changes in the kidneys of females. 
To investigate the effects of FB2 and FB3, Voss et al. (1998B) used culture material from a 
strain of F. rnoniliforrne that did not produce FBI. The toxicological and histopathological 
effects were similar to FB J viz. decreased body weight gains and kidney weights, increased 
serum liver function test results, increased Sa/So ratios, and apoptosis of hepatocytes and 
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epithelium in kidney tubules. Some animals, after being fed the control diet (no fumonisins) 
for a further 3 weeks, showed almost complete recovery from these effects. 
2.6.2 Equidae 
Equine leukoencephalomalacia (ELEM) is a neurotoxic disease characterised by liquefactive 
necrosis of white matter in one or both cerebral hemisheres, associated with consumption of 
mouldy maize contaminated with F. moniliforme (Badiali et ai., 1968; Wilson & Maronpot, 
1971; Kellerman et ai., 1972; Buck et ai., 1979; Kriek et ai., 1981; Meireles et at., 1994). In 
a breakthrough study, Marasas et ai. (1988A) provided experimental evidence that FBI was 
the causative agent of ELEM. Dosing two horses with culture material of F. moniliforme 
MRC 826 caused brain oedema and hepatosis. 
After extracting and purifying FBI from the culture material, it was injected into a horse 
(0.125 mg FBI/ kg body weight! day for 7 days) and caused symptoms typical ofELEM viz. 
apathy, nervousness, a wide-based staring stance, shuffling gait, inco-ordination and 
bumping into objects, trembling, ataxia, reluctance to move, paresis of the lower lip and 
tongue, inability to eat or drink with principal lesions being severe oedema of the brain and 
focal necrosis in the medulla oblongata. Other authors confirmed these findings (Wilson et 
ai., 1990; Kellerman et ai., 1990; Ross et ai., 1991A,1991B; Thiel et ai., 1991B; Wilkins et 
ai., 1994). After this discovery, levels offumonisins associated with field outbreaks of 
ELEM were recorded by several authors; others did studies on the amounts of FBI 
administered to induce ELEM (Tables 2.11 and 2.12). 
TABLE 2.11 CONCENTRATIONS OF FUMONISINS IN FEEDS ASSOCIATED 
WITH OUTBREAKS OF EQUINE LEUKOENCEPHALOMALACIA 
Feed (number of samples) Location Concentration of Reference 
fumonisin (u!!/!!) 
White maize (3) Arizona FBI: 37 - 122 Wilson et al., 1990 
FB2· detected 
Maize, screenings, sweet USA FB2 : <1 - 126 Ross et al., 1991A, 1991B 
feeds, commercial pellets (45 
and 98) 
Maize and commercial feed Southeastern FB!: 1.3 - 27 Thiel et al., 1991B; 
(14) USA FB2: 0.1 - 12,6 Sydenham et al., 1992 
FB3: 0 - 2.65 




TABLE 2.12 CONCENTRATIONS OF FUMONISIN BI CAUSING EQUINE 
LEUKOENCEPHALO~AC~ 
Concentration of FBI Duration Number of animals Reference 
administered Positiverrotal 
29.7 mg/kg body wt. 33 days 111 Kellerman et ai., 
42.1 mg/kg body wt. 29 days 111 1990 
< 1 - 22 ppm feed 225 days 1/4 Wilson et ai., 1992 
8 ppm (mg/kg feed) 180 davs 5/5 
Fumonisins can cause ELEM or hepatotoxicosis depending on the dose; effects are time and 
concentration dependent. Abnormal blood parameters are elevations in total bilirubin, AST, 
GGT and total protein (Kellerman et al., 1990; Wilkins et al., 1994). 
Riley et al. (1997) found that FB2 was able to induce symptoms ofELEM in ponies but FB3 
did not even though both caused changes in sphingolipids. It has been hypothesised that 
disruption of sphingolipid metabolism is linked with development of ELEM. 
2.6.3 Pigs 
In pigs, consumption of feed contaminated with fumonsins is associated with PPE. 
Symptoms ofPPE include acute onset of dyspnea, lethargy, weakness, increased respiratory 
rate, cyanosis and death; abortions; concurrent hydrothorax and pulmonary oedema (and in 
some cases icterus). Concentrations offumonisins in feed associated with outbreaks ofPPE 
ranged from 7 to 330 J.lg/g while feed from control farms showed very low or undetectable 
levels. The risk ofPPE increased as the concentration offumonisins increased; farms with 
~ 20 ppm fumonisins were at increased risk (Ross et ai., 1991B; Bane et al., 1992; Osweiler 
et al., 1992). 
Injecting pigs intravenously with FBI or feeding them naturally or artificially contaminated 
com screenings, caused decreased feed consumption, increased total bilirubin, cholesterol 
and liver enzymes (GGT, ALP, ALT, AST, arginase); mild to severe respiratory distress and 
interstitial pulmonary oedema with increased respiration rate and marked cyanosis as well as 
hepatic changes - disorganisation and necrosis of hepatocytes, loss of sinusoidal microvilli; 
pancreatic acinar cell degradation and the presence of membranous material in hepatic 
sinusoids and pUlmonary intravascular macrophages. Increased free Sa and Sa/So ratios in 
the liver, lung and kidney before histopathological or serum biochemistry changes were 
observed. The hypothesis is that fumonisins cause altered sphingolipid metabolism, which 
damages the liver resulting in release of membranous material into the circulation. 
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This is phagocytosed by pulmonary macro phages triggering the release of mediators 
resulting in pulmonary oedema. (Haschek et al., 1992; Osweiler et al., 1992; Colvin et al., 
1993; Riley et ai., 1993; Motelin et ai., 1994). 
Since pulmonary oedema can be caused by congestive heart failure due to increased 
capillary pressure (Colvin et al., 1993), investigations of cardiovascular function were done. 
Pigs fed culture material containing ~ 20 mg/kg fumonisins daily for 7 days showed a 
significant increase in mean pulmonary artery pressure, decreased heart rate, cardiac output 
and decreases in both arterial and mixed venous oxygen tension but the electrocardiograph 
(ECG) was normal. (Smith et al., 1996A, 1996B). 
At lower doses (23 - 101 ppm or <16 mg FBI/kg/day by intubation or 200 mg FBI/ kg feed), 
the effect was of hepatic disease while at higher doses (175 ppm or >16 mg FBI/kg/day by 
intubation) acute pulmonary oedema occurred. In some cases of liver failure, mild to 
moderate renal tubular necrosis occurred; reversibility of the hepatotoxic effects was also 
observed (Colvin et ai., 1993; Becker et al., 1995). The NOEL for elevation of free Sa was 
1- 10 ppm feed; based on liver enzymes was <12 ppm; based on liver histopathology was 
< 23 ppm and pulmonary oedema at 175 ppm. (Motelin et al., 1994; Rotter et al., 1996). 
These are within the range of FBI concentrations found in swine feed . 
2.6.4 Poultry 
Overall, poultry appear to be less susceptible to toxic effects of fumonisins than other 
animals. Day-old broiler chicks fed diets containing 100 to 400 or 75 to 525 mg FB1/kg feed 
for 14 to 21 days showed gross effects of diarrhoea, significant decreases in body weights 
and average daily gain (or feed conversion) and increases in relative weights ofliver, 
kidney, gizzard and proventriculus. Biliary hyperplasia, multifocal hepatic necrosis, muscle 
necrosis, intestinal goblet-cell hyperplasia and rickets occurred (Brown et al., 1992; Ledoux 
et ai., 1992; Weibking et al., 1993; Espada et al., 1994). 
Measured blood parameters showed increases in serum calcium, cholesterol, AST, GGT, 
LDH, creatine kinase (CK) but a decrease in triglycerides, uric acid and ALP (Ledoux et al., 
1992; Espada et al., 1994). Mean cell haemoglobin, free Sa and SaiSo ratio (at 75 mg FBI/kg 
feed) increased (Weibking et al., 1993). Other workers found cytotoxic effects on 
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lymphocytes and erythrocytes (poikilocytosis) after feeding rations with fumonisins and 
moniliformin - possibly an additive or synergistic effect (Dombrink-Kurtzman et ai., 1993). 
The higher the dose and/or the longer the feeding schedule, the more severe the effect. 
Lowest toxic doses are 10 mg/kg feed of pure FBI and 30 mg /kg of F. moniliforme culture 
material (Espada et ai., 1994). However, feeding lower levels (4 mg FBI/kg feed) to laying 
hens for 28 days resulted in no significant lesions (Vudathala et ai., 1994). Inoculation of 
fertile eggs with pure FBI or culture material caused 50 tol00% mortality, which was time 
and dose dependent. (Javed et ai., 1993). Zacharias et ai. (1996) found a dose and time 
dependent correlation between the amount of fumonisins injected into the yolk sac and an 
increase in the ratio of Sa/So at levels of FBI >72Ilg/egg for three or more days. 
An outbreak of an unusual disease in laying hens characterised by diarrhoea, severe 
reduction of food intake, body weight and egg production with 10% mortality was concluded 
to have occurred due to the FBI (5.2 to 8.5 mg/kg) in the diet. Livers of affected hens were 
pale yellow with peripheral congestion, mild haemorrhage in the proventriculus and watery 
accumulations in the intestine; withdrawal of the contaminated diet resulted in a return to 
normal (Prathapkumar et ai., 1997). 
Effects on turkey poults were also dose-dependent and similar to those on broiler chicks i.e. 
decreases in feed intake and body weight gains but increases in liver and pancreas weights 
and SaiSo ratios (~25 mg FBI/kg diet). Hepatocellular (all levels of FBI, 25 to 475 mg/kg 
diet) and biliary (150 to 300 mg FBI/kg diet) hyperplasia was evident (Weibking et al., 
1995; Kubena et ai., 1995, 1997; Ledoux et ai., 1996). 
2.6.5 Other Animals 
Diverse effects of fumonisins have been found in other animal species. Baboons fed culture 
material of F. moniliforme developed acute congestive heart failure and hepatic cirrhosis 
(Kriek et ai., 1981). Vervet monkeys developed hepatitis as shown by increased liver 
enzymes and histopathological changes (Jaskiewicz et al., 1987A). Monkeys fed a low fat 
carbohydrate diet plus added fumonisins developed an atherogenic lipid profile [increased 
cholesterol, low density lipoprotein (LDL)-cholesterol, apoprotein B, enzymes (AST, ALT, 
GGT, ALP), albumin, factor VII and fibrinogen] probably secondary to chronic liver toxicity 
(Fincham et al., 1992). 
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Of all animals cattle seem to be the least affected by fumonisins. After consuming diets 
containing fumonisins (148 or 400 Ilg/g FBI; 130 Ilg/g FB2) for 30 days they showed some 
signs ofhepatobiliary change (increased cholesterol, bilirubin and enzymes) but no change 
in feed intake, body weights or temperature. However, the animals were languid and visibly 
distressed and ate their food sluggishly (Osweiler et al., 1993; Smith & Thakur, 1996). 
As in equidae, fumonisins caused central nervous system changes in rabbits. Doses of 1.75 
mg/kg/day diet resulted in leukoencephalomalacia and haemorrhage in the brains of pregnant 
rabbits; hepatic and renal changes (predominantly apoptosis) were also observed (Bucci et 
al., 1996). Orally dosed culture material with total fumonisins 11.1 to 45.5 mglkg body 
weight caused hepato- and nephro-toxicity in lambs (Edrington et al., 1995). Liver and 
kidney abnormalities were also found in mink (Restum et al., 1995) and channel catfish 
(Lumlertdacha et al., 1995). 
2.6.6 Plants 
Fumonisins are phytotoxic causing mosaic like patterns on leaves and inhibiting growth; 
higher concentrations caused plants to wilt and die. Other effects were electrolyte leakage, 
autolysis and photo degradation of chlorophyll; effects were light and concentration 
dependent. The A series were less toxic; the TeA groups seem to be necessary for herbicidal 
activity (Abbas etal., 1991, 1992A, 1992B, 1993; Tanakaetal., 1993). Additionofa100 
ppm solution of FBI to germinating maize kernels inhibited radicle elongation of the maize 
seedlings by up to 75%. The mechanism appears to involve inhibition of amylases in the 
endosperm (Doehlert et al., 1994). 
2.7 TOXIC MECHANISMS 
2.7.1 Carcinogenic 
As shown by Lim et al. (1996) fumonisins can cause both cell proliferation and apoptosis in 
vivo; these two are key elements in carcinogenesis of nongenotoxic substances. Fumonisin 
BI also induced development of primary hepatocellular carcinoma and positive GGT and 
PSGT foci in rat liver proving it is a complete carcinogen (Gelderblom et al., 1991,1996A; 
Lu et al., 1997). Fumonisin B I is a poor cancer initiator: but is not genotoxic. Its cancer-
initiating ability is dependent on both dosage and duration of exposure and a balance exists 
between compensatory cell proliferation due to hepatotoxicity and inhibition of cell growth 
i.e. a critical dosage level exists for cancer initiation. An intact molecule and the presence of 
34 
a free amino group are required for cancer initiation. Cancer promotion (10 - 50 mg/kg diet) 
occurs at lower levels than initiation (100 - 250 mg/kg) and hepatotoxicity (Gelderblom et 
at., 1992A, 1993, 1994, 1996A). 
In studies of the mechanism of inhibition of cell proliferation in vitro, concentrations of 150 
to 300 IlM FBI for 44 hr in primary rat hepatocytes caused up to 90% inhibition of epidermal 
growth factor-induced DNA synthesis. Fumonisin B\ exerted its mitoinhibitory effect during 
late GI phase andlor during S-phase at levels below those causing cytotoxicity; removal of 
FBI reversed the effect. (Ge1derblom et at., 1993, 1995, 1996A). 
2.7.2 Sphingolipids 
Sphingolipids are found in cellular and subcellular membranes of animals, plants and some 
lower eukaryotes e.g. yeast. The term sphingolipid covers the biochemical entities of 
sphingomyelins and glycosphingolipids (cerebrosides and gangliosides); all of which are 
derivatives of the base So. Sphingosine has a double bond between C-4 and C-5; Sa is 
dihydro-sphingosine; ceramides are precursors of sphingolipids. Fumonisins are structurally 
similar to the sphingoid bases (Figure 2.1). 
Synthetic pathways are as follows: 
(1) Palmitoyl-SCoA + Serine ~ 3-Ketosphinganine ~ Sphinganine + CoA-SH + CO2 
(2) Sphinganine + NADP+ ~ Sphingosine + NADPH + W 
(3) Sphinganine/sphingosine + RCO-SCoA ~ Dihydroceramide/ceramide + CoA-SH 
Reaction (3) is catalysed by the enzyme ceramide synthase (sphinganine/sphingosine N-acyl 
transferase) which catalyses the addition of a fatty acid to the sphingoid base as part of the 
de novo synthesis of sphingolipids or in the re-acylation of long-chain bases from turnover of 
complex sphingolipids. Dietary sphingolipids are broken down to So and ceramides which 
may be absorbed or remain in the gastrointestinal tract; So and Sa are lipid soluble so can 
readily cross cell membranes and be found in the plasma or urine. 
Sphingolipids are of crucial biological significance. Their functions include structural 
components of membranes giving rigidity (with cholesterol); regulation of normal cell 
growth and differentiation; increase intracellular calcium; possibly mediators in apoptosis; 
inhibitors/ activators of protein kinase C and other kinases/phosphatases and are responsible 
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for cell-cell and cell-matrix interactions with bioactive substances such as bacterial toxins, 
glycoprotein hormones, interferons, viruses (Bohinski, 1987; Yoo et ai., 1992; Merrill et ai., 
1995B, 1996). 
High performance liquid chromatography methods using OP A derivatives have been 
developed and optimised for measuring free So and free Sa as well as total sphingolipids in 
serum, urine, kidney and liver of rats. Complex sphingolipids were estimated as total minus 
free bases (Merrill et ai.) 1988; Riley et al., 1994). Since these methods are time-consuming 
and labour intensive, rapid methods which reduced the number of steps in extraction and 
clean-up; and also improved precision and accuracy were developed for analysis of Sa and 
Soin cell cultures and serum (Yoo et ai., 1996B; Solfrizzo et ai., 1997; Castegnaro et at., 
1998). 
Cell culture is a useful technique for studying the toxic effects of mycotoxins. Several 
workers using different cell lines investigated the effect of fumonisins on sphingolipids. In 
all cases, it was found that FB1, even at levels as low as 1J.LM, inhibited ceramide synthase 
resulting in increased levels of free Sa and increased ratio of SaiSo. (Appendix 1, Table 
2.13). The implications of cell culture studies are that toxic effects of fumonisins may occur 
by disrupting sphingolipid biosynthesis which affects the rigidity and function of cell 
membranes; this disruption may be a critical event in the toxicity of fumonisins. However, 
the effects of fumonisins were reversible as, after removal of the toxin, cells showed normal 
growth and morphology. 
Experiments using p-chloroaniline, an inhibitor of serine palmitoyl transferase, only partially 
prevented the effects of fumonisin on cell growth and death because it exacerbated the 
depletion of more complex sphingolipids (Yoo et at., 1996A). Working with Swiss 3T3 
fibroblasts, Schroeder et at., (1994) concluded that fumonisin Bl stimulates DNA synthesis 
by disruption of sphingolipid metabolism and accumulation of sphingoid bases to a critical 
concentration for mitogenesis. Thus both increased sphinganine concentrations and 
decreased complex sphingolipid concentrations contribute to the cytotoxicity of FB1 but the 
actual intracellular concentration of Sa, which is cytotoxic, has not been established in vivo 
(Voss et at., 1996B). 
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The effects of FB2, FB3 and FB4 were found to be similar to FB1 but hydrolysed fumonisins 
lacking the TCA side chains, were l~ss effective inhibitors while N-acetylated FB1 did not 
block ceramide synthase (Norred et ai. , 1992, 1997). In contrast, Voss et ai. , (1998A) 
showed HFBI had the same effects as FBI on sphingolipid metabolism in vivo in rats. 
Measurement of sphingoid bases can be used as a biomarker for exposure to fumonisins as 
the changes in sphingolipids occurred before other markers e.g. elevation of serum liver 
enzymes or changes in tissue morphology (Wang et ai., 1992; Riley et ai., 1993, 1997; Voss 
et ai., 1995A, 1996B,1998A). Because of a significant correlation between the Sa/So ratio 
and the number of cells in the urine, Voss et ai. (1996B) suggested using urine samples to 
check for recent or ongoing exposure to fumonisins. 
Increased levels of free Sa and an increase in the ratio Sa/So was found in various animals 
and tissues; serum of ponies fed diets with FBI (15 - 44 Jlg/g), FB2 and FB3 (Wang et ai. , 
1992; Riley et ai., 1997); serum, liver, lung and kidney of pigs fed FB1 and FB2 (5 - 23 Jlg/g 
diet) (Riley et ai., 1993); urine, serum, liver and kidney of rats fed FB1 (15-150 Jlglg diet, 8-
71 Jlglg) (Riley et ai., 1994; Voss et ai., 1995A, 1996B, 1998A) and brain (FB1 0.8 
mglkglday) (Kwon et ai., 1997 A, 1997B); also precision-cut liver (0.1 JlM) and kidney slices 
(1 JlM) (Norred et ai., 1996). Also in serum of turkey poults and day old broiler chicks fed 
FB1 (75 Jlglg diet) (Weibking et ai., 1993, 1995). 
2.7.3 Other Mechanisms 
Although disruption of sphingolipid metabolism appears to be the major route of fumonisin 
action at a molecular level, how this translates into its toxic and carcinogenic effects is not 
clear. Workers have investigated the influence offumonisins on various enzymes and 
proteins but whether the effect is directly due to fumonisins or due to increased 
concentrations of sphingoid bases alone or in conjunction with fumonisins is not known. The 
results of several experiments are summarised below. 
Fumonisin BI may alter signal transduction pathways since it inhibits protein kin,se C 
(PKC) activity in monkey kidney CV -1 cells but stimulates transient and rapid activation of 
mitogen-activated protein kinase in Swiss 3T3 fibroblasts. Sphingosine is a potent 
inhibitor ofPKC which phosphorylates nuclear proteins (Huang et ai., 1995; Wattenberg et 
ai., 1996). By inhibiting dephosphorylation of the enzymes, FBI inhibited five protein 
serine/threonine phosphatases. 
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It is postulated this leads to genetic alterations (Fukuda et ai., 1996). Fumonisins and 
sphingoid bases interacted differently with GTP-binding proteins in rat brain plasma 
membranes and bovine retina rod outer segments. The binding was calcium dependent which 
suggests a role of calmodulin-calcium in the interactions. (Ho et al., 1996). In monkey 
kidney CV -1 cells but not monkey kidney COS-7 cells, FB1 affected cell-cycle regulatory 
proteins (Ciacci-Zanella et al., 1998). 
Fumonisin is mitogenic or inhibitory to cell proliferation i.e. can cause stimulation or 
inhibition of DNA synthesis, as has been shown both in vivo and in vitro. The presence of 
insulin augments stimulation of DNA synthesis in Swiss 3T3 cells both by fumonisin as well 
as by Sa and So. This led Schroeder et ai. (1994) to postulate that mitogenesis is due to 
direct action of the sphingoid bases whose intracellular concentration has been increased by 
the action of fumonisin. The bases might act via inhibition of PKC or phosphatidic acid 
phosphohydrolase or NaIK-ATPase or activation of epidermal growth factor receptor kinase 
or other protein kinases (Schroeder et ai., 1994; Lim et al., 1996). 
Fumonisins can affect lipid biosynthesis and alter the pattern and types of lipids produced in 
vivo in livers of rats. Gelderblom et al. (1997) found serum cholesterol and liver cholesterol 
and phosphatidylethanolamine were increased; liver sphingomyelin was decreased and there 
were changes in the types of fatty acids synthesised. Alterations in the lipids of yeast cells 
appear to be mediated by sphingoid bases as these inhibited key enzymes in the lipid 
biosynthetic pathways (Wu et al., 1995). 
2.8 ABSORPTION AND EXCRETION 
Since it is known that consumption of feed contaminated with fumonisins causes effects at 
molecular levels, fumonisins must be absorbed and excreted. Cytotoxicity studies led 
Gelderblom et ai., (1993) to surmise that the TCA moiety is needed for absorption of 
fumonisins; and the biological activities of the fumonisins depends on their polarity, the 
presence/absence of a free amino group and possibly the specific location of a hydroxyl 
group. In studies using a variety of animals and feeding them unlabelled or radiolabelled FB1 
(or FB2) the toxicokinetics were investigated (Tables 2.14 and 2.15). 
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In rats FB1 was rapidly absorbed after intraperitoneal injection, with rapid equilibrium of 
FB1 between body tissues and rapid elimination from plasma via the bile (67% of the total 
dose); 88% of the bile excretion occurred in the first 4 hr persisting for up to 24 hr. Oral 
dosing resulted in far less of the toxin appearing in the urine which implies either poor 
absorption from the gut or excretion of FBI by the liver (biliary) as a first pass effect. 
Most of the FB1 was excreted in faeces and urine within 24 hr with no major retention in the 
tissues (Table 2.14). .~ -. 
The recovered FB1 was unmetabolised; it seemed that after oral administration there was 
little enterohepatic circulation. In male BD IX rats excretion followed first order kinetics; the 
calculated tYl was18 min for FBI and 26 min for FB2. The toxicokinetics ofFB2 were similar 
to FBI - both were cleared rapidly after intraperitoneal injection; the FB2 recovered was 
unmetabolised (Shephard et al., 1992A, 1992C, 1994B, 1995A, 1995B). After intragastric 
dosing to fasting rats, Norred et al. (1993) concluded that FBI was absorbed from the gut 
and was retained in target tissues (liver and kidney) possibly by binding to an enzyme 
(perhaps cerami de transferase). 
Unlike rats, after intravenous injection of unlabelled FBI to vervet monkeys, both 
unmetabolised (11.7% and 19%) and partially hydrolysed (27.4% and 9.6%) FBI was 
recovered in the faeces «0.1 % as the aminopentol) and only unmetabolised FBI in the urine. 
The tYl was 40 min. Seventy-two hours after oral administration, most of the labelled FBI 
was found in the faeces as both unmetabolised (35.2% and 39.2%) and partially (27.1 % and 
27.8%) and fully hydrolysed FBI (Table 2.15). The partially hydrolysed FBI was an 
equilibrium mixture of the two mono-esters and was formed either in the liver (biliary 
excretion) or by intestinal enzymes or micro-organisms. After oral dosing only 76% of total 
radioactivity could be accounted for; and after intravenous injection < 50%.(Shephard et ai., 
1994A, 1994C). 
In swine, after intravenous injection of radio labelled FBI (total recovery 79.5% to 88.4%), 
large amounts were recovered in the bile of cannulated animals but for others excretion was 
mainly via the faeces. The calculated half-lives were t~a 2.2 min for initial phase; t~~ 10.5 
min for distribution phase; and t~y 182.6 min for elimination phase. After intragastric 
dosing, (total recovery 91.4% to 91.7%), most of the FBI was excreted in the faeces and only 
a small amount in the bile of cannulated pigs. 
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The authors concluded that although FBI has poor oral availability, a fraction was absorbed, 
distributed and remained in the tissues for an extended period despite enterohepatic cycling. 
The implications are that FB I may accumulate in the tissues if consumed over a period of 
time (Prelusky et al., 1994) (Table 2.15). 
TABLE 2.14 EXCRETION OF FUMONISIN B1/FUMONISIN B2 IN RATS 
Animal Route of administration Recovery Reference 
ofFBI/FB~_ 
Male BD IX rats Intraperitoneal injection, Urine 16.6% (24 hr) Shephard et al., 
Unlabelled FBI Urine 15.3%J48 hr) 1992A 
Male BD IX rats Oral (gavage), Urine <0.4% (24 hr) Shephard et al., 
Unlabelled FBI 1992A 
Male BD IX rats Intraperitoneal injection, Faeces 66% (24 hr) Shephard et al., 
14C_FBI Urine 32% (24 hr) 1992C 
Liver l± 0.4% (24 hr) 
Kidney, erythrocytes <1 % 
Plasma heart brain <0.5% 
Male BD IX rats Gavage, 14C_FBI Faeces 101% Shephard et al., 
1992C 
Male Sprague- Intragastric (stomach Faeces 80% (48 hr) Norred et al., 
Dawley rats tube), 14C_FBI Urine 2 - 3% (24 hr) 1993 
Liver 0.5% (4 hr) 
Liver, blood, kidney - trace 
(96 hr) 
Male Sprague- Intravenous (tail vein) Faeces 35% Norred et al., 
Dawley rats . . . 14C FB Urine 10% 1993 InJection, - 1 
Plasma 2% (96 hr) 
Liver 25% (96 hr) 
Kidney 10 - 12% (96 hr) 
Male Wistar rats Intraperitoneal injection, Bile 67% (24 hr) Shephard et al., 
14C_FB\ 1994B 
Male Wistar rats Gavage, 14C_FB\ Bile 0.2% (24 hr) Shephard et al., 
1994B 
Male BD IX rats Intraperitoneal injection, Faeces 84.1 % (24 hr) Shephard et al., 
Unlabelled FB2 Urine 1.2% (24 hr) 1995A, 1995B 
Plasma - undetectable (24 
and 72 hr) 
Male BD IX rats Oral (gavage), Urine - trace (24 hr) Shephard et al., 
Unlabelled FB2 Plasma - undetectable 1995A, 1995B 
(detection limit 20 ng/ml) 
Male BD IX rats Gavage, 14C-FB2 Faeces 98.9% Shephard et al., 
Urine 1% 1995A 1995B 
Pregnant female Intravenous injection Gastro-intestinal tissues and Voss et al., 
Sprague-Dawley (dorsal metatarsal vein), contents 45% (1 hr) 1996C 
rats 14C-FBl Blood 1.2% (l hr) 
Liver 14.5% (l hr) 
Kidney 4% (1 hr) 
Uterus 0.24 - 0.44% (1 hr) 
Placenta 0.13 - 0.22% (1 hr) 
Fetuses;S; 0.01% (1 hr) 
Skin, fat, skeletal muscle -
variable but high 
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TABLE 2.15 EXCRETION OF FUMONISIN Bl IN VARIOUS ANIMALS 
Animal Route of administration Recovery Reference 
of FBI 
Pigs (Yorkshire Intravenous injection Faeces 58.3% (72 hr) Prelusky et al., 
barrows) (jugular veiIll;_ 14C_FB~ Urine 21.2%J..72 hd. 1994 
Pigs (Yorkshire As above but gall bladder Faeces 1.5% (72 hr) Prelusky et a!. , 
barrows) cannulated Urine 16.2% (72 hr) 1994 
Bile 70.8% (72 hr) 
Liver 10% (72 hr) 
Kidney <1 % (72 hr) 
Muscle 6.5%J72 hr. 
Pigs (Yorkshire Intragastric; 14C-FBI Faeces 90.8% (72 hr) Prelusky et al., 
barrows) Urine 0.6% (72 hr) 1994 
Pigs (Yorkshire As above but gall bladder Faeces 89.8% (72 hr) Prelusky et al., 
barrows) cannulated Urine 0.4 - 12% (72 hr) 1994 
Bile 0.7 - 1.7%J72 htl 
White Leghorn Oral (crop intubation); Excreta (faeces and urine) Vudathala et al., 
laying hens 14C_FBI 96.6% 1994 
White Leghorn Intravenous (wing vein); Excreta (faeces and urine) Vudathala et a!., 
!ayinghens 14C_FBI 98.6% 1994 
Holstein steers Feeding for 30 d Faeces ~ 80% Smith & Thakur, 
(Detection limit 30 ng/ml) Urine trace 1996 
Blood 0.005% (30 min) 
Liver 2 100 ng/g 
Kidneys 23.4 ng/g 
Muscle 97 ng/g 
Two female vervet Intravenous injection; Faeces (72.6%; 72.0%) Shephard et a!., 
monkeys Unlabelled FBI Urine (5.9%' 20.3o/~ 1994A--,- 1994C 
Two female vervet Gavage; 14C-FBI Faeces 61 % (3 d) Shephard et al., 
monkeys Urine 1.2% (3 d) 1994A, 1994C 
Bile 0.1% 
Contents of intestine 12% 
Liver 0.4% 
Skeletal muscle 1 % 
Bile, plasma, kidney, 
heart, erythrocytes, 0.1 % 
each 
Brain 0.2% 
After both oral dosing and intravenous injection oflaying hens, most of the FBI was found 
in the excreta (faeces and urine). The pharmacokinetic parameters (tYza. 2.5 min for 
distribution; and tYz~ 48.8 min for elimination) indicated limited systemic absorption and 
poor but rapid distribution and clearance from the plasma (only trace levels detected 3 hr 
after dosing). Most of the toxin was excreted between 2 - 6 hr post dosing and 92 - 104% 
was eliminated after 24 hr. In contrast to other animals tissue residues were low (Vudathala 
et al., 1994) (Table 2.15). 
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As with other animals most of the FB 1 fed to cattle were eliminated unmetabolised via the 
faeces and urine (Table 2.15). In vitro experiments showed 35% degradation of FBI in 
rumen fluid over 9 hr; possibly by deamination or engulfment by protozoa since no partially 
or fully hydrolysed metabolites of fumonisin were found. The authors postulated that 
fumonisins were absorbed through the rumen wall and eliminated rapidly through the biliary 
system. Lack of de-esterification means fumonisins remain negatively charged and not 
lipophilic, and hence difficult to absorb through the gut walls. The relative low susceptibility 
of cattle to FB 1 may be because it is diluted in the rumen by the large volume and copious 
amounts of saliva (Smith & Thakur, 1996). Fumonisins were not excreted in the milk of 
lactating cows (Hammer et ai., 1996; Richard et al., 1996). 
2.9 DE-TOXIFICATION 
Because of the risk of fumonisin-related mycotoxicoses in humans and animals, various 
methods of de-toxification of infected corn have been investigated. Using cell culture 
techniques, it was found that the less polar the molecule, the higher its cytotoxicity i.e. FB2 > 
FB3> FB1 and the N-acetyl derivatives were less cytotoxic than parent molecules (indicating 
a cytotoxic role for the free amino group) while the hydrolysis products after removal of the 
TeA group were the most cytotoxic of all. These structural differences should be taken into 
account when devising decontamination strategies (Abbas et ai., 1993; Gelderblom et ai., 
1993). 
Lu et at. (1997) after reacting the amine group ofFB1 with fructose, found FBi-induced 
hepatotoxicity in rats was prevented and liver-associated natural killer cell activity was 
increased. This adds further evidence to the need of the amino group for toxicity. 
In investigations of feed associated with ELEM and PPE, the highest levels ofFB1 and the 
highest rate of mycotoxicosis comes from corn screenings (Ross et al., 1991B; Osweiler et 
at.,1992). Simply removing "fines" from bulk shipments of maize gave a 26.2 to 69.4 % 
reduction in total fumonisin levels (Sydenham et al., 1994). Other possible preventative 
strategies would be breeding F. moniliforme resistant corn or use of uncontaminated seed 
(Badria et at., 1996); or use of antagonistic rhizobacteria applied to corn kernels at 
planting (Bacon & Williamson, 1992). 
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Atmospheric ammoniation is ineffective as a decontaminant because although it reduced 
FB1 levels by 45% in naturally contamineted corn and by 30% in culture material, they were 
still toxic to rats (Norred et al., 1991; Voss et al. ,1992). In contrast, Park et al.(1992), found 
79% reduction in FB1 levels after ammonia treatment at high pressure/ambient temperature 
and/or low pressure/high temperatures but reaction products were not investigated for 
toxicity. 
Alkaline hydrolysis (nixtamalisation) is also ineffective as a de-toxification method 
because although fumonisin-contaminated corn treated with 0.1 M calcium hydroxide gave a 
74.1% transformation of FB1 to API (Sydenham et al., 1995A, 1995B), hydrolysed 
fumonisins also inhibit ceramide synthase in vitro (Merrill et al., 1993A) and in vivo (Voss 
et al., 1998A). Nixtamalised F moniliforme culture material containing 58 ppm of 
hydrolysed FB1 proved to be hepatotoxic and nephrotoxic to rats (Voss et al., 1996A, 
1998A). 
Water extraction (washing of freeze-dried culture material with deionised water) was more 
effective. The FBI content was reduced from 1 420 to 271 ppm and only induced mild 
hepatopathy in one rat; otherwise mild to moderate nephropathy. Water extracted culture 
material was less toxic and unaltered culture material was more toxic than the nixtamalised 
material (Voss et al., 1996A, 1998A). 
Heat is another possibility for decontamination but FB1 is thermostable at temperatures used 
in the main drying processes of corn (75 to1500C) and the usual conditions of baking or 
frying (Dupuy et al., 1993; Jackson et al., 1997). Heating corn meal at 220°C for 25 min 
caused complete loss ofFB1 and FB2 (possibly due to chemical decomposition) but 60 min 
at 190°C resulted in recoveries of 40% (Scott & Lawrence, 1994A). Heating milk at 62°C for 
30 min (to imitate pasteurisation) did not significantly reduce the measured concentrations of 
FB1 or FB2 (Maragos & Richard, 1994). In an aqueous model system (to remove matrix 
effects), 90% ofFB1 was decomposed to hydrolysis products after 60 min at ~ 175°C 
regardless of pH. Fumonisin B2 gave similar results. (Jackson et al. , 1996A, 1996B). 
Gamma irradiation of maize flour decreased fumonisin content by only about 20% and 
fumonisins were stable in irradiated maize for 4 weeks at 40°C and at least 6 months at 25°C 
(Visconti et al., 1996B). 
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More effective were activated carbons which removed about 95% of FB1 and about 99% of 
aflatoxin BI from an aqueous extract ofnaturdly contaminated com (Galvano et ai., 1997). 
2.10 HEALTH RISKS 
The public are largely ignorant about mycotoxins yet they might be responsible for many 
unexplained diseases including cancer, especially in countries with hot, humid conditions 
favouring fungal growth; and inadequate storage facilities. The potential for exposure of 
animals and humans to fumonisins is a world-wide problem since maize and maize based 
products are a dietary staple for humans and animals particularly in developing countries. 
Poor people are often forced to eat mouldy grain or starve as they do not have the money to 
purchase good grain. Daily maize intakes in Eastern and Southern Africa average 200 
g/personlday (up to 470 g) which translates to 245 Jlg offumonisins/day or 14 Jlg FB1/kg 
body weight/day (Thiel et at., 1992; Badria et at., 1996; Doko et at., 1996). 
Fusarium moniliforme (which is tasteless and not always visible) and fumonisins are found 
on both mouldy and physically sound maize so visual assessment followed by separation of 
ears into two groups does not ensure that maize used for human consumption is free of 
mycotoxins. Drinking beer made from mouldy maize probably results in exposure to high 
levels of fumonisins (Sydenham et at., 1990B). Fusaric acid has a synergistic toxic response 
with FB1 implying that the combination of these toxins may be causing enhanced and 
unpredicted toxicity in animals and humans (Bacon et at., 1995). Generally whole grain and 
products that undergo little/mild processing retain highest levels of fumonisins (Patel et at., 
1997) and products for animal consumption have higher levels and a higher incidence of 
fumonisins than those for humans (Rava, 1996; Perilla & Diaz, 1998). Some of the highest 
recorded levels ofFBt from naturally infected com are 117.52 Jlg/g (South Africa) and 250 
Jlg/g (Sardinia) (Rheeder et at., 1992; Bottalico et at., 1995). 
Levels of fumonisins (FB1 and FB2) in commercially available maize-based foods for human 
consumption ranged from <100 to 600 ng/g in South Africa but from <1000 to 4 000 ng/g in 
the USA (Thiel et at., 1992). 
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TABLE 2.16 mGHEST NATURALLY OCCURRING LEVELS OF FUMONISIN BI 
Type of Sample Country FBI Reference 
(Ile/e) 
Rain affected maize India 65.0 Shetty et al. 1997B 
Maize USA 37.9 Murphy et al. 1993 
Maize-based mixed feeds USA 16.8 Sydenham et al., 1992 
White/yellow maize South Africa 12.963 Rava, 1996 
Maize screenings South Africa 8.878 Rava et al. 1996A Rava, 1996 
Maize kernel China 8.4 Ueno et al. 1993 
Maize Argentina 6.695 Sydenham et al. 1993 
Puffed com Italy 6.1 Doko & Visconti 1994 
Maize India 5.0 Shetty et ai., 1997B 
Maize-based products for humans E~pt 2.98 Sydenham et ai., 1991 
Maize-based animal feed Columbia 2.964 Perilla & Diaz, 1998 
Maize meal for humans USA 2.79 Sydenham et al. 1991 
Maize kernels Zimbabwe 2.735 Doko et ai., 1996 
Corn-grits Japan 2.6 Ueno et al. 1993 
Corn-grits USA 2.545 Sydenham et al. 1991 
Polenta United Kingdom 2.124 Patel et ai. 1997 
Yellow maize animal feed South Africa 1.993 Rava et al., 1996, Rava 1996 
Maize meal Zimbabwe 1.91 Doko et ai., 1996 
Maize kernels Kenya 0.78 Doko et al., 1996 
Sorghum meal India 0.51 Shettv et al. 1997B 
Poultry feed India 0.26 Shetty et al. 1997B 
Com-grits South Africa 0.19 Sydenham et al., 1991 
(For the purpose of comparison, values for concentrations of FBI (Table 2.16) were adjusted 
to ~g/g). 
TABLE 2.17 LOWEST TOXIC DIETARY LEVELS OF FUMONISIN B, 
Animal Effect FBI (Ile/e) Reference 
Humans High risk area for OC 1.6 (0.05 -7.9) good com Rheeder et al., 
(South Africa) 23.9 (3.45 - 46.9) mouldy com 1992 
Humans (China) High risk area for OC 35.3 (20 - 60) good com Chu & Li, 1994 
74 (18 - 155) mouldy com 
Humans (USA) High risk area for OC 0.1 - 1.9 Sydenham et al., 
1991 
Rodents Hepatotoxicity 15 Voss et al., 1993, 
1995A 
Rodents Nephrotoxicity 3 - 27 Voss et al. 1995B 
Equidae ELEM 1.3 - 27 Thiel et al. 1991 B 
Pigs Hepatotoxicity 12 - 23 Motelin et al., 
1994 
Pigs PPE 7 -55 Bane et al., 1992 
Poultry Diarrhoea; 5.2 rrathapkumar et 
Hepatic abnormalities al., 1997 
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Comparing the highest naturally occurring levels of FB \ with the lowest toxic dietary levels 
(Tables 2.16 and 2.17) clearly shows that worldwide humans and animals are at risk of 
developing fumonisin-related mycotoxicoses. Concentrations ofFB\ in corn! maize and 
com-based products ranged from 0.26 to 37.9 Ilg/g in asymptomatic samples. Toxic dietary 
concentrations of FB \ ranged from 0.1 to 60 Ilg/ g . Although there are different toxic effects 
in different animals, all animals gave symptoms of liver damage. In 75% ofELEM cases and 
71% ofPPE, the level of FB1 was >10 Ilg/g but these may not be the lowest levels causing 
the mycotoxicosis (Pestka et al., 1994). 
In assessment of potential toxicity, it is important to take into account the time of exposure 
as well as the concentration. The effective dosage level ofFB1 for cancer initiation in rats 
was 30.8 mg FB1/100 g body weight for 21 days; whereas 29.7 mg FB1/100 g body weight 
for 7 days did not initiate cancer (Gelderblom et al., 1994). 
Because fumonisins have been found in commercially available com-based foodstuffs for 
human consumption in many countries in the world, humans are at risk of toxic effects 
through ingestion of these products (Ueno et al., 1993; Doko & Visconti, 1994; Rava,1996). 
However, reported results for com-based foods should be treated with caution as recoveries 
differ with different matrices; control recoveries should be done for each type of food (Scott 
& Lawrence, 1994). In measuring levels to elucidate health risks, care must be taken not to 
underestimate (possible by HPLC) or overestimate (possible by ELISA) the fumonisin 
concentration - bearing in mind that FB2, FB3 and hydrolysis products are also toxic 
(Gelderblom et al., 1993; Voss et al., 1998A). 
In addition to the risk of DC, consumption of fumonisins seems to pose a risk of secondary 
vascular disease caused by elevated LDL-cholesterol and apoprotein B (Fincham et al., 
1992). Hence, lipid profiles should probably be done in people consuming food 
contaminated with fumonisins. 
Strategies to reduce human (and animal) exposure to fumonisins include prevention by use 
of resistant maize varieties (Nelson et al., 1993), improving agricultural and storage 
practices, detoxification and fortifying the staple food viz. maize with appropriate minerals 
and vitamins (Rose, 1982; Marasas et al., 1993). In experiments with various cell lines, 
Badria et al., (1996) concluded that the only structural features needed for biological activity 
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are a long alkyl chain, a free amino group and probably a hydroxyl group on an adjacent 
carbon atom. 
This means that the fumonisin molecule can be changed extensively without destroying its 
toxicity and normal cooking procedures are unlikely to reduce the potential threat of toxic 
effects. 
Concerns may be raised that fumonisins ingested by animals could be passed on to humans 
or animals. The carry-over rate of fumonisins into milk was negligible and neither FB1, API 
nor their copjugates were detected in milk from cows dosed orally or intravenously with FB1 
(Scott et al., 1994B; Hammer et al., 1996). 
Various biomarkers to detect exposure to furnonisins are used including serum enzymes 
associated with liver abnormalities (GGT, LD, AST), total cholesterol (a relatively easy 
assay), So and Sa and the Sa/So ratio. However, Castegnaro et al. (1998) found no 
significant differences in Sa and So results between controls and OC patients nor between 
untreated and treated rats (oral daily dose of 1 mg FB1/kg body weight 5 days a week for 5 
weeks). Interestingly, healthy South African Asian females had higher serum So levels and 
lower ratios than their French counterparts; also, there were large inter-individual variations 
in the ratio. Thus, it seems that genetic and environmental factors are of importance in 
interpreting results. 
"The Pan African and worldwide contamination of maize with the fumonisins makes it 
imperative that realistic, scientifically sound and economically reasonable tolerance levels 
for maize should be established as soon as possible" (Maras as et al., 1993). 
At present recommended amounts are <5 Ilg/g in the non-roughage portion of feed for horses 
and <10 Ilg/g for pigs (Miller et al., 1996). For humans there are no current regulations but 
levels> 1 Ilglg are of concern (Perilla & Diaz, 1998). 
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CHAPTER 3 
PRODUCTION OF POL YCLONAL ANTIBODIES TO FUMONISIN Bl 
3.1 INTRODUCTION 
Antibodies against fumonisin (as opposed to kits for analysis) are not readily commercially 
available so the first step was to attempt to raise them. Antibodies are produced when a 
complex non-self or foreign molecule (the immunogen) stimulates the innate humoral immune 
response mechanism in an animal. The immunogen is processed by the lymphoid system; 
macrophages ingest and enzymatically degrade the immunogen to smaller fnigments. A small 
amount of immunogenic material is retained or received at the macrophage cell surface and on 
contact activates B-cell (or T-cell) lymphocytes. The activated B-cells give rise to effector cells 
(which remain in the lymph node) and memory cells (which circulate in the blood). Individual 
B-cells proliferate and differentiate to form a clone of plasma cells that produce identical 
antibodies (immunoglobulins) with specificity for a particular epitope. An epitope is the 
smallest biochemical unit capable of stimulating formation of a specific antibody; complex 
molecules like proteins contain many different epitopes so a heterogeneous collection of 
antibody molecules will be produced in an immune response i.e. polyclonal antiserum. Smaller 
molecules, termed haptens (molecular weight less than 5000 Daltons), have fewer epitopes so 
are not immunogenic in themselves but have to first be covalently linked to a larger more 
complex carrier molecule - usually a protein. 
Animals are injected with the immunogen and then given booster injections at suitable time 
intervals. Initially the antibodies are immunoglobulin M (IgM) but later molecules of the G 
class (IgG) are produced (Ritchie, 1986; Crowther, 1995). 
Since FBI is a hapten (molecular mass 721.8 Daltons) it was necessary to first link it to a carrier 
protein, KLH, to make an immunogenic molecule. Keyhole limpet hemocyanin is an oxygen 
carrying copper protein derived from an invertebrate, the mollusc Megathura crenulata with a 
molecular mass of3 - 7.5 x 106• It is often used as a carrier as it is immunogenic in its own right 
but is also easy to conjugate to haptens since it contains many lysine residues. It has good 
solubility in water and buffers. Glutaraldehyde is a bifunctional reagent linking through an 
amine group - as is found in FBI. The reaction mechanism is poorly understood (Boehringer 
Mannheim, Germany, package insert; Merck Index 1996; http://www.appliedbiosystems.com). 
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Both polyclonal and monoclonal antibodies against fumonisins (usually FBI) have been 
raised. To form the immunogen, FBI was linked to various carrier proteins (CT, KLH, BSA 
and OVA) usually by the glutaraldehyde method (Azcona-Olivera et al., 1992A, 1992B; 
Fukuda et at., 1994; Usleber et al., 1994; Abouzied et at., 1996; Chu, 1996; Yeung et at., 
1996; Yu & Chu, 1996). Briand et at., (1985) found that using 1 % glutaraldehyde gave 
stable conjugates but the coupling reaction may affect the activity of the antigen. 
3.1.1 Objectives 
1. To prepare a FBI-KLH conjugate to use as an immunogen. 
2. To immunise chickens and rabbits and collect eggs and blood samples respectively. 
3. To extract immunoglobulin Y (lgY) from the eggs and immunoglobulin G (lgG) from 
serum and measure the protein concentrations of all batches. 
4. To optimise an indirect ELISA method to check for antibody titre. 
5. To check all IgY and IgG extracts for antibody titre. 
3.1.2 Ethical Approval 
Ethical approval for working with animals (chickens and rabbits) was obtained from Dr. T.H.T. 
Coetzer, convenor of the Research Committee for Animal Ethics, University of Natal, 
Pietermaritzburg. 
At all times the animals were handled humanely and under the supervision of Dr. Coetzer. 
3.2 MATERIALS 
3.2.1 Chemicals 
Fumonisin B j , Freund's Adjuvant-Complete, Freund's Adjuvant-Incomplete, Horseradish 
Peroxidase conjugated Rabbit Anti-Chicken IgG, Horseradish Peroxidase conjugated Goat 
Anti-Rabbit IgG and ABTS (2,2'-Azino-bis (3- ethyl)benzthiazoline-6-sulphonic acid) were 
purchased from Sigma Chemical Co., USA. 
Keyhole limpet hemocyanin, Precinorm U and bovine serum albumin, Fraction V, were 
purchased from Boehringer Mannheim, Germany. 
Polyethylene glycol 6000, casein, Tween 20 and Parafilm were from Merck and H20 2 from 
Polychem. 
Serum Protein Electrophoresis kit was purchased from Beckman; Humatrol Nand 
Humatrol P from S.A. Scientific. 
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Pre-immunisation rabbit IgG and a horseradish peroxidase enzyme-labelled second antibody 
for chickens were kindly donated by Dr. T.H.T. Coetzer, Department of Biochemistry, 
University of Natal, Pietermaritzburg. 
Other chemicals (all Analar grade) were from Saarchem. 
3.2.2 Buffers/Solutions 
The following buffers were used in the production of polyclonal antibodies: 
O.lM Sodium carbonate buffer (PH 8.5) (Appendix 2, 2.l) 
Phosphate buffered saline (PBS) (PH 7.2) (1 Ox) (Appendix 2, 2.2) 
O.IM (100mM) Sodium phosphate buffer (PH 7.6),0.02% sodium azide 
Borate buffered saline (PH 8.6) 
O.IM Carbonate buffer (pH 9.6) 
0.15M Citrate-phosphate buffer (pH 5.0) 
Stopping buffer: 0.1 % sodium azide in citrate-phosphate buffer 
3.2.3 Fumonisin BI Stock Standards 
(Appendix 2, 2.3) 
(Appendix 2, 2.4) 
(Appendix 2, 2.5) 
(Appendix 2, 2.6) 
(Appendix 2, 2.7) 
Fumonisin Bl (1 mg) was dissolved in 10 ml PBS (pH 7.2) to give a final concentration of 
100 Ilg/ml. Aliquots (125 Ill, 10 Ilg/I00 JlI) were stored in Eppendorfmicro test tubes (AEC 
Amersham) and sealed with Parafilm (Merck) at either 4°C or - 20°C. 
3.3 METHODS 
3.3.1 Preparation of Immunogen viz. Fumonisin B\-Keyhole limpet hemocyanin 
conjugate (FBI-KLH) 
This was based on the method ofUsleber et ai. (1994).33.3 mg ofKLH (30% protein) was 
dissolved in 1ml 0.1 M sodium carbonate buffer (PH 8.5) and the concentration checked by 
measuring absorbance at 280 nm (Milton Roy Spectronic 3 000 Spectrophotometer). The 
solution was dialysed (SpectraIPor cellulose membrane dialysis tubing, molecular weight 
cut-off(MWCO) 12000 Daltons or greater, capacity approximately 10 ml/ft., 10 mm flat 
width, 6 mm diameter, Sigma Chemical Co., USA) against 2 x 500 ml PBS (PH 7.2) first for 
2 hr then overnight at 4°C and the protein concentration checked again. 20 III glutaraldehyde 
(1 % in water) was added to 1 mg FBI and incubated at room temperature (RT) for 2 hr. To 
this, 800 JlI of KLH solution was added, mixed and incubated at R T for 3 hr, mixing every 
30 min. The conjugate was dialysed against PBS (3 x 1 000 ml) at 4°C. The protein 
concentration was determined by reading absorbance at 280 nm of a 1 :50 dilution (in PBS). 
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The conjugate was aliquoted to give 250 I-lg per aliquot, and stored in sealed Eppendorftubes at 
-70°C. 
3.3.2 Immunisation of Chickens and Rabbits 
Two White Amberlink chickens (Ukulinga Research Farm, University of Natal, 
Pietermaritzburg) and two female rabbits of mixed breed, one brown and one black (supplied 
by the Biochemistry Department, University of Natal, Pietermaritzburg) were used to raise 
antibodies. All animals were kept in cages, treated humanely and given free access to food 
and water at all times (Figures 3.1, 3.2 and 3.3). 
FIGURE 3.1 CIDCKEN 1 (SPECKLED) & CIDCKEN 2 (WIllTE) 
FIGURE 3.2 RABBIT 1 (BLACK) 
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FIGURE 3.3 RABBIT 2 (BROWN) 
The same immunisation schedule was followed for chickens and rabbits viz. initial injection 
at week 0 and boostets at weeks 2, 6 and 10. Emulsions (about 2 ml for two animals) of 
KLH-FBI and adjuvant were freshly prepared; animals were injected with about 1 ml each. 
The emulsions contained 2 aliquots (500 Ilg) of the immunogen plus 1.2 ml Freund's 
adjuvant i.e 250 Ilg KLH-FBI per animal per injection. At week 0 complete Freund's 
adjuvant was used and at weeks 2,6 and 10 incomplete Freund's adjuvant. Chickens were 
injected intramuscularly on either side of the breastbone; rabbits were injected 
subcutaneously behind the neck. 
Eggs were collected daily, dated and stored at 4°C. Blood was collected from the ear vein of 
the rabbits at weeks 4,8 and 12. After standing overnight at 4°C serum was separated by 
centrifuging twice for 10 minutes at 1 410 g (3000 rpm) at RT. For pre-immunisation 
samples, eggs and blood were collected during the week prior to the first injection. 
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3.3.3 Extraction of Immunoglobulin Y from Egg Yolks 
Eggs were sorted into weekly batches (3 - 7 eggs/week) and extraction of Ig Y was done per 
batch. Egg white was separated from yolks, the yolks washed with distilled water and the 
combined egg yolk volume measured. Two volumes of 100 mM sodium phosphate buffer, 
pH 7.6, were added and polyethylene glycol 6 000 (PEG) 3.5% (m/v) was dissolved by 
gentle stirring. The precipitated vitellin fraction was removed by centrifugation at 4 420 g 
for 30 min at RT (Beckman J2-21 refrigerated centrifuge with JA-I7 rotor). 
After slowly filtering the supernatant through absorbent cotton wool (to give a clear solution 
free of lipids) PEG (8.5% m/v) was added (giving a 12% solution) which was mixed 
thoroughly and centrifuged at 12 000 g for 10 min at RT. The pellet was redissolved in the 
buffer in a volume equal to the volume obtained after filtration. Polyethylene glycol 6 000 
(12% m/v) was added, mixed and centrifuged again at 12000 g for 10 min at RT. The final 
pellet was dissolved in 1/6 of the original egg yolk volume using 100 mM sodium phosphate 
buffer (PH 7.6). 
For final clarification, the extract was filtered through cotton wool again before storing at 
4°C in scintillation vials (Analytical and Diagnostic Production) sealed with Parafilm. 
The extracts are stable under these conditions for a number of years but must not be frozen 
(Dr. T.H.T. Coetzer, personal communication; Polson et al., 1985). 
The batches of extract were numbered according to the chicken and the week; e.g. Cl/6 is 
week six for chicken one; C2/P is pre-immunisation for chicken two. 
3.3.4 Extraction of Immunoglobulin G from Serum 
After measuring rabbit serum volumes, two volumes of borate buffered saline (PH 8.6) and 
14% (m/v) PEG were added and dissolved by gentle mixing. The mixture was centrifuged at 
12000 g for 10 min at RT. The pellet was re-dissolved in the original serum volume using 
100 mM sodium phosphate buffer, pH 7.6. Again 14% (m/v) PEG was added, mixed and 
centrifuged at 12 000 g for 10 min at RT. The final pellet was dissolved in Yz the original serum 
volume using 60% (v/v) glycerol in the sodium phosphate buffer. Aliquots (125 JlI) of the 
extracts were stored in sealed Eppendorftubes at -20°C (Dr. T.H.T. Coetzer, personal 
communication; Polson et al., 1964). 
The batch numbering system for the extracts was according to the rabbit and the week e.g. 
R1I4 is week four for rabbit one. 
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3.3.5 Measurement of Protein Concentration 
Duplicate 1:40 dilutions of each extract (chicken and rabbit) were made in 0.1 M sodium 
phosphate buffer (PH 7.6) and the absorbances read at 280 nm. Using correct extinction co-
efficients viz. E = 1.25 for IgY (Coetzer, 1985) and E = 1.43 for IgG (Hudson & Hay, 1989), 
protein concentrations in mg/ml were calculated. For IgY the blank was buffer alone; for IgG it 
was 60% glycerol in sodium phosphate buffer. Absorbance at 280 nm is mainly due to aromatic 
rings of tyrosine, tryptophan and phenylalanine; this content varies from protein to protein 
(Bohinski, 1987). 
The IgY concentrations were checked (in duplicate) using the biuret method (Cobas Mira 
Plus Selective Automated Analyser, Boehringer Mannheim). Precinorm U was used as the 
standard and Humatrol Nand Humatrol P for method controls. Because of insufficient 
serum, protein concentrations of IgG antibodies were not checked by the biuret method. 
The biuret method involves a formation of a complex between cupric ions in alkaline 
medium and peptide linkages. The absorbance of the complex is proportional to the number 
of peptide linkages and hence the concentration of protein (Koller, 1984). 
3.3.6 Electrophoresis 
To check the efficacy of the extraction procedure, protein electrophoresis was carried out on 
two of the IgY and one of the IgG extracts (at various stages of the extraction procedure) 
using the Beckman serum protein electrophoresis (SPE) kit and the Beckman Paragon 
system. The egg samples analysed were aliquots (200 Ill) from the redissolved pellet 
solutions after the addition of3.5%, 8.5% and 12% PEG. The blood samples analysed were 
the original serum and aliquots (200 Ill) after the first and the second 14% PEG 
precipitations. In addition a normal (human) serum sample was run as a method control. 
In the Beckman Paragon system, all reagents except acetic acid and methanol were supplied 
with the SPE kit. The support medium was agarose gel and the electrophoresis buffer was a 
barbital buffer (PH 8.6). The samples were diluted 1:5 in barbital buffer and 3 - 5 III of each 
applied to designates lanes on the gel using the template supplied. The gel was 
electrophoresed for 25 min at 100 volts. The proteins were fixed by dipping the gel into an 
acid alcohol solution (20% glacial acetic acid and 30% methanol in de-ionised water). The 
gel was dried and stained with Paragon Blue stain prepared according to the manufacturer's 
instructions. Excess stain was removed by dipping the gel into 5% acetic acid solution. 
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The gel was dried and scanned using the Beckman Appraise Densitometer System. The 
electrophoresis was a non-denaturing procedure. 
3.3.7 Indirect ELISA for Antibody Titre 
The format for the indirect ELISA was as shown below: 
SAg + Ab l ~ SAg-Abl + Ab2
E -+ SAg-Abl-Abl 
The antigen (Ag), is attached to the solid phase (S) i.e. the wells of the microtitre plate. Then 
the primary antibody (Abl) is added and allowed to bind to the Ag; after incubation excess 
Abl is removed by washing. In a second incubation, an enzyme-conjugated second antibody 
against primary antibody (Abl) reacts with Ab1 to form the final complex (Voller & 
Bidwell, 1986; Crowther, 1995). 
For application of this format, the Ag was FBI, Abl was the antibody from chickenslrabbits and 
the relevant Ab2E was obtained commercially. 
Since RT in the laboratory can vary by lOoC, only temperatures of 37°C (incubator) or 4°C 
(refrigerator) were used for incubation. 
For optimisation of the method various experimental parameters were checked using 
checkerboard titrations i.e. varying different conditions each time to assess which was the 
best. A decision as to the best result was based on which gave the steepest curve or the 
lowest value for the blank and maximum absorbance of 0.8 to 1.0 (Crowther, 1995). 
For each parameter, the corresponding well for the pre-immunisation extract and for the non-
specific binding blank (no Abl) was included. Extracts C1/8, ClIP and C2/8, C2/P were used 
for the optimisation and results checked with rabbit antibody RIP and Rl112, RlI14. All 
wells were done in duplicate. The ABTS solution (a clear light green) was prepared just 
before use and kept covered with aluminium foil since it is light sensitive. 
In the summary below the final optimised method is shown first and the tested alternatives 
for each step are shown underneath in Italics. 
1. The wells of the microtitre plate (Nunc 96 well Maxisorb, AEC Amersham) were 
coated directly with FBI, 100 ng/ml in PBS, 150 III per well. The plate was covered 
and incubated for 18 hr at 4°C. 
Use of PBS (pH 7.2) or O.IM carbonate buffer (PH 9.6). 
Concentration of FB I - 1 000, 100, 10, I, 0.1 ng/ml. 
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2. The wells were blocked with 1.0% casein (m/v) in PBS, 200 ~l per well, and 
incubated for 1 hr at 37°C. 
Blocking agent was PBS plus 0.5% BSA or 2% or 1% or 0.5% casein. 
3. The plate was washed three times with 0.1 % (v/v) Tween 20 in PBS. 
4. Dilutions of first antibody (Ab!), 100 ~l in 0.5% BSA(mlv) in PBS, were added and 
incubated for 2 hr at 37°C. 
Concentrations 0/ Ab 1 - 1 000, 100, 10, 1 j).g/ml made up in PBS plus 
0.5% BSA or 0.5% or 1 % or 2% casein. 
5. The plate was washed three times with 0.1 % (v/v) Tween 20 in PBS. 
6. The second antibody, (Ab2
E
) anti-chicken IgG (or anti-rabbit IgG) conjugated with 
horseradish peroxidase, 1:2 000, 120 ~l per well, was added and incubated for 1 hr at 
37°C. 
Ab/ (from Dr. Coetzer) 1:350 dilution/or chickens and rabbits. 
Ab/ (from Sigma) 1:500 or 1:1 000 or 1:2 000 or 1:5 000 or 1:10 000 or 1:20 000 
or 1:30 OOOfor chickens. 
Ab/ (from Sigma) 1:1 000 or 1:2 000 or 1:5 000 or 1:10 OOOfor rabbits 
7. The plate was washed three times with 0.1 % (v/v) Tween 20 in PBS. 
8. 150 ~l of substrate, 7.5 mg ABTS plus 7.5 ~l H202 in 15 ml citrate-phosphate buffer 
(PH 5) was added to each well. The colour was allowed to develop for 15 min in the 
dark at RT. 
9. 50 ~l stopping buffer was added to each well. 
10. The absorbance of each well was read at 405 nm (Bio-Rad Model 550 Plate Reader). 
3.3.8 Measurement of Antibody Titre 
Using the optimised method, all batches ofigY and all batches ofigG at concentrations of 
1 000, 500, 250, 100, and 25 ~g/ml were tested for titre. On each plate the relevant pre-
immune sample (at the same concentrations) and a non-specific binding (no Ab1) blank were 
run. 
Results for antibody titre were calculated by taking the means of duplicate absorbance 
readings, subtracting the mean of the relevant pre-immune absorbance value and the 
absorbance value for non-specific binding (i.e. no Ab1 blank). Duplicates were only 
considered acceptable if differences were <10% preferably <5%. 
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3.4 RESULTS 
3.4.1 Immunogen and Immunisation 
The recommended loading ratio for formation of the immunogen is 1 000:1 (hapten:carrier) 
and the protein concentration ofKLH (mg/ml) = dilution factor x absorbance (at 280 run) x 
0.388 (Package insert for KLH). 
Concentration of KLH before dialysis 
Concentration of KLH after dialysis 
= 7.60 mg/ml (absorbance 0.392, dilution 1:50) 
= 6.65 mg/ml (absorbance 0.343, dilution 1 :50) 
800 III of dialysed KLH i.e. 5.32 mg was added to 1 mg FBI. 
Molecular Mass ofKLH is 3 - 7.5 X 106 (average 5.25 x 106) and for FBI is 721.8 
No. mmoles KLH = 5.32 -:- 5.25 X 106 = 1.013 X 10-6 
No. mmoles FBI = 1 -:-721.8 = 1.385 X 10-3 
Ratio 1.385 x 10-3 : 1.013 x 10-6 
Loading achieved 1 367:1 
Concentration ofFBI-KLH after dialysis = 5.30 mg/ml (absorbance 0.273, dilution 1 :50). 
Thus to give 250 Ilg per aliquot needed 47 J.lI of conjugate plus 400 J.lI PBS to make up to a 
suitable volume for injection. 
All four animals were healthy and showed no ill effects for the entire period of immunisation 
and egg/blood collection. The chickens were allowed to live for their allotted life span; the 
rabbits were given away as pets. 
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3.4.2 Immunoglobulin Y and Immunoglobulin G Extracts 
TABLE 3.1 SUMMARY OF EXTRACTION OF IMMUNOGLOBULIN Y (CmCKEN 1) 
Batch Number Yolk volume Final Appearance Protein Protein 
number of eggs (ml) volume of final concentration concentration 
of (ml) extract (280 nm) (biuret) 
extract [mvml) (me/ml) 
CliP 4 67 11.2 Opalescent 25.09 24.79 
CliO 7 123 20.5 Pale yellow 19.87 20.52 
ClIl 5 86 14.3 Pale yellow 26.72 27.84 
C1I2 5 80 13.3 Pale yellow 21.89 22.88 
CI/3 5 84 14.0 Light yellow 31.30 30.79 
ClI4 3 48 8.0 Pale yellow 31.71 32.34 
CI/5 9 160 26.7 Pale yellow 30.08 30.99 
ClI6 6 110 18.3 Pale yellow 27.58 27.29 
CII7 6 110 18.3 Pale yellow 31.10 31.62 
ClI8 6 107 17.8 Pale yellow 39.42 39.17 
ClI9 6 99 16.5 Pale yellow 34.62 35.67 
ClIlO 6 115 19.2 Light yellow 34.40 34.25 
C1I11 5 90 15.0 Pale yellow 33.79 34.22 
Cl112 6 112 18.7 Pale yellow 36.19 36.78 
ClI13 7 129 21.5 Pale yellow 30.72 32.14 
ClII4 5 100 16.7 Pale yellow 30.21 30.85 
Hen 1 produced more fatty yolks than hen 2, whilst hen 2 had more albumin. 
TABLE 3.2 SUMMARY OF EXTRACTION OF IMMUNOGLOBULIN Y (CmCKEN 2) 
Batch Number Yolk volume Final Appearance Protein Protein 
number of eggs (ml) volume of final concentration concentration 
of (ml) extract (280 nm) (biuret) 
extract (mvml) (m2lml) 
C21P 4 67 11.2 Opalescent 17.50 18.27 
C2/0 6 100 16.7 Pale yellow 27.68 28.32 
C211 3 47 7.8 Pale yellow 27.74 28.84 
C2/2 1 15 2.5 Pale yellow 29.79 29.54 
C2/3 1 15.5 2.6 Yellow 42.56 44.55 
C2/4 I 16 2.7 Yellow 41.41 41.84 
C2/5 6 108 18.0 Pale yellow 33.79 36.61 
C2/6 6 103 17.2 Pale yellow 34.05 34.70 
C217 5 78 13.0 Pale yellow 39.87 40.80 
C2/8 7 127 21.2 Light yellow 37.06 38.38 
C2/9 7 124 . 20.7 Light yellow 37.34 38.10 
C2/10 6 115 19.2 Pale yellow 33.12 33.56 
C2/11 4 72 12.0 Pale yellow 34.05 35.47 
C2112 8 145 24.2 Pale yellow 36.51 38.31 
C2113 7 122 20.3 Pale yellow 36.51 37.79 
C2114 5 93 15.5 Pale yellow 32.35 33.11 
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Statistics using a one-way analysis of variance (AN OVA) showed there was no difference in 
the protein results as measured by the two methods. 
Generally the chickens produced 4 to 7 eggs per week (about one egg per day) except for 
week 4 for chicken 1 (only 3 eggs); and for chicken 2 week 1 (3 eggs) and weeks 2,3 and 4 
(1 egg per week). The batches from the weeks when fewer eggs were laid gave smaller final 
volumes of extract (2.5 to 8.0 ml) compared to other weeks (11.2 to 21.5 ml). 
The highest final volume (26.7 ml) was from the batch for week 5 for chicken 1 when 9 eggs 
were laid; the highest final volume for hen 2 was 24.2 ml from week 12 (8 eggs). 
Protein concentrations for the two chickens were similar and ranged from 19.87 to 
39.42 mg/ml for chicken 1 and from 17.50 to 42.56 mg/ml for chicken 2 (Tables 3.1 and 
3.2). 
TABLE 3.3 SUMMARY OF EXTRACTION OF IMMUNOGLOBULIN G 
Batch number of Serum volume Final volume Protein concentration 




R1I4 4.55 2.28 11.19 
Rl/8 6.10 3.05 10.35 
Rl/12 7.10 3.55 11.24 
RlI14 32.10 16.05 11.94 
RABBIT 2 
R2/4 3.30 1.65 12.25 
R2/8 3.15 1.58 24.34 
R2/12 3.45 1.73 13.90 
R2/14 12.10 6.05 15.41 
The highest final volumes for both rabbits were from week 14 but the volume for rabbit 1 
(16.05 ml) was greater than for rabbit 2 (6.05 ml). Smaller volumes of serum and smaller 
volumes of extracted IgG were obtained from rabbit 2 compared to rabbit 1. 
The protein concentrations were similar for both rabbits and ranged from 10.35 to 11.94 
mg/ml for rabbit 1 and from 12.25 to 24.34 mg/ml for rabbit 2. The highest protein 
concentration was from rabbit 2 for week 8 (Table 3.3). 
Overall larger volumes of extracted immunoglobulins were obtained from the two chickens 
compared to the rabbits (Tables 3.1,3.2 and 3.3). The IgY extracts also had higher protein 








FIGURE 3.4 PROTEIN ELECTROPHORETOGRAM OF SAMPLES AT DIFFERENT 
STAGES OF EXTRACTION OF IMMUNOGLOBULIN Y AND 
IMMUNOGLOBULIN G 
Key to Figure 3.4 
Lanes 1,2,3 chicken 1 Lanes 4,5,6 chicken 2 Lane 7 control serum Lanes 8, 9, 10 rabbit 1 
For the chickens, lanes 1 and 4 were after addition of3 .5% PEG; lanes 2 and 5 were after addition of 
8.5% PEG (to make up to 12%); lanes 3 and 6 were after final addition of 12.0% PEG. 
Lane 8 was rabbit serum, lane 9 after first addition of 14% PEG and lane 10 after final addition of 
14% PEG. 
Since the control serum gave a normal pattern, it was concluded that the electrophoresis had 
been done correctly. The albumin band travelled the fastest and was closest to the anode; the 
gamma globulin band was closest to the cathode. The progressive steps of purification of 
IgYand IgG with different concentrations of PEG 6000 gave a reduction in the albumin 
bands but an increase in the gamma-globulin bands (Figure 3.4) 
60 
---,- -------------
3.4.3 Optimisation of Indirect ELISA for Antibody Titre 
Step 1. 
The buffers commonly used for coating the micro well plates with antigen are PBS( pH 7.2) 
and carbonate (PH 9.6) (Crowther, 1995). 
TABLE 3.4 COMPARISON OF TWO COATING BUFFERS USING TWO DIFFERENT 
IMMUNOGLOBULIN Y EXTRACTS 
PBS (pH 7.2) Carbonate (pH 9.6) 
ClIS C1/S 
FBI (n2/ml) 1000 100 10 1 1000 100 10 1 
Ab l (Jl2/ml) 
1000 2.586 2.341 2.295 2.423 2.586 2.268 1.910 2.164 
100 2.557 2.056 1.365 1.122 2.415 1.407 0.952 1.058 
10 1.846 1.131 0.671 0.458 1.433 0.651 0.408 0.581 
C2/S C2/S 
FBJ (n2/ml) 1000 100 10 1 1000 100 10 1 
Ab l (Jl2/ml) 
1000 2.591 2.427 2.292 2.297 2.591 2.313 1.959 1.996 
100 2.499 1.957 1.424 1.275 2.118 1.581 0.978 1.045 
10 1.730 0.955 0.706 0.580 1.407 0.693 0.449 0.63 
Kev to Table 3.4 
Results are means of duplicate absorbance values at 405 nm after subtraction of the mean of the non-
specific binding (no Ab 1) blank. 
Coating with PBS gave similar results to coating with carbonate buffer at the same coating 
concentrations ofFB\ (Table 3.4). It was decided to use PBS since then the same buffer 
could be used for coating and for other steps in the method. 
TABLE 3.5 COMPARISON OF CONCENTRATIONS OF FUMONISIN BI FOR 
COATING MICROWELL PLATES 
FBI (n2/ml) 100 10 1 0.1 
Ab l (ue/ml) 
1000 1.281 0.643 0.624 0.395 
100 1.098 0.144 0.114 0.000 
10 0.411 0.081 0.009 0.000 
1 0.000 0.000 0.000 0.000 
Kev to Table 3.5 
Results are means of duplicate absorbance values at 405 nm after subtraction of the mean of the no 
Ab 1 blank. Batch number e2/8 of Ab1 was used. 
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At concentrations of FB I < 100 ng/ml for coating, the antibody does not titrate out and 
curves were flat (Table 3.5). Similar results were obtained for batch ClI8. 
Step 2. 
After coating with antigen (FBI), wells were blocked to prevent non-specific binding of 
Abland Ab2. The no Abl blank (which must be run for each coating concentration of FBI) 
estimates non-specific binding of either antibody Ab2 or HRPO. The no Ab2 well was a 
reaction blank effectively giving the lowest absorbance for the substrate solution and can be 
omitted. It was run at the highest concentration of Abl. 
TABLE 3.6 COMPARISON OF REACTION BLANKS WITH DIFFERENT BLOCKING 
AGENTS 
Blocking Agent No Abl Blank No Ab2 Blank 
0.5% BSA in PBS 0.113 0.082 
2% casein in PBS 0.078 0.076 
1 % casein in PBS 0.082 0.076 
0.5% casein in PBS 0.083 0.079 
Kev to Table 3.6 . 
Results are means of duplicate absorbance values at 405 nrn. 
Bovine serum albumin at a concentration of 0.5% was not an effective blocking agent as 
both blanks gave higher absorbance readings than casein. Casein at concentrations of 0.5% 
or 1 % or 2% casein give similar and better blanks than BSA. It was easier to make up 1 % 
than 2% casein which was difficult to dissolve. The results for 1 % casein were better than 
for 0.5% (Table 3.6). 
Step 4. 
TABLE 3.7 COMPARISON OF DILUENTS FOR PRIMARY ANTIDODY 
Diluent 0.5% BSA 0.5% casein 1 % casein 2% casein 
AbdJ.l.2/ml) 
1000 1.340 0.884 0.935 1.002 
100 1.185 0.313 0.310 0.471 
10 0.507 0.000 0.000 0.005 
Key to Table 3. 7 
Results are means of duplicate maximum absorbance values at 405 nm after subtraction of the mean 
of the no Ab( blank. All diluents were made up in PBS. 
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Bovine serum albumin at a concentration of 0.5% proved to be the best diluent for antibodies 
since casein gave low absorbance values at lower concentrations of antibody; also the 
titration graph was steeper for BSA than for casein (Table 3.7). 
Initially wide ranges of concentrations of Ab, (10 times differences) were used to find the 
region in which a suitable reaction was obtained. The range of 100 to 1 000 Jlg/ml gave 
satisfactory results. (Tables 3.4, 3.5 and 3.7). 
Stev 6. 
Below is an example of a plate set-up for checkerboard titrations. This one was used to 
check which concentration of Sigma Ab2 E to use for rabbit antiserum (Table 3.8). 
TABLE 3.8 SET-UP OF A PLATE FOR CHECKERBOARD TITRATION TO 
DETERMINE THE DILUTION OF THE SECOND ENZYME-LABELLED 
ANTIBODY (SIGMA) TO USE FOR ANTffiODY TITRE OF RABBIT 
IMMUNOGLOBULIN G 
Dilution 1:1000 1:2000 1:5000 1:10000 
of Sigma 
Ab2E 
Batch RlI RlI RlI RlI RlI RlI RlI RlI RlI RlI RlI 
Number P 12 14 P 12 14 P 12 14 P 12 
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FIGURE 3.5 RESULTS OF CHECKERBOARD TITRATION TO DETERMINE THE 
DILUTION OF THE SECOND ENZYME-LABELLED ANTIBODY (SIGMA) 
TO USE FOR ANTIBODY TITRE OF RABBIT IMMUNOGLOBULIN G 
USING BATCH RlI14 
Figure 3.5 clearly shows a 1:.2 000 dilution of the Sigma Ab2 E is the best to use as indicated 
by the steepest graph and suitable absorbance value (Crowther, 1995). The 1: 1 000 dilution 
') 
gave a steep curve but lower absorbance values; the curves for the 1: 5 000 and 1: 10 000 
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FIGURE 3.6 SUMMARY OF RESULTS OF EXPERIMENTS TO DETERMINE OPTIMUM 
BLOCKING AGENT, DILUENT AND DILUTION OF SECOND ENZYME-
LABELLED ANTIBODY FOR TITRE OF CmCKEN IMMUNOGLOBULIN Y 
Key' to Figyre 3.6 
Code Diluent Blocking Agent AbE -2 
B/Ab2C 0.5%BSA 0.5%BSA Dr. Coetzer 1 :350 
BI Ab2S15 0.5%BSA 0.5%BSA Sigma 1:500 
BI Ab2S/20 O.5%BSA 0.5%BSA Sigma 1: 2 000 
CI Ab2CIO.5 0.5% casein 0.5% casein Dr. Coetzer 1: 350 
C/A~S/20 1% casein 1% casein Sigma 1: 2 000 
BCI Ab2C 0.5%BSA 1% casein Dr. Coetzer 1: 350 
BCI Ab2S/20 0.5%BSA 1% casein Sigma 1: 2 000 
CI Ab2CIl 1% casein 1% casein Dr. Coetzer 1: 350 
(Data used to generate Figure 3.6 are in Appendix 1, Table 3.10). 
The best results were using the second antibody supplied by Dr. Coetzer, 0.5% BSA as 
diluent and either 1 % casein or 0.5% BSA as blocking agent (BCI Ab2C and BI Ab2e). 
However, as there was unfortunately insufficient of this antibody, the Sigma antibody diluted 
1: 2000, 1% casein for blocking and 0.5% BSA for diluent was used (BCI Ab2S/20) (Figure 
3.6). 
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Use of other combinations of diluent and blocking agent gave unsuitably low absorbance 
values for the highest concentration of primary antitody, 1 000 Jlg/ml (Table 3.11). 
TABLE 3.11 SUMMARY OF MAXIMUM ABSORBANCE VALUES USING DIFFERENT 
DILUENTS, BLOCKING AGENTS AND DILUTIONS OF SECOND 
ENZYME-LABELLED ANTIBODY 
Dilution of Si~ma Ab2 E Absorbance Diluent Blockin~ a~ent 










Kev to Table 3.11 . 
Results are means of duplicate absorbance values at 405 nm after subtraction of the mean ofthe 
relevant pre-immune absorbance value (C lIP) and the absorbance value for the no Ab, blank. 
Fumonisin B, at a concentration of 100 ng/ml was used for coating and Ab, was batch number C2/S. 
3.4.4 Antibody Titre 
Table 3.12 shows an example of a typical set-up of a plate to check antibody titre. 
TABLE 3.12 EXAMPLE OF A PLATE TO CHECK ANTmODY TITRE (CmCKEN 2 EVEN 
WEEKS) 
Ab1 1000 1000 1000 500 500 250 250 100 100 25 25 
(flg/ml) No 
Ab2 









The pre-immune extract (C2/P) was run at the same protein concentrations (1 000,500, 100 





Column 1 was for the no Ab2 blank; column 12 for the no Abl blank. The plate set-up was 
similar for all other titre experiments. 
The final colour of the plate (Table 3.12) is shown in Figure 3.7. 
1 2 3 4 5 6 7 8 9 10 11 12 
FIGURE 3.7 PHOTOGRAPH OF PLATE TO CHECK ANTffiODY TITRE 
FOR CHICKEN 2 (EVEN WEEKS) 
In Figure 3.7 the darker the colour the higher the amount of antibody). The blank columns 
viz. no Ab1 in column 1 and no Ab2 in column 12 were clearly lighter than other columns. 
TABLE 3.13 DATA TO CHECK ANTIBODY TITRE FOR CHICKEN 2 (EVEN WEEKS) 
Batch 1000 p.g/ml 500 250 100 Jig/ml 25 Jig/ml NoAbt NoA~ 
number "wml Jig/ml 
C21P 0.311 0.232 0.154 0.119 0.092 0.083 0.089 
C2/2 0.255 0.114 0.078 0.000 0.000 
C2/4 1.569 1.053 0.643 0.342 0.083 
C2/6 1.484 1.070 0.689 0.304 0.041 
C2/S 1.698 1.330 1.034 0.648 0.168 
C2/10 1.129 0.876 0.616 0.330 0.030 
C2112 1.487 1.284 0.961 0.616 0.080 
C2114 1.471 1.180 0.723 0.340 0.023 
K?)! to Table 3.13 
Except for C21P, no Ab} and no Ab2, results are the means of duplicate absorbance readings at 405 
nm after subtracting the mean of the relevant pre-immune absorbance value (C21P) and the mean of 
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FIGURE 3.8 ANTmODY TITRE FOR CHICKEN 2 (EVEN WEEKS) 
Results for all other batches ofIgYand IgG are shown in Figures 3.9 to 3.11 
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FIGURE 3.9 ANTIBODY TITRE FOR CHICKEN 2 (ODD WEEKS) 
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The highest titres for chicken 2 are batches from weeks 7, 8 and 12. 
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FIGURE 3.10 ANTmODY TITRE FOR CHICKEN 1 (EVEN WEEKS) 
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FIGURE 3.11 ANTmODY TITRE FOR CHICKEN 1 (ODD WEEKS) 
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FIGURE 3.12 ANTIBODY TITRE FOR RABBITS 1 AND 2 
2.6 
The highest titres for rabbit 1 are from batches for weeks 12 and 14; 
and for rabbit 2 from week 8. 
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Both chickens started producing antibodies at week 2 and continued to week 14 when 
collection of eggs ceased. Both rabbits produced antibodies for every bleed viz. weeks 4~ 8~ 
12 and 14. 
Checks of the blanks done on all the plates for checking antibody titre gave inter-plate CV of 
6.33% (n = 42~ mean 0 .079~ SD 0.005) for no Ab1 and 6.58% (n = 40~ mean 0.076~ SD 
0.005) for no Ab2. 
Figure 3.13 shows a comparison of highest titres for each animal . 
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25 100 250 500 1000 
Protein Concentration (pglml) 
FIGURE 3.13 COMPARISON OF lHGHEST ANTffiODY TITRES 
The highest titres in order are from chicken 2 week 8, chicken 1 week 8, rabbit 1 week 14 
and rabbit 2 week 8. 
3.5 DISCUSSION 
3.5.1 Immunogen and Immunisation 
Successful production of antibodies is largely a matter of chance. Certain factors can be 
controlled and others e.g. genetic make-up and humoral response of a particular animal are 
beyond the researcher's control (Ritchie, 1986). Since mycotoxins are not immunogenic it 
was necessary to conjugate them to a carrier by first introducing a reactive group (Chu, 
1985; Chu, 1996). Fumonisin Bl has two reactive carboxyl and hydroxyl groups and a 
primary amine (Chu 1996; Yeung et al., 1996; Yu & Chu, 1996). 
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In this study, conjugation of FBI to KLH was presumed successful as antibodies were 
produced. Commercial antibodies from Neogen could helve been used to check if the 
immunogen was only KLH or FBI-KLH but this was too expensive. 
Although it was not possible to check whether or not the FBI had bound to the KLH (as 
there were no readily available methods with sufficient sensitivity), a suitable loading ratio 
of hapten to carrier (1 367:1) was achieved (the recommended ratio was 1 000:1). 
Usleber et al. (1994) used FBI: KLH at 700:1 while Azcona-Olivera et al. (1992A, 1992B) 
and Fukuda et al. (1994) used 50: 1. Using FBI linked to KLH, Abouzied et al. (1996) 
produced polyclonal antibodies in sheep; Usleber et al. (1994) and Yu & Chu (1996) in 
rabbits; and Fukuda et al. (1994) produced monoclonal antibodies in mice. 
It was a long 8 month wait until checks for antibody could be done. 
Chickens (laying hens) are seldom the first choice of animal for raising antibodies yet they 
were easy to handle and to inject. Collection of eggs was a non-invasive and easier 
procedure than the collection of blood from the ear vein of the rabbits; also the volumes of 
egg yolks with which to begin the extraction ofIgY were greater than the volumes of serum 
obtained from the rabbits (Tables 3.1, 3.2 and 3.3). Clarke et al. (1993) successfully 
produced antibodies against Ochratoxin A in laying hens (using a BSA conjugate as 
immunogen and injecting intramuscularly into the pectoral muscles) but this study is the first 
report of antibodies against fumonisin being produced in hens. 
3.5.2 Extraction of Immunoglobulin Y and Immunoglobulin G 
It is preferable to perform some type of purification of antibodies (at the least the removal of 
albumin) as the amount of specific antibody in serum is only 1-5% of the total protein 
(Crowther, 1995). Ammonium sulphate precipitation is an acceptable method to fractionate 
antisera (Hebert et al., 1973) or antibodies can be purified by ammonium sulphate 
precipitation followed by use of an affinity column (CH-Sepharose 4B) conjugated with FBI 
(Chu et al., 1995) but the affinity column used 4 mg of FBI which was far too costly for this 
study. Usleber et al. (1994) purified rabbit antibodies using 70% ammonium sulphate; Yu & 
Chu (1996) used 35% while Yeung et al. (1996) did no purification but simply diluted rabbit 
sera with '1.l1 equal volume of 50% glycerol in water and stored aliquots at -20°C. 
Using PEG 6 000 as a precipitant was relatively easy and cheap. The extraction ofIgY 
required good technical skills and careful work to ensure effective precipitation and 
complete removal of interfering albumin and lipids. 
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It is important to use PEG with the correct molecular mass otherwise the extraction does not 
work (Polson et al., 1985; Dr. T.H.T. Coetzer, personal communication). Extraction ofIgG 
was easier except for working with smaller volumes. The volumes of the final IgY extracts 
were on the whole larger than for the IgG extracts (with the exception of batch RlI14) 
because of larger starting volumes. This is another advantage of using chickens/eggs over 
rabbits/serum. 
The rabbit antibodies (IgG) are stable for long periods if stored at -20°C with 60% 
(v/v)glycerol but the hen antibodies (IgY) are denatured by freezing (Dr. T.R.T. Coetzer, 
personal communication). During the time period of this study, it was noted that the IgY 
extracts were stable for at least 4 years at 4°C. 
3.5.3 Electrophoresis 
The electrophoretogram (Figure 3.4) clearly showed a progressive reduction in protein 
concentration in the albumin and 0.1-,0.2- and ~-globulin regions with an increase in the 
gamma globulin regions indicating successful purification. 
3.5.4 Protein Concentration 
Measurement of protein concentration was a simple procedure but again needed careful 
work to get correct and reproducible results. From the results for protein concentration 
(Tables 3.1,3.2 and 3.3) and the statistical evaluation, the two different methods were in 
good agreement. Measurement of the protein concentration was necessary to be able 
calculate the amounts of Ab) to use for titre experiments. 
Because the extracted IgY and IgG will contain antibodies other than those against FBI (e.g. 
antibodies against KLH), a high protein concentration did not necessarily indicate a high 
antibody titre. For example, chicken 2 had highest protein concentration at week 3 (when 
only one egg was laid) yet the highest titre was for week 8 yet for the other animals the batch 
with highest titre also had the highest protein concentration viz. week 8 for chicken 2, week 
14 for rabbit 1 and week 8 for rabbit 2 (Tables 3.1, 3.2 and 3.3 and Figure 3.13). 
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3.5.5 Optimisation of ELISA for Antibody Titre 
Checkerboard or chess board titrations are an accepted method of optimising ELISA 
methods. Good results are indicated by a steep curve, low values for no Ab l and no Ab2 
blanks (less than lowest absorbance value for other wells), suitable maximum absorbance 
values « 2 or between 1.0 and 1.5) and low results for pre-immune sera compared to post-
immunisation sera (Dr. T.H.T. Coetzer, personal communication, Crowther, 1995). 
Antigens or antibodies adhere to plates by adsorption / hydrophobic interactions (Crowther, 
1995). Some authors (Abouzied et at.,1996; Azcona-Olivera et at., 1992A, 1992B; Yeung et 
at., 1996 Yu & Chu, 1996) used FBI-OVA or FBI-BSA conjugate (Fukuda et at., 1994) to 
coat microtitre plates but since FBI is like a large amino acid and charged in solution at 
pH 7, coating directly with FBI was tried. Fumonisin B\ at a concentration of 100 ng/ml in 
PBS attached readily to the microwell plates (Table 3.5). Optimal antigen concentrations 
were 1-1 0 ~g/ml to saturate the available sites on the plate (Crowther, 1995). 
Casein at a concentration of 1 % in PBS was a cheap and effective blocking agent although it 
was not as easy to dissolve as BSA (Table 3.6). Blocking agents used by other authors were 
1 % polyvinyl alcohol in PBS (Abouzied et al., 1996),2% instant skim milk powder in PBS 
(Clarke et al., 1993),0.1 % non-fat dry milk (Fukuda et al., 1994) or 0.1 % gelatin in PBS 
(Yu & Chu, 1996). 
For stability, it was necessary to have a protein in the diluent for antibody solutions. Bovine 
serum albumin at a concentration of 0.5% in PBS proved to be the best (Table 3.7). The 
range of primary antibody concentrations in titre experiments should be 100 to 500 Jlg/ml 
(Dr. T.H.T. Coetzer, personal communication) and the use of25, 100,500 and 1 000 Jlg/ml 
gave good results. For the second incubation, the enzyme-labelled second antibody from 
Sigma at 1:2 000 dilution gave the best results (Figure 3.6). 
In conclusion, for all titre experiments coating was done with 100 ng/ml FBI in PBS, 
blocking with 1 % casein, washing with 0.1 % Tween 20 in PBS, antibody diluent was 0.5% 
BSA in PBS, concentrations of Ab l were 25 to 1 000 Jlg/ml and Abl (Sigma) at 1:2 000. 
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3.5.6 Antibody Titre 
Antibody titre was checked for all batches ofIgY and IgG. Good inter-plate CV values were 
obtained for no Ab i and no Ab2 blanks from all plates run for titre indicating good 
reproducibility of the method. Although antibodies were successfully produced in both 
chickens and rabbits, the chickens produced higher titres as shown by high maximum 
absorbance values and steep curves on the graphs. The highest titre was from chicken 2 for 
week 8 (Figure 3.13). Highest titre has been assessed as the maximum dilution (> 1 :50 000) 
to give absorbance 2 x pre-immune (Azcona-Olivera et al., 1992A; Abouzied et al., 1996) or 
taken as the steepest curve and highest absorbance plotting A vs. dilution of antisera (Yu & 
Chu, 1996). 
The chickens produced antibodies as early as two weeks after initial immunisation and 
continued for the 14 week period of the study; the rabbits produced antibodies at every bleed 
(4,8, 12 and 14 weeks). Abouzied et al. (1996) produced successful antibodies 8 weeks after 
initial injection whereas Yeung et al. (1996) obtained highest titres after 5 to 7 months. 
Usleber et al. (1994) detected antibodies 4 weeks after initial exposure and Yu & Chu (1996) 
found antibodies at 5 weeks with highest titre at 12 weeks; and better titre with a FBI-KLH 
conjugate than FB1-BSA. 
3.6 CONCLUSION 
Keyhole limpet hemocyanin linked to FBI proved to be an effective immunogen as 
polyclonal antibodies against fumonisin B I were successfully raised in both chickens and 
rabbits. Antibodies were extracted from egg yolks (Ig Y) for chickens and from blood for 
rabbits (IgG). Electrophoresis showed the extraction to be efficient giving relatively pure 
gamma globulin fractions. 
Using checkerboard titrations, an indirect ELISA method was successfully optimised for 
measurement of titre. Thereafter the titre of all batches of Ig Y and IgG was measured as the 
steepest titration curve. Chickens had higher titres than rabbits - probably due to different 
genetic make-up. The highest titre was from chicken 2 for week 8. 
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CHAPTER 4 
COMPETITIVE DIRECT ELISA 
4.1 INTRODUCTION 
Immunoassays such as ELISA methods, because of their sensitivity and specificity, are an 
obvious choice for analysis of mycotoxins as mycotoxins and their metabolites are usually 
present in small amounts. Generally ELISA methods are ten to a hundred times more sensitive 
than radio-imrnunoassays (RIA) when purified toxins are used (Chu, 1985). 
Quantitative ELISA methods to measure antigen can be direct or indirect competitive, or can 
use a capture antibody. Because of their small size (low molecular weight), sandwich assays are 
not suitable for fumonisins. Sandwich assays are used for large antigens with at least two 
antigenic determinants (Crowther, 1995). Below is the equation for a direct competitive format 
using enzyme-labelled antigen. 
S-Ab + Ag + AgE ~ S-Ab-Ag + S-Ab- AgE 
The primary antibody (Ab) is attached to the solid phase (S). Labelled (AgE) and unlabelled 
antigen (Ag) compete for binding to the Ab. Separation is by washing which removes any 
unreacted reagents. The amount of antibody coated to the solid phase and the amount of labelled 
antigen is constant while the amount of unlabelled antigen varies - being either standards or 
samples. Only the S-Ab- AgE can be measured by addition of a suitable substrate. By the law of 
mass action, the more Ag present the more S-Ab-Ag will be formed and the less S-Ab-AgE i.e. 
there is an inverse relationship between the amount of coloured product formed (measured as 
absorbance) and the amount of Ag present (Crowther, 1995, Voller & Bidwell, 1986). 
For application of this format to fumonisins, the primary antibody (Ab) was that raised in 
chickens and rabbits (as described in Chapter 3), the solid phase was the wells of the microtitre 
plate and the antigen was FB I. 
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In ELISA assays two enzymes are commonly used viz. alkaline phosphatase and horseradish 
peroxidase. Horseradish peroxidase [Hydrogen-peroxide oxidoreductase (EC 1.11.1.7)] is a 
glycoprotein with a molecular mass of 40 000 Daltons. Since it has both a carbohydrate moiety 
and amino groups, it can be linked to other proteins using sodium periodate or carbodiimide. 
Sodium periodate forms·aldehyde groups on the carbohydrate moiety by oxidation. The 
aldehyde forms Schiff bases with a. or E amino groups; sodium borohydride stabilises the Schiff 
base (Nakane & Kawaoi, 1974). As FBI has a free amino group, the periodate method can be 
used to link it to HRPO. 
Other workers successfully prepared FB(-HRPO conjugates using the sodium periodate method 
(Azcona-Olivera et al., 1992B; Usleber et al., 1994; Abouzied et at., 1996). They then used the 
conjugates to develop CD-ELISA methods to measure fumonisins in maize/food samples. 
However, none of their methods were adapted for physiological samples. 
Usleber et al. (1994) produced a successful CD-ELISA with detection limits of 0.17 ng/ml in 
buffer and 10 ng/g in maize, a standard range ofO.l to 5.0 ng/ml, maximum absorbance of 1.1, 
%BlBo (absorbance of bound fraction expressed as a percentage of the absorbance for the zero 
point on the standard curve) from 20 to 80%, intra-assay CV of7.5%, inter-assay CV of 14% 
and IDso of 0.62 ng/ml. Coating was done using 100 J..l.I of poly clonal antibodies overnight at RT 
in carbonate buffer(pH 9.6). 
In the method of Abouzied et al. (1996), sample extracts or standards were mixed with FBI-
HRPO in mixing wells prior to being transferred to reaction wells already coated with 
polyclonal antibodies. The range of the standard curve was from 0 to 15 ng/ml, detection limits 
were <0.1 ng/ml FBI in 10% methanol in water, intra-assay CV (same day) was 3.8% and inter-
assay CV (different days) was 7.6%. Recovery from maize was 74 to 91 % and detection limits 
in com were < 0.2 - 6 J..l.g/g. This method is now marketed as the Veratox ® Fumonisin Kit 
(Neogen Corporation). 
Using monoclonal antibodies, Azcona-Olivera et al., (1992B), coated overnight at 40°C in 
carbonate-bicarbonate buffer (PH 9.6), then added 50 J..l.I standard or sample followed by 50 J..l.I 
FB1-HRPO (2 J..l.g/ml) in 1 % OVA in PBS. The maximum absorbance values were 1.2 in PBS, 
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1.3 in 27% methanol and 1.3 in13 % acetonitrile. Standard curves were similar for all three 
solvents with a range from 50 to 5 000 ng/ml. Detection limits were 200 ng/g in maize, recovery 
from maize samples was103%, intra-assay CV was 11.5% and inter-assay CV was 14.8%. This 
method is also commercially available as Fumonisin Agri-Screen kits (Neogen Corporation). 
In their method, Yu & Chu (1996) used FB1-HRPO (50 ~l, 25 ng/ml) prepared by the 
carbodiimide method. They coated with antibody overnight at 4°C in PBS (100 111, 6 Ilg/ml), 
blocked with 0.1 % BSA in PBS and then added 50 ~l FBd well followed by). The range of the 
standard curve was from 0.01 to 100 ng/ml, maximum absorbance was 1.8, IDso was 0.45 ng/ml 
and detection limits were 0.05 ng/ml in buffer and < 50 ppb in maize. 
4.1.1 Objectives 
1. To prepare the antigen-enzyme conjugate, FBI linked to HRPO. 
2. To use the antibodies already raised in chickens to develop a CD-ELISA. 
4.2 MATERIALS 
4.2.1 Chemicals 
Sodium periodate (NaI04), and sodium borohydride (NaBH4) were purchased from Sigma 
Chemical Co., USA. 
Horseradish Peroxidase was purchased from Boehringer Mannheim, Germany. 
Ethanol was purchased from Merck and glycerol from Saarchem. 
Coomassie Brilliant Blue viz. Serva Blue G (Research Grade) was obtained from Serva 
Feinbiochemica; 89% o-phosphoric acid from M & B laboratory chemicals. 
Primary antibody was prepared as described in Chapter 3. 
FB I stock standards were prepared as described in Chapter 3> section 3.2.3. 
For all other chemicals refer to Chapter 3, section 3.2.1. 
4.2.2 Buffers/Solutions 
The following buffers were used in the CD-ELISA: 
Phosphate buffered saline (PBS) (PH 7.2) (Appendix 2, 2.2) 
O.IM (l00 mM) Sodium phosphate buffer (PH 7.6), 0.02% sodium azide (Appendix 2,2.3) 
0.15M Citrate - phosphate buffer (PH 5.0) (Appendix 2,2.6) 
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Stopping buffer: 0.1 % sodium azide in citrate-phosphate buffer 
1 mM Sodium acetate buffer (pH 4.4) 
200 mM Sodium carbonate buffer (pH 9.5) 
O.lM Carbonate/bicarbonate buffer (pH 9.6) 
4.3 METHODS 
(Appendix 2, 2.7) 
(Appendix 2, 2.8) 
(Appendix 2, 2.9) 
(Appendix 2, 2.10) 
4.3.1 Preparation of Fumonisin Bl - Horseradish peroxidase conjugate (FBI-HRPO) 
The method was based on that ofUsleber et al. (1994) and Nakane & Kawaoi (1974). Four 
milligrams (4 mg) ofHRPO (copper coloured crystals) were dissolved in 1 ml ultra-pure water 
(reverse osmosis and de-ionised). To activate the enzyme 200 III of freshly prepared sodium 
periodate (100 mM, 0.2139 g in 10 ml ultra-pure water) was added and the resulting green 
solution mixed at RT for 20 min. The solution (1170 Ill) was dialysed at 4°C overnight 
(SpectraIPor cellulose membrane dialysis tubing, MWCO 12000 to 14000 Daltons, 10 mm flat 
width, 6 mm diameter, capacity approximatelylO mllft., Sigma Chemical Co., USA) against 
one litre of ImM sodium acetate buffer (pH 4.4). The pH of the activated HRPO was adjusted to 
9.5 using 200 mM sodium carbonate buffer (pH 9.5) (giving a yellow-brown solution,) and 
immediately 1 mg FBI dissolved in 1 ml ultra-pure water was added and mixed. 
After incubation for 2 hr at RT, 100 III of freshly prepared sodium borohydride (41.7 mg in 10 
ml ultra-pure water) was added, mixed and incubated at 4°C for 2 hr. The solution (2.55 ml) was 
dialysed for 3 x 12 hr at 4°C against one litre PBS, pH 7.2. The dialysate (2.3 ml) was diluted 
1: 1 with 60% glycerol and stored in 55 III aliquots in sealed Eppendorf micro test tubes (AEC 
Amersham) at - 20°C. 
4.3.2 Measurement of Protein Concentration of Fumonisin Bl - Horseradish peroxidase 
conjugate using the Bradford Assay 
Fifty ml of 89% o-phosphoric acid and 23.5 ml ethanol were added to 50.3 mg Serva Blue G 
and the solution was made up to 500 ml with distilled water. After mixing for 1 hr at RT, it was 
filtered through Whatman No. 1 filter paper and used the same day (Bradford, 1976; Read & 
Northcote, 1981; Compton & Jones, 1985). Since there was insufficient HRPO to use as a 
standard, a stock protein standard was made by dissolving 50.7 mg BSA, fraction V, in 50 ml 
30% glycerol in PBS (to have the same diluent as the FBI-HRPO conjugates). 
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The concentration was checked by reading absorbance at 280 run (Milton Roy Spectronic 3 000 
Array Spectrophotometer). 
From this stock solution a range of standards were prepared viz. 800,600,400,200, 100 and 50 
Ilg/ml in 30% glycerol in PBS. Duplicate 50 III volumes of standard or FB1-HRPO conjugate 
were pipetted out, 2.5 ml Bradford reagent was added and mixed. 
After 5 minutes (and within 1 hr) absorbances were read at 595 run against a blank of 30% 
glycerol in PBS. 
4.3.3 Measurement of Protein Concentration of Primary Antibody 
Chicken antibodies had given the highest titres and volumes (Chapter 3, section 3.4.4) 
ImmunoglobulinY batches C2/8 and C2/12 from chicken 2 were combined to use as primary 
antibody. A 1 :40 dilution of the combined extracts was made in O.lM sodium phosphate buffer 
(PH 7.6) and the absorbance was read at 280 run. Using an extinction coefficient, E, of 1.25 
(Coetzer, 1985), the protein concentration in mg/ml was calculated. 
4.3.4 Development of Competitive Direct ELISA Method 
The method was based on that ofUsleber et al.(1994). For development and optimisation of the 
method various parameters were checked using checkerboard titrations. Certain experiments 
required the use of a second enzyme-labelled antibody. In the summary below the tested 
alternatives for each step are shown in Italics. 
1. The wells of the microtitre plate (Nunc 96 well Maxisorb, AEC Amersham) were coated 
directly with primary antibody, 150 III per well. 
The plate was covered and incubated for 18 hr. 
Incubation temperature - RT or 4°C. 
Concentrations of Abj - 500, 400,300,200, 100, 10, 1, O.B, 0.6, 0.4, 0.2, 0.1 J.l.g/ml. 
Buffer - PBS (PH 7.2) or 0.1 M carbonate/bicarbonate buffer (pH 9. 6) 
2. The wells were blocked, 200 III per well. 
0.5% BSA or 1% casein in PBS, for 1 hr at RT or 37°C. 
3. The plate was washed three times with 0.1 % (v/v) Tween 20 in PBS. 
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4. 50 III of FBI standards were pipetted out in duplicate; 50 III FBI-HRPO was added per 
well and incubated. 
Concentration of FB j standards - 0, 1, 5, 10, 25, 50 nglml in PBS. 
Concentration ofFBj-HRPO-IO, 25, 50, 100, 250, 500 nglml and 1,2,5,10 flglml 
in 0.5% BSA or 1% casein in PBS. 
Incubationfor 1 or 2 hr at RT or 37°C. 
5. The plate was washed three times with 0.1 % (v/v) Tween 20 in PBS. 
6. 150 III of substrate, 7.5 mg ABTS plus 7.5 III H202 in 15 ml citrate-phosphate buffer, pH 
5.0 was added to each well. The colour was allowed to develop for 15 min in the dark at 
RT. 
7. 50 III stopping buffer was added to each well . 
8. The absorbance of each well was read at 405 nm (Bio-Rad Model 550 Plate Reader). 
4.4 RESULTS 
4.4.1 Protein Concentration of Fumonisin Bl - Horseradish peroxidase conjugate 
Duplicate absorbance readings of the BSA stock standard at 595 nm were 0.674 and 0.671; the 
mean was 0.673. 
The extinction coefficient of BSA at 280 nm for a 1 % solution (1 gil 00 ml) i.e. E280 1 % is 6.67 
(Hudson & Hay, 1989). 
Concentration ofBSA stock standard = (0.673 x 10) -:- 6.67 = 1.009 mg/ml. 
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FIGURE 4.1 PROTEIN STANDARD CURVE USING BOVINE SERUM ALBUMIN 
(BRADFORD ASSAY) 
(The data used to generate Figure 4.1 is in Appendix 1, Table 4.1). 
The equation for the graph was y = 0.0009x + 0.0482. 
Duplicate absorbance readings ofFB1-HRPO conjugate samples at 595 nm were 0.433 and 
0.426; the mean waS 0.430. 
Protein concentration ofFB1-HRPO = (0.430 - 0.0482) -;- 0.0009 = 424 Jlg/ml. 
4.4w2 Protein Concentration of Primary Antibody 
Duplicate absorbance readings of 1:40 dilutions of combined IgY extracts at 280 nm were 1.149 
and 1.153; the mean was 1.151. 
Protein concentration of Ab1 = (1.151 -;- 1.25) x 40 = 36.83 mg/ml. 
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4.4.3 Competitive Direct ELISA Method 
SWl.L. 
Initial experiments were done to check the coating buffer [PBS (PH 7.2) or carbonate/ 
bicarbonate (pH 9.6)] and the coating temperature (RT or 37°C) using two blocking agents 
(1 % casein or 0.5% BSA in PBS). 
TABLE 4.2 COMPARISON OF COATING BUFFERS AND COATING TEMPERATURES 
PBS for coatinl!: Absorbance at RT Absorbance at 4°C 
Blockinl!: Al!:ent 1% casein 0.5%BSA 1% casein 0.5%BSA 
No Ab. blank 0.087 0.085 0.094 0.091 
Ab. (ul!:/ml) 
0.1 0.778 0.624 0.669 0.718 
1 2.583 2.448 1.959 1.944 
10 >3.000 >3.000 2.353 2.323 
100 2.842 2.844 2.349 2.309 
Carbonate/bicarbonate Absorbance at RT Absorbance at 4°C 
buffer for coatinl!: 
Blockinl!: Al!:ent 1 % casein 0.5% BSA 1% casein 0.5% BSA 
No Ab. blank 0.103 0.110 0.114 0.102 
Ab. (ul!:/ml) 
0.1 0.576 0.666 0.678 0.776 
1 1.660 1.668 2.130 2.208 
10 2.396 2.461 2.684 2.714 
100 2.490 2.628 2.641 2.635 
Key to Table 4.2 
Absorbance values at 405 nm are the means of duplicates after subtraction of no Ab1 blank. 
Other experimental conditions were blocking for 1 hr at 37°C, no FBI or FB1-HRPO but addition of 
120 III Ab2
E
, 1:2000 incubated for 1 hr at 37°C. 
The best conditions for coating the plate with Ab l were using PBS at RT (and 1 % casein for 
blocking) as these gave the highest absorbance values for each antibody concentration with a 
low absorbance reading for the no Ab1 blank (Table 4.2). Even though the RT varies throughout 
the year, it was more constant at night and incubation was done overnight. 
S!Jw.l. 
Next experiments were done to decide on the blocking agent (1 % casein or 0.5% BSA in PBS), 
and blocking temperature (1 hr at RT or 37°C) using various dilutions of primary antibody in 
PBS. 
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TABLE 4.3 COMPARISON OF BLOCKING AGENTS AND BLOCKING TEMPERATURES 
Absorbance at RT Absorbance at 37°C 
1 % casein 0.5% BSA 1% casein 0.5%BSA 
No Ab l blank 0.106 0.107 0.105 0.105 
Ab1 (Ilg/ml) 
0.1 1.030 0.924 1.028 0.959 
0.2 1.644 1.495 1.605 1.453 
0.4 2.305 2.146 2.239 2.141 
0.6 2.490 2.341 2.354 2.291 
0.8 2.593 2.451 2.466 2.347 
1.0 2.824 2.605 2.398 2.342 
Key to Table 4.3 
Absorbance values at 405 nm are the means of duplicates after subtraction of the no Ab l blank. 
Other experimental conditions were no FBI or FBI-HRPO but addition of 120 J.l.1 Abl, 1:2 000 incubated 
for 1 hr at 37°C. 
As a blocking agent, 1 % casein gave higher absorbance results with lower values for the no Ab) 
blank than 0.5% BSA. This was fortunate since casein is cheaper than BSA. Results at the two 
temperatures (RT and 4°C) were similar (Table 4.3). The range of concentrations of antibody for 
this and other experiments was selected to cover a wide range. To saturate available sites on the 
plate, Crowther (1995) recommended using 50 - 500 ng/well in a volume of 50 ~l (but the 
concentration could be increased if a larger volume were used). 
However, for efficient use of Ab) it would also be preferable to use the lowest possible 
concentration that gave satisfactory results. 
SteD 4. -
Having established coating and blocking conditions, to assess the viability of the enzyme 
triplicate dilutions of various concentrations ofFB1-HRPO conjugate were reacted with 
substrate. 
TABLE 4.4 CHECK FOR ACTMTY OF ENZYME IN FUMONISIN B.-HORSERADISH 
PEROXIDASE CONJUGATE 
FB1-HRPO 10 ng/ml 25 ng/ml 50 ng/ml 100 200 500 1000 
ng/ml ne/ml ne/ml ne/ml 
Absorbance 0.493 1.155 2.068 >2.5 >2.5 > 2.5 >2.5 
Kev to Table 4.4 
Absorbance values at 405 nm are the mean of duplicates after subtraction of substrate blank. 
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The high absorbance values confirmed that the enzyme was still active (Table 4.4). 
At a concentration of25 ng/ml forFBI-HRPO, a suitable maximum absorbance value was 
achieved. The maximum absorbance value should be <2 , preferably between 1.0 and 1.5 
(Crowther 1995). 
Experiments were then done to check the zero point on the standard curve i.e. no FBI standards 
but at varying concentrations of antibody and FBI-HRPO. 
TABLE 4.5 ZERO POINT ON STANDARD CURVE AT IDGHER 
ANTIBODY CONCENTRATIONS 
FB1-HRPO 25De/ml 50 ne/ml 100 ne/ml 
Total 1.310 2.242 >2.3 
No Ab 1 blank 0.078 0.078 0.082 
Abl (l1!!/ml) 
10 0.102 0.112 0.118 
100 0.106 0.113 0.122 
500 0.102 0.104 0.108 
Key to Table 4.5 
The results are means of duplicate absorbance values at 405 nm. Other experimental conditions were 
coating at RT overnight, blocking with 1% casein for 1 hr at 37°C, incubation with 50 III PBS and 50 III 
FB1-HRPO for 2 hr at 37°C. Total tubes were included to give a measure of the maximum possible 
absorbance for FB1-HRPO. 
In another experiment, different concentrations of Ab 1 and FBI-HRPO were used and the 
incubation reaction between the conjugate and the antibody were done at RT and at 37°C. 
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TABLE 4.6 ZERO POINT ON STANDARD CURVE AT LOWER ANTIBODY 
CONCENTRATIONS 
FB1-HRPO 10 nl?/ml 100 n2/ml 1 ue:/ml 10 tl2/ml 
Total 00441 10487 2.573 >3.0 
RT 37°C RT 37°C RT 37°C RT 37°C 
No Abt blank 0.085 0.070 0.081 0.077 0.088 0.087 0.171 0.144 
Abt (tl2/ml) 
0.1 0.082 0.076 0.080 0.081 0.084 0.090 0.140 0.155 
0.2 0.080 0.074 0.081 0.080 0.088 0.090 0.147 0.147 
004 0.087 0.079 0.087 0.089 0.096 0.099 0.173 0.151 
0.6 0.084 0.082 0.088 0.088 0.097 0.104 0.167 0.157 
0.8 0.090 0.086 0.098 0.111 0.110 0.112 0.161 0.160 
1.0 0.090 0.088 0.100 0.099 0.112 0.117 0.193 0.179 
Key to Table 4.6 
The results are the means of duplicate absorbance values at 405 nm. 
Other experimental conditions were coating at RT overnight using PBS as coating buffer, blocking with 
1% casein for 1 hr at 37°C, incubation with 50 III PBS and 50 III FB,-HRPO. Total tubes were included 
to give a measure of the maximum possible absorbance for FB,-HRPO. 
Further experiments using different concentrations of antibody and FB(-HRPO also gave 
disappointing results. 
TABLE 4.7 ZERO POINT ON STANDARD CURVE USING DIFFERENT ANTIBODY AND 
FUMONISIN B.-HORSERADISH PEROXIDASE CONCENTRATIONS 
FB1-HRPO 50 n2/ml 100 ne/ml 250 ne:/ml 500 n2/ml l_tlg/ml 2 tl2/ml 
Total 1.013 1.823 2.715 2.940 2.890 2.868 
NoAb t blank 0.093 0.102 0.096 0.095 0.102 0.128 
Ab t tl2/ml 
1 0.107 0.097 0.115 0.109 0.096 0.101 
5 0.113 0.102 0.112 0.103 0.103 0.151 
10 0.108 0.110 0.118 0.137 0.118 0.117 
50 0.109 0.105 0.108 0.148 0.162 0.143 
100 0.128 0.105 0.108 0.133 0.116 0.116 
Key to Table 4. 7 
The results are the means of duplicate absorbance values at 405 nm. 
Other experimental conditions were coating at RT overnight using PBS as coating buffer, blocking with 
1 % casein for 1 hr at RT and incubation for reaction of conjugate and antibody for 1 hr at 37°C. 
86 
TABlE 4.8 ZERO POINT ON STANDARD CURVE USING HiGHER FUMONISIN B1-
HORSERADISH PEROXIDASE CONCENTRATIONS 
FB1-HRPO 50 n2/ml 100 n2/ml 500 n2/ml 1112/ml 2 112/ml 5 112/ml 
Total 0.827 1.520 2.617 2.383 1.156 1.006 
No Ab l blank 0.090 0.093 0.102 0.129 0.115 0.204 
Ab l (p2/ml) 
1 0.098 0.098 0.100 0.122 0.113 0.187 
10 0.100 0.103 0.109 0.118 0.118 0.136 
100 0.105 0.104 0.107 0.112 0.108 0.136 
500 0.100 0.100 0.101 0.107 0.102 0.104 
Kev to Table 4.8 , 
The results are the means of duplicate absorbance values at 405 nm. 
Other experimental conditions were coating at RT overnight using PBS as coating buffer, blocking with 
1 % casein for 1 hr at RT and incubation for reaction of conjugate and antibody for 1 hr at 37°C. 
The FB1-HRPO was made up in 0.5% BSA or 1 % casein in PBS. Results in Table 4.8 were for 
0.5% BSA in PBS; results for 1 % casein were similar i.e. low absorbance values. 
In the experiments to establish the zero point of the standard curve (which should give the 
highest absorbance value) results were disappointing as at a variety of concentrations of 
antibody and FBI-HRPO, maximum absorbance values were only between 0~096 and 0.187. 
These results were too close to the values for the no Abl blank which varied from 0.070 to 
0.204. The total and zero point absorbances increased with increasing concentrations of FBI-
HRPO but so did the results for the no Abl blank. The highest value obtained (0.187) was using 
5 Ilg/ml per well ofFB1-HRPO but the blank was 0.204. 
The variation in results for total tubes was due to the light sensitivity of the ABTS. The plate 
reader used was located in a different department so there was an unavoidable delay between 
adding the stopping buffer and reading the plate which caused a drop in the total absorbance 
values particularly at higher readings (Tables 4.5, 4.6, 4.7 and 4.8). 
Using RT or 37°C for the incubation temperature for the competition step gave similar results 
(Table 4.6). Since no satisfactory result was obtained for the zero point, no attempt was made to 
run a standard curve. 
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Since this ELISA format was unsuccessful, a sandwich experiment was done to see if the FB 1-
HRPO conjugate would bind by initially coating the plate with FBI. Thus the final sandwich 
was FBI - Abl - FBI-HRPO. 
TABLE 4.9 ZERO POINT ON STANDARD CURVE USING SANDWICH ASSAY 
FBt for 10 ng/ml 100 ng/ml 200 ng/ml 
Coatine 
FBt-HRPO 2 10 50 2 10 50 2 10 50 
n2/ml J!g/ml n2/ml n2/ml n2/ml n2/ml nl?/ml n2/ml n2/ml 
Total 0.530 1.030 2.508 0.533 1.049 2.483 0.544 1.070 2.473 
NoAb, blank 0.079 0.087 0.102 0.083 0.082 0.092 0.078 0.087 0.084 
Abt (1l2/ml) 
10 0.082 0.081 0.080 0.083 0.085 0.081 0.078 0.081 0.077 
100 0.084 0.084 0.083 0.091 0.083 0.093 0.076 0.083 0.092 
200 0.080 0.085 0.082 0.082 0.089 0.098 0.082 0.091 0.110 
Kev to Table 4.9 
The results are means of duplicate absorbance values at 405 nm. 
Other experimental conditions were coating FBI overnight at 4°C, blocking with 1 % casein in PBS for 1 
hr at 37°C, Ab l incubated for 2 hr at 37°C, FBI-HRPO (no FBI standard) for 2 hr at 37°C. 
4.5 DISCUSSION 
For effective use in a CD-ELISA, the enzyme-antigen conjugate must retain both enzymatic and 
immunological activity (Voller & de Savigny, 1981). This appears not to have been the case in 
the experiments described in this chapter. Mycotoxin-enzyme conjugates can have stability 
problems with the enzyme (Chu, 1985). 
Coating with Abl at 0.8 or 1 J.l.g/ml and using 10 J.l.g/ml FBI-HRPO gave the best results but 
differences between absorbance for the zero point and no Abl blank were still only ± 0.022 to 
0.035 which was unacceptably low (Table 4.6). Using high concentrations of conjugate was not 
acceptable as there would then have been sufficient to run only a few plates before making a 
new batch. This would not be economical as both FBI and HRPO are costly items. Also, 
increasing the concentration of coating antibody (Abl) or antigen-enzyme conjugate (FB I-
HRPO) would decrease ""he sensitivity of the method (Schneider et aI., 1995). 
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The similarity in results between the zero point and no Ab l blanks indicated that the conjugate is 
probably not binding to the antibody (Tables 4.5, 4.6 and 4.7). There could have been a problem 
with the conjugate; either the FBI did not attach to the HRPO or it could have linked in most of 
the conjugates at the same or adjoining sites required to bind antibody causing steric hindrance. 
The little colour obtained could be from non-specific binding of HRPO to the plate. Possibly the 
BSA or casein in the diluent were preventing binding ofFBI-HRPO to Ab l . Another possibility 
is incomplete blocking or washing but this is unlikely as these techniques had been successful 
with the method for antibody titre (Chapter 3). 
The sandwich assay to check binding of the FBI-HRPO conjugate to antibody was also 
unsuccessful as again absorbance values were close to those for no Ab l blanks (Table 4.9). 
Again this could be because the FBI did not attach to HRPO and the conjugate extract was only 
HRPO with the FBI having been removed during dialysis. Alternatively, assuming the conjugate 
to have been correctly prepared, the antibody may not have two binding sites for FBI; or there 
was steric hindrance. 
Briand et at., (1985) suggested that if coupling is unsuccessful with one agent another should be 
tried. Possibly use of the carbodiimide method as used by Yu & Chu (1996) should have been 
attempted but due to limited funding, purchase of more FBI was not possible. 
Alternatively a different ELISA format using antibody labelled with HRPO could have been 
attempted. However, this would have required purification of the primary antibody to remove 
anti-KLH and other antibodies by use of irnmunoaffinity methods. Again these would require 
purchase of more FBI which was not possible on the limited bUdget. 
4.6 CONCLUSION 
Despite 4 months careful work, this method was not successful. The problem seemed to be the 
fumonisin-enzyme conjugate which did not bind to the antibody. It was decided to attempt an 
indirect competitive method. 
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CHAPTERS 
COMPETITIVE INDIRECT ELISA 
5.1 INTRODUCTION 
For a quantitative method, an indirect competitive ELISA (CI-ELISA) can be used instead of a 
direct competitive method. Indirect competitive ELISA methods usually have better sensitivity 
and use ten to a hundred times less antibody than a direct competitive method but they are more 
costly (need for a second enzyme-labelled antibody bought commercially) and more time 
consuming (second incubation with second antibody). The second antibody is from a different 
animal to the first antibody e.g. Rabbit anti-chicken; goat anti-rabbit. conjugate is used to coat 
the plate (Chu, 1985). 
The format for a CI-ELISA is as follows:-
S-Ag + Ab l + Ag ~ S-Ag-Ab l + Ag-Ab1 
S-Ag-Ab1 + Ab2E ~ S-Ag-Abl - Abl 
In the first reaction, antigen (Ag) bound to the microtitre plate competes with free antigen 
(standard or sample) for binding to the primary antibody (Ab l ). After washing to remove 
unreacted free antigen and antibody as well as the antigen-antibody complex in solution, a 
second enzyme-labelled antibody (Abl), anti-Ab l , is added. By the law of mass action, the 
more free Ag is present the less S-Ag-Ab l and hence the less S-Ag-Ab l - Abl will be formed 
i.e. there is an inverse relationship between the amount of free Ag present and the amount of 
coloured product formed (Crowther, 1995; Voller & Bidwell, 1986). 
Optimisation of a CI -ELISA method is also more complex because of more steps in the assay 





coating buffer and concentration of antigen for coating the microtitre plates 
concentration of primary antibody for competition to cover suitable range of antigen 
concentrations 
buffer/diluent, blocking agent, incubation times 
concentration of second antibody to give best results 
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For application of this format to analysis offumonisins, the antigen was FBI, the primary 
antibody was from chickens or rabbits (prepared as described in Chapter 3), the solid phase was 
the wells of the microtitre plate and the second enzyme-labelled antibody was rabbit anti-
chicken IgG-HRPO or goat anti-rabbit IgG-HRPO (Sigma Chemical Co., USA). 
Competitive indirect ELISA methods were successfully developed (Azcona-Olivera et al., 
1992A; Fukuda et a!., 1994; Shelby et al., 1994;Yeung et al., 1996; Yu & Chu, 1996) but these 
were primarily to check for cross-reactivity with FBI analogues (Azcona-Olivera et aI., 1992A; 
Fukuda et a!., 1994; Yu & Chu, 1996). Only Shelby et al. (1994) and Yeung et al. (1996) 
adapted their methods to analyse for fumonisin in maize samples. 
5.1.1 Objectives 
1. To use HPLC to check the stability of the FBI stock standards that had been kept at 4°C 
(refrigerator) and -20°C (freezer) for close to 2 years. 
2. To use the chicken antibodies (combination ofIgY extracts C2/8 and C2/12) to develop 
a sensitive CI-ELISA for analysis offumonisins. 
3. To investigate methods of data reduction to obtain the most accurate quantitative results. 
4. To check the cross-reactivity of the rabbit (IgG extract R1I14) and chicken antibodies to 
FB2, FB3 and So. 
5. To determine range, detection limits, intra-assay and inter-assay CV of the method. 
At all times the over-riding factors were that the method must be sensitive so that it could be 




D-sphingosine and o-phthaldialdehyde were purchased from Sigma Chemical Co., USA.. 
Methanol (HPLC grade) and acetonitrile (HPLC grade) were from BDH. 
FBI stock standards (for ELISA) were prepared as described in Chapter 3, section 3.2.3. 
Anti-FBI antibodies previously raised in chickens and rabbits (Chapter 3). 
FB2 and FB3 were kindly donated by Dr. M. Castegnaro, !ARC, France. 
For all other chemicals refer to Chapter 3, section 3.2.1. 
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5.2.2 Buffers/Solutions 
The following buffers were used in the CI-ELISA: 
Phosphate buffered saline (PBS) (pH 7.2) (Appendix 2, 2.2) 
O.l5M Citrate-phosphate buffer (pH 5.0) (Appendix 2,2.6) 
Stopping buffer: 0.1 % sodium azide in citrate-phosphate buffer (Appendix 2, 2.7) 
O.IM Sodium phosphate buffer (PH 3.35) (Appendix 2, 2.11) 
5.3 METHODS 
5.3.1 High Performance Liquid Chromatography 
This was done to check the aqueous standards and was based on the methods of Shephard et al. 
(1992B), Thiel et al. (1993) and Duncan et al. (1998). 
A stock fumonisin BI standard for HPLC was made by dissolving 1 mg FBI in 1 ml 
acetonitrile:water (1 : 1). Suitable dilutions of the stock standard were made in acetonitrile:water 
(1 : 1) to give standards of 50, 100 and 200 Ilg/ml. 
The mobile phase was composed ofO.1M sodium phosphate buffer (PH 3.35) : methanol 
(27:73). It was degassed for 15 minl300 ml at 20°C and 220V (UMC 10 waterbath, Ultrasonic 
Manufacturing Co.) 
The Spectra-Physics HPLC instrument (Thermo Separation Products, SMM Instruments, South 
Africa) had a C I8 guard column (Hichrom) and a C I8 analytical column (Nova-Pak stainless 
steel column, 3.9 x 150 rnm, 4 jlm packing material, Waters). For fluorometric detection (xenon 
lamp), the excitation wavelength was 336 nm and the emission wavelength was 440 run; the 
flow rate was 1 mllmin and the pressure was ± 1800 psi. 
Twol00 III aliquots of PBS and four 100 III aliquots of aqueous FBI standards (two kept at 4°C 
and two kept at -20°C) were pipetted into Eppendorf micro-test tubes (AEC Amersham) and 
freeze dried. The powders were re-dissolved in acetonitrile:water (1: I). Just before analysis, 
25 III of re-constituted FB I standard or buffer was added to 225 III o-phthaldialdehyde (OP A) 
(Appendix 2, 2.13), and mixed for exactly I minute. Using a 100 III Hamilton syringe, 40 III of 
the mixture was injected through the septum; 20 III was transferred to the column via the 
injection loop. Each sample/standard was derivatised and injected in duplicate. Thetime from 
derivatisation to loading on to the column was 2 min. 
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Each standard/sample was run for 6 min in case there was any FB2 or FB3 present (These elute 
after FBI)' Calculations of peak area were done using PC-lOOO software (Thermo Separation 
Products). The same experiment was repeated twice. 
5.3.2 Competitive Indirect ELISA 
In the summary below the final optimised method is shown first and the tested alternatives for 
each step are shown underneath in Italics. Unless otherwise stated experiments were done using 
chicken antibodies. 
Checkerboard titrations were done to ascertain the optimum concentration of coating antigen 
(10 to 1 000 ng/ml), the concentration of first antibody (100 to 500 ).1g/ml) to give a suitable 
range for the standard curve, the diluent for antibody solutions (containing BSA or casein) and 
incubation times and temperatures . 
Since room temperature in the laboratory could vary by 10°C, only temperatures of 4°C 
(refrigerator) or 37°C (incubator) were used for incubation. 
1. The wells of the microtitre plate (Nunc 96 well Maxisorb, AEC Amersham) were coated 
directly with FBI, 200 ng/ml in PBS, 100 ).11 per well. The plate was covered and 
incubated for 18 hr at 4°C. 
Concentrations of FBI - 50, IOO, I50, 200, 250 ng/ml. 
2. The wells were blocked with 1.0% casein (m/v) in PBS, 250 ).11 per well and incubated 
for 1 hr at 37°C. 
3. The plate was washed three times with 0.05% (v/v) Tween 20 in PBS. 
0.05% or 0.1% Tween 20 in PBS. 
4. FB I standards (0, 1,2, 3, 5, 8, 10, 20 ng/ml in PBS) were pipetted in triplicate into 
relevant wells, 50 ).11 per well. 
Concentration of FBI standards - 0, I, 2, 3, 5, 8, 10, I5, 20, 25, 30, 40, 50 ng/ml. 
5. The primary antibody (Ab!) was added to relevant wells, 300 ).1g/ml in 0.5% BSA in 
PBS, 50 ).11 per well. 
Concentration of primary antibody - IOO, 200, 300, 400, 500 jJ.g/ml. 
6. The plate was mixed by gentle tapping and incubated for 1 hr at 37°C. 
1 or 2 hr at 37°C. 
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7. The plate was washed three times with 0.05% (v/v) Tween 20 in PBS. 
O. 05% or 0.1 % Tween 20 in PBS. 
8. The second antibody (Abl), anti-chicken IgG (or anti-rabbit IgG) conjugated with 
horseradish peroxidase was added, 1:4000, 120 III per well and incubated for Ihr at 
37°C. 
Dilution of second antibody - 1: 2 000, 1: 3 000, 1: 4 000, 1: 5 000 
100 or 120 pl per well. 
9. The plate was washed three times with 0.05% (v/v) Tween 20 in PBS. 
0.05% or 0.1% Tween 20 in PBS. 
10. 150 III of substrate, 7.5 mg ABTS plus 7.5 III H202 in 15 ml citrate-phosphate buffer (pH 
5.0) was added to each well. The colour was allowed to develop for 15 min in the dark at 
RT. 
11. 50 III of stopping buffer was added to each well. 
12. The absorbance of each well was read at 405 nm (Bio-Rad Model 550 Plate Reader). 












All glassware was washed thoroughly with detergent, rinsed 5x in tap water then 3x in 
glass distilled water and air dried. 
New plates and new tips were used every time. 
PBS (1 Ox), citrate-phosphate buffer and stopping buffer were prepared every 2 weeks. 
PBS and PBS-Tween were prepared freshly the day before every run. 
1 % casein in PBS was prepared the day before any run and allowed to stand overnight at 
4°C to dissolve. 
All other reagents were prepared 15 to 20 min before use except ABTS where the H20 2 
was added just before use. 
Plates were mixed by tilting and gentle tapping. 
The plate was covered with a lid. 
For incubation at 37°C, plates were placed in a sealed constant humidity box in the 
incubator. 
All samples/standards/controls were assayed in triplicate. 
Triplicate absorbance results were only acceptable if CV ± 5%. 
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* A no Ab 1 blank (which gives measure of non-specific binding) was included on every 
plate. 
* Washing steps were done for 3 x 30 sec. 
5.3.3 Calculations 
Various alternative ways of calculating quantitative results using suitable software were 
investigated. This was necessary as the plate reader (Bio-Rad Model 550) only gave absorbance 
readings. 
Initially a curve fit was done to determine the parameters in the selected equation (curve type) 
for the standard curve graph and then backfitting to solve the equation for x using the values 
obtained for the parameters. 
A suitable curve type has to be selected viz. linear regression, linear interpolation, logit-log, 2nd 
order polynomial, 3rd order polynomial or 4-parameter non-linear regression equation. Scales on 
the axes can be linear or logarithmic. For a partly sigmoid curve (as obtained with an indirect 
competitive ELISA), the recommended equation is a 2nd order polynomial (y = ax2 + bx + c) or 
a 4-parameter non-linear regression (y = (a-d)/(l + (x/c) b) + d. Curve fitting is done more than 
once (iterations) until the best fit is obtained. If the curve fit is good, the deviation between 
known concentrations and measured concentrations are small; deviations must be randomly 
distributed over the entire curve. In a 4-parameter curve, parameter a is the upper asymptote, b 
is the slope, c is the concentration at the inflection point of the curve and d is the lower 
asymptote. In a 2nd order polynomial parameter c is the y intercept, a and b are constants for that 
curve. (ELISA+ booklet, Meddata Inc., New York; Sigmaplot instruction book, Jandel 
Scientific; Rodgers, 1986). 
The backfit equation for a 2nd order polynomial is x = (- b - (b2 - 4a(c _ y))o.5)/2a 
The following options for curve fitting were examined:-
y-axIs x-axIs Equation 
Method 1 Absorbance [FBd ng/ml 2nd order polynomial 
Method 2 Absorbance Log [FBI] ng/ml 2nd order polynomial 
Method 3 %BlBo [FBd ng/ml 2nd order polynomial 
Method 4 %B/Bo Log [FBd ng/ml 2nd order polynomial 
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Method 5 Absorbance [FBI] nglml A-parameter equation 
Method 6 Absorbance Log [FBI] ng/ml 4-parameter equation 
Method 7 %B/Bo [FBd ng/ml 4-parameter equation 
Method 8 %B/Bo Log [FBI] 4-parameter equation 
Method 9 Absorbance [FBI] nglml 4-parameter equation 
Method 10 %B/Bo [FBI] ng/ml linear regression 
Method 11 %B/Bo [FBI] ng/ml logit-Iog 
In methods 6 and 8, parameter dependencies for c and d were close to 1 and very close to each 
other, so the equation was altered to remove parameter d (as recommended in the Sigmaplot 
instruction book, Jandel Scientific). These were recorded as methods 6A and 8A. 
Method 9 was a check on the calculations using ELISA software (ELISA +, Meddata, Inc. New 
York) linked to the plate reader at the Natal Blood Transfusion Service (NBTS) with the kind 
assistance of Mr. R. Parkinson. 
Some methods were tried with and without weighting viz. 3,4, 7, 8 but the results were no 
better. Furthermore, if using weighted methods the standard error and coefficient of variation of 
the parameters have no meaning (Sigmaplot). 
Absorbance values were means after subtraction of the mean value for the no Ab i blank. 
%B/Bo was the ratio of the mean absorbance value expressed as a percentage of the mean value 
for the zero point on the standard curve (Crowther, 1995). 
In addition to standard curves, results from low (± 4 ng/ml) and high (± 8 ng/ml) method 
controls (FBI made up in PBS, n = 20) were used to decide on the best method of data 
reduction. 
Criteria for an acceptable method of data reduction were as follows:-
* low values for the chi square statistic ('l <0.01) 
* low values for SE «0.1) and CV of parameters «10%) 
* 
* 
low value for norm of fit results (Sigmaplot) 
low values for CV of low and high controls 
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Acceptable standards at NBTS are X2 < 0.01 and number of iterations < 9 (Mr. R. Parkinson, 
personal communication). 
To further check the correctness of selected method of calculation, method control results were 
compared with those obtained using ELISA+ software for calculation. 
Also, plasma sample results (Chapter 6) were compared with those from a Bio-Rad Model 3550 
Plate Reader with dedicated software. This calculated results using a quadratic curve fit and 
plotted absorbance vs. concentration. Unfortunately this plate reader was not available for 
regular use. 
5.3.4 Method Parameters 
The range of the standard curve was established by running a series of standards in triplicate viz. 
1,2,3,5,8, 10, 15,20,25,30,40,50 ng/ml. 
Intra-assay (same plate) and inter-assay (different plates) reproducibility were calculated using 
the fumonisin method controls (± 4 and ± 8 ng FBI /ml in PBS). 
Ruggedness was estimated as the reproducibility of the concentration of FBI giving 50% 
inhibition in the competition (i.e. 1Dso value). 
Detection limits were calculated using Student's two sample t-test on results of diluted FBI 
standards (0.5, 004, 0.3, 0.2, 0.1, 0.0 ng/ml, n = 11 for each). 
5.3.5 Cross-reactivity 
The cross-reactivity of chicken and rabbit antibodies with FB2, FB3 and So was done by 
constructing standard curves at concentrations of 2,3,5,8, 10,20 and 40 ng/ml (in triplicate). 
The concentration of Ab) for both chicken (combined IgY extracts C2/8 and C2/12) and rabbit 
(IgG extract Rl/14) antibodies was 300 Ilg/ml. Graphs were plotted as %B/Bo vs. log [FBrJ . 
Concentrations of FBI, FB2, FB3 and So at 50% binding were used to calculate 1Dso. 
Cross-reactivity was calculated as IDso for FBI / IDso for analogue x 100. 
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5.4 RESULTS 
5.4.1 High Performance Liquid Chromatography 
TABLE 5.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHECK ON STORED 
FUMONISIN Bl STANDARDS 
Sample Retention time Peak area FBJ (JJ2:/ml) 
PBS (i.e. OPA) 1.433 N/A 
Standard SO ~g/ml 2.381 10012 
Standard SO Ilg/ml 2.447 9079 
Standard 200 Ilg/ml 2.443 37025 
FBI standard stored at 4°C 2.431 18883 100.5 
FBI standard stored at - 20°C 2.419 18384 97.8 
PBS (ie. OPAl 1.479 N/A 
Standard SO J.lg/ml 2.360 16490 
Standard SO J.lg/ml 2.371 16517 
Standard 100 Ilg/ml 2.363 26068 
Standard 100 J.lg/ml 2.362 32746 
FBI standard stored at 4°C 2.353 30693 98.7 
FBI standard stored at - 20°C 2.360 27663 88.9 
The PBS samples only show a peak for OPA Le. no fumonisin present. Using the peak areas of 
the standards, the concentrations of the stored fumonisin standards were calculated. 
Mean at 4°C 





The expected result was 1 00 ~g/ml. 
5.4.2 Competitive Indirect ELISA 
The initial checkerboard titration experiment was to determine the concentration of FBI to use 
for coating and a suitable concentration of Ab l to give a workable standard curve. In the titre 
experiments it had already been found that FBI in PBS coated directly to the microtitre plate 
(Chapter 3, section 3.4.3). 
The no Ab1 blank gives an indication of non-specific binding of Abl to the plate; the no Ab2 
blank is a substrate blank for ABTS and an indicator of non-specific binding of ABTS to bound 
Ab1. 
The absorbance values for no Ab1 and no Ab2 blanks (Table 5.2) were about the same therefore 
Abl is not binding to coated FBI and/or casein. 
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Even though the checkerboard did not titrate out, results already looked more promising than 
those for the competitive direct method. 
TABLE 5.2 CHECKERBOARD TITRATION FOR CONCENTRATION OF FUMONISIN BI 
FOR COATING AND CONCENTRATION OF PRIMARY ANTIBODY 
Coating concentration of FBI 10 ng!ml 
No Ab l blank 0.098 
No Ab1 blank 0.101 
Concentration of Ab t 10 Ilg/ml 5 OJ!g/m I 100 Ilg/ml 
FBI standards (n{!/ml) 
0 0.111 0.158 0.207 
5 0.110 0.145 0.181 
10 0.108 0.154 0.182 
50 0.111 0.150 0.180 
100 0.105 0.141 0.187 
250 0.112 0.145 0.204 
500 0.109 0.142 0.174 
Coatin{! concentration of FBI 100 ng/ml 
No Ab t blank 0.103 
No Ab2 blank 0.098 
Concentration of Ab l 10 Ilg/ml 50 Ilg/ml 100 Ilg/ml 
FBI standards (ng/ml) 
0 0.150 0.328 0.492 
5 0.116 0.161 0.252 
10 0.122 0.157 0.208 
50 0.133 0.163 0.194 
100 0.114 0.151 0.186 
250 0.158 0.172 0.192 
500 0.130 0.155 0.191 
Kev to Table 5.2 
The results are the means of duplicate absorbance values at 405 nm. 
Other experimental conditions were coating with 1 % casein in PBS for 1 hr at 37°C; incubation for 
competition for 1 hr at 3rC; 120 /!I per well of Ab2E at 1:2 000 dilution, incubated for 1 hr at 37°C and 
substrate reaction as described in steps 9 to 12 (section 5.3.2). 
Step 1. 
The next experiment was to determine the concentration ofFB, for coating. Lower 
concentrations of FBI standards were used as the objective was to develop a sensitive ELISA 
assay. 
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TABLE 5.3 COMPARISON OF COATING CONCENTRATIONS OF FUMONISIN Bl 
Coatin!! concentrations of FB~ (m~/mn 
50 100 150 200 250 
FBI standards (ng/ml) 
0 0.360 0.905 0.984 1.180 1.297 
1 0.338 0.862 0.912 1.035 1.091 
2 0.318 0.664 0.886 0.969 1.023 
5 0.290 0.595 0.735 0.715 0.713 
10 0.273 0.440 0.457 0.492 0.539 
20 0.307 0.330 0.397 0.412 0.336 
50 nd 0.303 0.479 0.385 0.345 
Kev to Table 5.3 . 
Results are means of duplicate absorbance values at 405 nm after subtraction of the mean of the no Ab l 
blank. Other experimental conditions were coating with 1 % casein in PBS for 1 hr at 37°C; [Ab l ] 300 
~lg/ml, incubation for competition was 1 hr at 3rC; 120 ~l per well of Ab2
E at 1:2000 dilution, incubated 
for 1 hr at 37°C and substrate reaction as described in steps 9 to 12 (section 5.3.2). 
A coating concentration of 50 ng FB dml did no titrate out; at 100 and 150 ng/ml the standard 
curves were not steep enough at low concentrations of FBI standards (Appendix 1, Figure 5.1). 
Results for coating with 200 or 250 ng/ml FBI were similar but it was more economical to use 
200 nglml (Table 5.3 and Appendix 1, Figure 5.1). 
Step 3. 
Using 0.05% Tween 20 for washing gave less foaming than 1 % Tween 20; the presence of foam 
can cause errors as the next reagent may not be able to react with reagents already bound to the 
plate (Crowther, 1995). 
Step 5. 
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FIGURE 5.2 OPTIMUM CONCENTRATION OF PRIMARY ANTIBODY (CHICKEN 
ANTIBODIES) 
Kev to Figure 5.2 
The results are the means of duplicate absorbance readings at 405 run after subtraction of the mean of the 
no Ab l blank. Other experimental conditions were coating with 1% casein in PBS for 1 hr at 37°C; Ab l 
was a combination ofIgY extracts C2/8 and C2/12; incubation for competition was 1 hr at 37°C; 120,...,1 
per well of Ab2E at 1:2 000 dilution, incubated for 1 hr at 37°C and substrate reaction as described in 
steps 9 to 12 (section 5.3.2). The data used to generate Figure 5.2 is in Appendix 1, Table 5.4. 
Plotting results as %BlBo instead of absorbance takes into account inter-plate variation and any 
time differences between adding stopping buffer and reading on the plate reader. 
The absorbance values for the curve at 100 f.lg/ml were too low (0.199 to 0.475). The curves 
using 400 and 500 f.lg/ml were not steep enough at low concentrations of FBI. The best results 
were using 300 f.lg/ml which gave a steep graph at low concentrations of FBI «10 ng/ml) and a 
reasonable absorbance value (0.764) for the zero point on the standard curve (Appendix 1, Table 
5.4). 
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The results for the experiment to determine the optimum concentrution of Ab) for rabbit 
antibodies (IgG extract RlI14) are in Appendix 1, Figure 5.3 and Table 5.5. 
Optimisation of Ab) concentration using rabbit antibodies also showed 300 Jlg/ml gave the best 
results even though the zero absorbance (0.702) was low. The curves for the rabbit antibodies 
showed an upturn from the 20 to the 50 nglml standard probably due to insufficient Ab l at 
higher concentrations of FBI to combine with the FB) coated on to the plate i.e. most of the 
antibody has combined with the free FBI and been removed by washing (Appendix 1, Figure 5.3 
and Table 5.5). 
Step 6. 
Incubation for competition studies was done at 37°C because the temperature could be 
controlled by using an incubator. The time of incubation (lor 2 hr) was checked. 
The curves (Figure 5.4) had a similar shape but the shorter incubation time (1 hr) had a wider 
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FIGURE 5.4 COMPARISON OF INCUBATION TIMES FOR COMPETITION STEP IN 
COMPETITIVE INDIRECT ELISA METHOD 
Key to Figure 5.4 
The results are the means of duplicate absorbance readings at 405 run after subtraction of the mean of the 
no Ab1 blank. Other experimental conditions were coating with 1% casein in PBS for 1 hr at 37°C; Ab1 
was a combination ofIgY extracts C2/8 and C2/12; 120 J.11 per well of Ab2
E at 1:2000 dilution, incubated 
for 1 hr at 37°C and substrate reaction as described in steps 9 to 12 (section 5.3.2). 
HRI - incubation for 1 hr HR2 - incubation for 2 hr 
The data used to generate Figure 5.4 is in Appendix 1, Table 5.6. 
Step 8. 
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FIGURE 5.5 SELECTION OF OPTIMUM DILUTION OF SECOND ENZYME-LABELLED 
ANTIBODY (CHICKEN ANTIBODIES) 
Key to Figure 5.5 
The results are the means of duplicate absorbance readings at 405 nm after subtraction of the mean of the 
no Abl blank Other experimental conditions were coating with 1% casein in PBS for 1 hr at 37°C; Ab1 
was a combination ofIgY extracts C2/8 and C2112; incubation for competition was 1 hr at 37°C; 1201-11 
per well of Ab2
E
, incubated for 1 hr at 37°C and substrate reaction as described in steps 9 to 12 (section 
5.3.2). The data used to generate Figure 5.5 in Appendix 1, Table 5.7. 
The 1:5 000 dilution (Figure 5.5) did not give a sufficiently steep slope at low concentrations of 
FBI . The curves for the other dilutions were very similar with the 1:3 000 and the 1:4 000 
dilution being almost identical. Therefore the last optimisation experiment was to decide 
between using a 1:2000 dilution (as used in the titre method, Chapter 3, section 3.3.7) or a 
1: 4 000 which would be more economical. The checkerboard also checked if it was possible to 
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Log [FB1] nglml 
FIGURE 5.6 COMPARISON OF VOLUME AND DILUTION OF SECOND ENZYME-
LABELLED ANTIBODY (CHICKEN ANTIBODIES) 
Key to Figure 5.6 
100/20 - 100 f..llof 1:2000 dilution 
100/40 - 100 f..ll of 1:4000 dilution 
120/20 - 120 f..ll of 1:2 000 dilution 
120/40 - 120 f..ll of 1:4000 dilution 
The results are the means of duplicate absorbance readings at 405 nm after subtraction of the mean of the 
no Ab1 blank. Other experimental conditions were coating with 1% casein in PBS for 1 hr at 37°C; Ab1 
was a combination ofIgY extracts C2/8 anq C21l2; incubation for competition was 1 hr at 37°C; 
incubation for second antibody was 1 hr at 37°C and substrate reaction as described in steps 9 to 12 
(section 5.3.2). 
The data used to generate Figure 5.6 is in Appendix 1, Table 5.8. 
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FIGURE 5.7 SELECTION OF OPTIMUM DILUTION OF SECOND ENZYME-LABELLED 
ANTIBODY (RABBIT ANTIBODIES) 
Key to Figure 5.7 
The results are the means of duplicate absorbance readings at 405 nm after subtraction of the mean of the 
I 
no Ab1 blank. Other experimental conditions were coating with I % casein in PBS for 1 hr at 37°C; Ab1 
was IgG extract RlI14 (300 tJgIml) and incubation for competition was 1 hr at 3rC; incubation for 
second antibody was 1 hr at 37°C and substrate reaction as described in steps 9 to 12 (section 5.3.2). The 
data used to generate Figure 5.7 is in Appendix 1, Table 5.9. 
Results for rabbit antibodies (Figure 5.7) also showed that a 120 III of 1:4000 dilution was the 




TABLE 5.10 DATA TO DECIDE BEST METHOD OF CALCULATION I CURVE FITTING 
Method 1 2 3-nw 3-W 4-nw 4-W 5 6 
Norm 0.02899 0.06204 3.01194 0.38047 6.43408 0.888105 0.03714 0.044436 
SEIP 
a 0.001219 0.07089 0.01232 8.042 0.01712 0.02485 
b 0.00252 0.09584 0.2713 11.74 0.l937 0.5977 
c 0.008527 0.02843 1.055 3.875 0.9115 0.6171 
0.06256 0.5592 
CVIP 
a 6.371 60.52 6.163 93.45 1.771 2.715 
b 3.662 31.56 3.795 32.68 13.52 29.66 
c 0.8739 3.04 1.046 3.98 14.2 49.06 
d 26.0 338 
·l 0.001398 0.007519 0.1462 0.002456 0.784077 0.014329 0.00263 0.003637 
MeanlHC 8.412 9.257 8.404 8.373 9.251 9.11 8.485 8.599 
CVIHC 5.33 7.11 5.33 5.32 7.11 7.41 6.53 7.04 
MeanlLC 4.055 3.651 4.054 4.046 3.649 3.529 3.901 3.802 
CVILC 11.61 13.1 11.6 11 .56 13.09 12.97 10.92 10.66 
Method 6A 7-nw 7-W 8-nw 8-W 8A 9 10 
Norm 0.045406 3.86369 0.52729 4.6096 0.61643 4.70727 
SEIP SO 
a 0.01989 2.368 2.578 2.547 0.016803 2.687 
b 0.2236 0.2318 0.601 0.2326 0.19029 3.424 
c 0.03461 0.7919 0.6119 0.03639 0.88497 
D 5.821 57.37 0.060944 
CVIP 
a 2.184 2.378 2.727 2.709 1.7362 2.699 
b 9.959 15.55 29.78 10.32 13.2847 7.287 
c 3.205 12.75 48.82 3.379 13.7985 
d 22.01 343.8 25.2147 
"i 0.003555 0.276149 0.005122 0.379394 0.0067 0.006683 0.019944 1.007921 
MeanlHC 8.473 8.479 8.386 8.591 8.436 8.43 8.479 8.903 
CVIHC 7.01 6.53 6.5 7.04 6.98 6.97 6.53 8.25 
MeanlLC 3.837 3.899 3.904 3.801 3.829 3.832 3.899 3.32 
CV/LC 10.23 10.91 10.68 10.64 10.21 10.19 10.91 12.49 
All curve fitting met the requirement of all converged and tolerance satisfied (Sigmaplot). 













Key to Table 5. J 0 








standard error of parameters 
coefficient of variation of parameters (%) 
chi square value 
mean value for high control in nglml 
coefficient of variation of high control (%) 
mean value for low control in nglml 
coefficient of variation of low control (%) 
Using the criteria as set out in section 5.3.3, the best method was 1 (plotting absorbance vs. 
concentration ofFB\ and using a 2nd order polynomial for curve fitting. The next best was 6A 
(plotting absorbance vs. log [FBIJ and a 4-parameter equation for curve fitting (Table 5.1 0). 
For method 1 the norm of fit value was 0.02899, the standard errors of the parameters were all 
less than 0.01, the CV of the parameters were all less than 6.4%, the chi square value was 
0.00l398 and the CV for the high control was 5.33%. The only criterion that was not met was 
the CV of the low control which was 11.61 %. 
For method 6A, the norm of fit value was 0.045406, the standard errors of two of the parameters 
(a and c) were less than 0.04, the CV of the parameters were all less than 10%, the chi square 
value was 0.003555 and the CV of the high and low controls were 7.01% and 10.23% 
respectively. In both methods the number of iterations was <5. 
In all further experiments if X2 >0.01 or number of iterations> 5 the run was repeated. 
Parameter values for methods 5 and 9 were as follows:-
Parameter MethQd 5 Method 9 
a 0.9665 0.96778 
b 1.4329 1.4324 
c 6.4211 6.4135 
d 0.2407 0.2417 
Comparison of the parameter values from methods 5 and 9 show good agreement i.e. the 
method of calculation using Sigmaplot rather than dedicated software attached to a plate reader 
is acceptable. (Method 5 used Sigmapiot for curve fitting and method 9 used ELISA+ software). 
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TABLE 5.11 COMPARISON OF CALCULATION OF RESULTS OF 
METHOD CONTROLS 
Control Number FBI (ng/ml) FBI (ng/ml) 
Sizmaj!lot ELISA + 
Low Control 1 4.426 4.234 
Low Control 2 4.235 4.058 
Low Control 3 4.311 4.128 
Low Control 4 3.841 3.702 
Low Control 5 3.633 3.517 
Low Control 6 4.140 3.972 
Low Control 7 4.146 3.977 
Low Control 8 4.673 4.462 
High Control 1 8.441 8.505 
High Control 2 8.368 8.415 
High Control 3 8.496 8.574 
High Control 4 8.413 8.471 
High Control 5 8.690 8.819 
High Control 6 8.738 8.879 
High Control 7 8.514 8.597 
High Control 8 8.653 8.772 
The same means of triplicate absorbance readings (405 nm) were used to calculate results by 
both methods. 
Statistical evaluation of the results (Table 5.11) using both a paired Student's t test and a one-
way ANOV A showed there was no significant difference between the two methods of 
calculation. 
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TABLE 5.12 COMPARISON OF CALCULATION OF RESULTS OF PLASMA SAMPLES 
Sample FBI (ng/ml) FBI (ng/ml) Sample FBI (ng/ml) FBI (ng/ml) 
Number Sigmaplot Plate Reader Number Sigmaplot Plate Reader 
Model 3550 Model 3550 
1 3.725 3.949 26 7.133 7.112 
2 8.088 8.811 27 0.350 0.366 
3 4.375 5.385 28 2.415 2.400 
4 8.390 9.737 29 4.062 4.117 
5 3.991 4.331 30 3.990 4.042 
6 4.835 5.315 31 9.644 10.103 
7 7.004 7.971 32 7.027 7.239 
8 9.652 11.007 33 4.438 4.508 
9 8.416 9.645 34 3.045 3.498 
10 9.183 9.338 3S 4.125 4.802 
11 9.533 10.847 36 2.751 3.430 
12 17.667 18.941 37 3.045 3.736 
13 16.495 13.119 38 4.872 5.526 
14 18.670 17.046 39 4.827 5.489 
15 22.549 17.478 40 5.949 6.605 
16 19.866 21.823 41 7.180 7.822 
17 4.356 4.721 42 4.508 4.987 
18 3.748 3.988 43 3.393 3.700 
19 10.049 11.418 44 2.606 2.888 
20 10.710 10.887 45 3.282 3.580 
21 12.114 13.538 46 3.307 3.609 
22 11 .674 13 .023 47 4.605 4.926 
23 5.244 5.212 48 2.728 3.015 
24 4.133 4.103 49 3.983 4.285 
2S 11.224 11.325 50 3.951 4.257 
The same means of triplicate absorbance readings (405 run) were used to calculate results by 
both methods. 
Statistical evaluation of the results (Table 5.12) using a one-way ANOV A showed there was no 
significant difference between the two methods of calculation. 
5.4.4 Standard Curves 
In analyses done after the CI-ELISA method had been optimised, the typical set up of a plate for 
a run included standards, controls and samples (Table 5.13). 
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TABLE 5.13 EXAMPLE OF A TYPICAL PLATE FOR COMPETITIVE INDIRECT ELISA 
ANALYSES 
1 2 3 4 5 6 7 8 9 
A 0 0 0 NAI NAI NAI S6 S6 S6 
B 1 1 1 LC LC LC S7 S7 S7 
C 2 2 2 HC HC HC S8 S8 S8 
D 3 3 3 SI SI SI S9 S9 S9 
E · 5 5 5 S2 S2 S2 S10 S10 S10 
F 8 8 8 S3 S3 S3 Sl1 Sl1 Sl1 
G 10 10 10 S4 S4 S4 S12 S12 S12 
H 20 20 20 S5 S5 S5 S13 S13 S13 
Key to Table 5.13 
Columns 1,2,3 and rows A to Hare fumonisin standards 
NAI no Ab 1 blank 
HC high method control (± 8 nglml) 
LC low method control (± 4 nglml) 
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FIGURE 5. 8 TYPICAL STANDARD CURVE FOR FUMONISIN Bl 
(CHICKEN ANTIBODIES) 
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10 11 12 
S14 S14 S14 
S15 S15 S15 
S16 S16 S16 
S17 S17 S17 
S18 S18 S18 
S19 S19 S19 
S20 S20 S20 
S21 S21 S21 
18 20' 
The data used to generate Figure 5.8 is in Appendix 1, Table 5.14. Similar results were 
obtained with tile rabbit antibodies (Appendix 1, Figure 5.9 and Table 5.15). 
Both sta.ndard curves have a suitable value for the zero point viz. 1.418 for chicken antibodies 
and 1.083 for rabbit antibodies. Also they both have a steep slope over the range 0 to 20 ng/ml 
i.e. a sensitive assay. 
5.4.5 Method Parameters 
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FIGURE 5.10 RANGE OF STANDARD CURVE (CmCKEN ANTIBODIES) 
Key to Figure 5.10 
Absorbance values were the mean of triplicates at 405 run after subtraction of the mean of the no Ab
l 
blank. The data used to generate Figure 5.11 in Appendix 1, Table 5.16. 
The working range of the standard curve was from 0 to 20 ng/ml as above 20 ng/ml the graph 
levelled out (Figure 5.10). 
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5.4.5.2 Reproducibility 
The intra-assay reproducibility was done on same microtitre plate on the same day; the inter-
assay reproducibility was done on different plates and different days over 18 months. 
TABLE 5.17 REPRODUCffiILITY OF COMPETITIVE INDIRECT ELISA 
Mean FBI (n2/m)) CV n 
HIGH CONTROL 
Intra-assay 8.412 5.33 % 20 
Inter-assay 7.548 7.41 % 31 
LOW CONTROL 
Intra-assay 4.102 10.47 % 20 
Inter-assay 4.077 7.37 % 30 
5.4.5.3 Ruggedness 
The ruggedness ofthe assay was shown by a low average coefficient of variation, 12.2% for 
1Dso, over a year. 
5.4.5.4 Detection Limits 
The detection limit in buffer was 0.2 nglml, calculated as the concentration of FBI that gave 
absorbance readings significantly different from zero (Thompson, 1984). 
Mean absorbance readings (n = 11) for 0,0.1 and 0.2 nglml FBI were 1.541, 1.509 and 1.483 
respectively. The difference between 1.541 and 1.483 was significant (p<0.05) but there was no 











0.2 0.4 0.6 0.8 1.2 1.4 1.6 
Log [FBI] ng/ml 
FIGURE 5.11 COMPETITIVE INDIRECT ELISA STANDARD CURVES FOR CROSS· 
REACTIVITY (CHICKEN ANTmODIES ) 
Key to Figure 5.11 
Results are the means of duplicate absorbance readings at 405 run after subtraction ofthe no Ab1 blank 
and then expressed as a percentage of the value for the zero point. Data used to generate Figure 5.12 is 
in Appendix 1, Table 5.18. 
The concentration at 50% (IDso) for each analyte was calculated using curve fitting and , 
Sigmaplot software. 
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FIGURE 5.12 COMPETITIVE INDIRECT ELISA STANDARD CURVES FOR CROSS-
REACTIVITY (RABBIT ANTIBODIES) 
Kev to Figure 5.13 
Results are the means of duplicate absorbance readings at 405 nm after subtraction of the no Abl blank 
and then expressed as a percentage of the value for the zero point. Data used to generate Figure 5.13 is 
in Appendix 1, Table 5.19. 
The concentration at 50% (ID50) for each analyte was calculated using curve fitting and 
Sigmaplot software. 
There was no cross-reactivity with So. 
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TABLE 5.20 CROSS-REACTIVITY OF ANTIBODIES WITH 
FUMONISIN Bl AND FUMONISIN B3 
ID'\o (ng/ml) Cross-reactivity 
CHICKEN ANTIBODY 
FBI 8.91 100.0 % 
FB2 9.12 97.7 % 
FB3 26.92 33.1 % 
RABBIT ANTIBODY 
FBJ 13.18 100.0 % 
FB2 15.14 87.1 % 
FB3 34.67 38.0% 
Cross-reactivity (Table 5.20) was calculated as the ratio of the concentration at 50% binding 
(IDso) for FBI to that ofFB2 or FB3 and expressed as a percentage. 
5.5 DISCUSSION 
5.5.1 High Performance Liquid Chromatography 
The fumonisin standards stored in PBS for 2 yr at 4°C and - 20°C had minimal deterioration 
(Table 5.1). Some of the fumonisin BI may have been lost during freeze-drying. Since storage at 
4°C gave better stability than at -20°C, henceforth only stock standards stored at 4°C were used. 
Other authors have stored their stock standards, 1 and 0.1 mg/ml in acetonitrile:water (3:1) at 
4°C (Yeung et al., 1996) 
5.5.2 Competitive Indirect ELISA 
Good results in checkerboard titrations are indicated by a steep curve with no plateau region at 
high absorbances, low absorbance values for the no Ab l blank « value for highest standard), 
absorbance value for the zero point on the standard curve < 1.6 and a steep sigmoid curve 
(Crowther, 1995). These were used as guidelines for all decisions made from checkerboard 
titrations. 
In optimising the CI-ELISA method in this study, method parameters that had already been 
checked in the titre experiments (Chapter 3, section 3.3.7) were not altered viz. coating with FBI 
in PBS directly overnight at 4°C, blocking with 1 % casein in PBS, using 0.5% BSA in PBS as 
diluent for antibody solutions and the ABTS reaction. 
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The optimal concentration of 200 ng FBI/ml for coating gave a suitably steep standard curve at 
low concentrations of FBI and was more economical than 250 ng/ml (Table 5.3 and Appendix I, 
Figure 5.1). However, to reduce costs, a smaller volume of FBI (100 Ill) was used as compared 
to titre experiments (150 Ill). To compensate the volume of 1 % casein used for blocking was 
increased from 200 to 250 III to fill the wells to capacity (section 5.3.2). 
Other groups coated with FBI bound to a protein, either FBI-OVA (Azcona-Olivera et al., 
1992A;Yu & Chu, 1996) or FBI-BSA (Fukuda et al., 1994; Shelby et al., 1994). For blocking a 
variety of agents was used e.g. 1 % OVA in PBS (Azcona-Olivera et al., 1992A); 0.1 % gelatin in 
PBS (Yu & Chu, 1996); 0.1 % non-fat dry milk powder in borate buffer (PH 6.5) (Fukuda et al., 
1994) while Shelby et al. (1994) omitted a blocking step. For washing, either 0.02%, 0.05% or 
0.5% Tween 20 in PBS was used (Azcona-Olivera et al., 1992A; Shelby et al., 1994;Yu & Chu, 
1996). 
In the competition step 300 Ilg/ml for the primary antibody for both chicken and rabbit 
antibodies was selected as it gave steep graphs at low concentrations of FBI «10 ng/ml) and 
acceptable readings for the absorbance of the zero point on the standard curve (Figure 5.2 and 
Appendix 1, Table 5.4,5.5 and Figure 5.3). It was found possible to use shorter incubation times 
viz.! hr instead of2 hr (Figure 5.4 and Appendix 1, Table 5.6). Further refinements of this 
method should include checks to use shorter times for other steps of the assay but due to time 
restraints these were not done. Instead the same times as for the titre experiments were used for 
blocking, the second antibody and the ABTS reaction. 
For the competition step, Shelby et al. (1994) used 50 III of maize sample extracts or FBI 
standards with 50 III ofmAb (1 Ilg/ml in 0.5% Tween 20 in PBS) and incubated for 15 min at 
RT. In contrast, Yeung et al. (1996), first added 1 ml of a 1 :30 000 dilution of Ab l (in 0.1 % 
BSA in PBS) to 25 III of maize samples/standard and incubated for 1 hr at 4°C. Then 200 III of 
the mixture was added to coated plates and incubated for a further 30 min at 4°C. 
The main objectives in developing this CI-ELISA method were to produce a sensitive, easy and 
cost-effective method able to measure low concentrations of FBI in physiological fluids. 
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Hence more than one experiment was done to check the optimal dilution and volume of Ab2
E 
so 
that a minimum amount of this expensive reagent was used. The selected dilution of the second 
antibody (1 :4 000) gave a steep titration curve and a maximum absorbance of between 1.0 and 
1.4 as recommended (Crowther, 1995) (Figures 5.5, 5.6 and 5.7; and Appendix 1, Tables 5.7, 
5.8 and 5.9). Other groups used 100 III of the second enzyme-labelled antibody (1:500 to 
1:10000 dilutions) and incubated for 15 min at RT or 30, 45 or 60 min at 37°C (Azcona-Olivera 
et aI., 1992A; Fukuda et al., 1994; Shelby et al., 1994; Yu & Chu, 1996). 
The ABTS reaction had already been optimised (Dr. Coetzer, personal communication) to give 
zero order kinetics for the enzyme reaction so it would have been foolish to alter the 
concentration of ABTS. Even though the optimum pH for reaction ofHRPO and ABTS is 4.0, 
use of pH 5.0 gives a slower reaction but does not affect the linearity of the kinetics (Crowther, 
1995). Any change in the volume of ABTS used would have necessitated a change in the 
volume of stopping buffer. Pipetting of substrate solution and stopping buffer must be accurate 
so for this a multi-channel pipette (Finpipette, 8 channel, 300 lll, AEC Amersham) was used. 
A fixed time was used for the ABTS incubation to reduce inter-plate variability. 
In conclusion, for all experiments done using this CI-ELISA method, coating was done with 200 
ng/ml FBI in PBS, blocking with 1 % casein, washing with 0.05% Tween 20 in PBS, antibody 
diluent was 0.5% BSA in PBS, concentration of Ab l was 300 llglml, standards were 0, 1,2,3, 5, 
8, 10 and 20 ng FBI Iml, and Abl was diluted 1:4 000. Incubation for coating was overnight at 
4°C; for the competition step and for the second antibody reaction incubation was for 1 hr at 
37°C. Every run included a no Ab l blank and FBI method controls. 
5.5.3 Calculations 
Since ELISA methods give sigmoid curves a statistically sound curve-fitting programme is 
necessary to obtain quantitative results. The formula chosen should have as small a number of 
parameters as possible; it is iteratively fitted to the data obtained using non-linear least squares 
methods (Rodgers, 1986). For a partially sigmoid curve as obtained with the CI-ELISA, a 2nd 
order polynomial is the recommenJed curve type; a 4-parameter equation is best suited to a 
fully sigmoid curve. (Elisa+ , Meddata Inc., New York). 
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Statistically the chi square value and the sum of squares give a measure of the goodness of fit 
with low values showing a good curve fit. The sum of squares is the sum of the squares of 
differences between observed and expected values and the chi square test statistic is this sum 
divided by the expected values (Sigmaplot instruction book, Jandel Scientific). 
Both Sigmaplot and Elisa+ use the Levenberg-Marquardt algorithm to fit the curves. The 
parameters derived from this algorithm minimise the sum of squares. In the iterative process the 
parameters are checked again and again until convergence is reached i.e. the differences 
between the residual sum of squares no longer decreases significantly (Sigmaplot instruction 
book). 
Generally it is better to have three parameters rather than four (Mr. D. Singh, personal 
communication). The norm value is an index of closeness of fit and decreases as the fit 
improves (Sigmaplot instruction book). 
It is vitally necessary to select valid and statistically sound computation methods that are 
sufficiently flexible, easy to interpret geometrically and having as small a number of parameters 
as possible. Differences in data-processing methods must be taken into account in comparative 
studies and data-processing errors are not negligible. Commercial packages sold as an adjunct to 
a plate reader generally have good instructions for use but minimal documentation on the 
numerical methods employed. It is also essential to run proper control samples with every 
ELISA assay and to use these results to validate the method and sample results (Rodgers, 1986). 
The calculation method finally selected met the criteria for an acceptable method of data 
reduction viz. plotting absorbance vs. [FBI] ng/ml and using a 2nd order polynomial for curve 
fitting (Table 5.10). The backfit equation was used in Excel (Microsoft Windows 98) to enable 
quantitative results to be computed easily. The validity of this approach is shown by the good 
agreement in results (no significant difference) between fumonisin controls calculated by this 
method and by ELISA+ (Table 5.11). The number of iterations was 5 and the norm of fit value 
was low. Further verification of this approach is that sample results calculated by this method 
and results from dedicated software on the Model 3550 Plate Reader also owed no significant 
difference. However, it is interesting to note that different methods of calculation gave different 
answers (Table 5.12). 
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Other methods of calculation have also been used. Shelby et al. (1994) used a regression 
equation and plotted absorbance at 490 nm vs.log ppm FBI while Yeung et al. (1996) used a 
least squares plot of logit of absorbance vs. log FBI concentration. Other workers plotted 
%B/Bo vs. log FBI and used specific software with a cubic spline function to calculate results 
(Usleber et al., 1994). 
5.5.4 Method Parameters 
5.5.4.1 Standard Curves 
Criteria for selection of an acceptable standard curve are the steepest slope and straightest line 
(Dr.Coetzer, personal communication). A suitable range for absorbances for a standard curve 
are 0.025 to 1.3 (Mr.R. Parkinson, personal communication). The standard curve must also have 
a working range to meet the proposed applications of the method. 
The absorbance values for the zero point were within acceptable range (1.0 to 1.6, (Crowther, 
1995)] and the no Ab l blanks were low (0.129 and 0.105). The actual values varied with every 
plate run but remained within designated limits. In the CD-ELISA established by Usleber et al., 
(1994), the absorbance for the zero point, Bo was 1.1. 
The CV of quadruplicate points on their standard curve was 1.2 - 7.3%. An acceptable CV of 
triplicates is <10% (Mr.R. Parkinson, personal communication). The CV of triplicates for the 
chicken antibody standard curve was 0.36 - 5.91 % and for the rabbit antibody 1.79 - 5.40% 
(Appendix 1, Tables 5.14 and 5.15). 
Good standard curves covering the range of 0 to 20 ng/ml were obtained with both chicken and 
rabbit antibodies (Figures 5.8 and 5.10 and Appendix 1, Figure 5.9). Shelby et al., (1994) in a 
CI-ELISA used serial 1:2 dilutions of FB I to give a standard range from 0.1 to 100 ppm (~g/ml) 
while Yeung et at., 1996 had a very limited but sensitive range of 0.05 to 0.75 ng/m!.. In 
between are the ranges of 0.1 to 30 ng/ml (Abouzied et ai., 1996) and 50 to 5 000 ng/ml 
(Azcona-Olivera et al., 1992B). The latter two were both competitive di~ect ELISA methods. 
5.5.4.2 Reproducibility 
An acceptable intra-plate CV at NBTS is < ± 10% (Mr.R. Parkinson, personal communication). 
Yeung et at. (1996) obtained intra-assay CV <10% and inter-assay varying from 7.3 to 17.8% 
depending on the concentration of added FBI (lower CV's for higher concentrations). 
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In their CD-ELISA methods, Usleber et ai. (1994) obtained intra-assay CV below 7.5% and 
inter-assay below 14%; Abouzied et ai. (1996) obtained 3.8% for intra-assay and 7.6% for inter-
assay; Azcona-Olivera et al.(1992B) obtained 11.55% for intra-assay and 14.85 % for inter-
assay. 
Thus the results of 5.33 % (high control) and 10.47% (low control) for intra-assay coefficients 
of variation and 7.41 % (high control) and 7.37% (low control) for inter-assay obtained in this 
CI-ELISA method (Table 5.17) are similar to other workers and acceptably low. This shows a 
good method and good technical skills. 
5.5.4.3 Detection Limits / Sensitivity 
The IDso value gives an indication of the affinity of the antibody; the lower the value, the higher 
the affinity and the greater the sensitivity of an assay. The IDso is the concentration ofFB t 
causing 50% inhibition of binding to antibody (Chu, 1996). The chicken antibodies are of higher 
affinity (IDso, 8.91 ng/ml) than the rabbit antibodies (IDso, 13.18 ng/ml) and compare 
favourably with results from other workers 260 ng/ml (Azcona-Olivera et ai., 1992A); 630 
ng/ml (Azcona-Olivera et ai., 1992B); 144 ng/ml (Fukuda et al., 1994); 5.5 ng/ml (Abouzied et 
ai., 1996) but not as good as an affinity as Yu & Chu (1996) with 0.45 and 1.33 ng/ml or 
Usleber et al. (1994) with 0.623 ng/ml or Yeung et al., (1996) with an 1Dso of 0.66 ng/ml. 
Reproducibility of the IDso gives a measure of the ruggedness of an assay and the CV result of 
12.2% over a year compares favourably with the 8.5% obtained by Yeung et al. (1996) over one 
month. 
With a detection limit of 0.2 ng/ml this is a sensitive CI-ELISA which compares well with the 
work of Usleber et al. (1994) whose CD-ELISA method had detection limits of 0.17 ng/ml. 
Other sensitive methods with detection limits of <1 ng/ml (Abouzied et ai., 1996) and 0.05 
ng/ml (Yeung et al., 1996) contrast with that of Azcona-Olivera et al. (1992A) whose detection 
limit in a CI-ELISA with polyclonal antibodies was 100 ng/ml and for monoclonal antibodies 
was 50 ng/ml (Azcona-Olivera et ai., 1992B). 
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5.5.5 Cross-reactivity 
The cross-reactivities of the antibodies against FB2 and FB3 viz. 97.7% and 33.1 % respectively 
for chickens and 87.1 % and 38.0% respectively for rabbits (Table 5.20 and Figures 5.11 and 
5.12) are similar to those for the pAb produced by Azcona-Olivera et al. (1992A) in mice. In 
their CI-ELISA there was 87% cross-reactivity with FB2 and 40% with FB3 but no cross-
reactivity with TCA or the hydrolysed backbone of fumonisin. 
In a CD-ELISA using mAb, cross reactivity with FB2 was 38% and with FB3 was 33% (Azcona-
Olivera et al., 1992B). They suggested the epitope lies in the C-l1 to C-20 region of the 
fumonisin B 1 molecule near the linkage of the TCA moieties. Because of similar values for 
cross-reactivity, it seems possible that the chicken and rabbit antibodies in this study recognised 
the same region. Unfortunately suitable pure preparations of other fumonisins (FB4, A and C 
series) and metabolites (partially and fully hydrolysed fumonisins) were not available to check 
their cross- reactivities . Other workers produced pAb with varying cross-reactivities (Chapter 2, 
Table 2.7). 
5.6 CONCLUSION 
A sensitive CI-ELISA method of analysis for fumonisin with excellent reproducibility was 
successfully developed and optimised. The method is rapid, easy to perform and not expensive. 
Standard curves with a good range for low concentrations of FBI were achieved using both the 
chicken and the rabbit antibodies raised as described in Chapter 3. Furthermore, it was 
established that FBJ for use as a standard can be stored for more than two years in PBS at 4°C. 
Investigation of a range of alternative ways of calculating the CI-ELISA data came up with a 
simple and accurate method to obtain quantitative results. 
The chicken and rabbit antibodies cross-reacted mainly with FB2 and to a lesser extent with FB3 
but there was no cross-reactivity with So. It is intended that this method be applied to analyses 
in physiological fluids. 
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CHAPTER 6 
ANALYSIS OF PLASMA and URINE SAMPLES 
6.1 INTRODUCTION 
Very little work has been done on analysis offumonisins in physiological samples. Most of the 
immunoassay and HPLC methods of analysis have been applied to maize and maize-based 
products; also beer and milk. In application of ELISA methods, no prior extraction was done for 
beer and milk, whereas, for maize/maize-based samples, extraction with acetonitrile or methanol 
and water in various combinations was needed (Chapter 2, Tables 2.4, 2.5 and 2.8). 
Chromatographic methods for analysing FB I and FB2 in plasma, urine, faeces and bile samples 
from rats and vervet monkeys who had been given FBlor FB2 by intraperitoneal injection or by 
gavage were developed. These involved a final extraction into organic solvents suitable for 
application to HPLC i.e. except for an initial extraction of faecal samples into O.lM EDTA 
(pH5.2), a purely aqueous medium was not used (Shephard et ai., 1992A, 1992B, 1992C, 
1994A, 1994B, 1994C, 1995A, 1995B). 
In studies on the absorption and excretion of FB I and FB2, unlabelled or radiolabelled 
fumonisins were fed to a variety of animals. It was found that in rats fumonisins were poorly 
absorbed from the gut, and rapidly eliminated unmetabolised mainly via the faeces, bile and urine. 
After oral administration of labelled FBI to vervet monkeys, within seventy-two hours, most of it 
was excreted in the faeces and urine as unmetabolised, partially and fully hydrolysed FBI 
(Shephard et al., 1994A, 1994C). Laying hens and cattle also excreted FBI unmetabolised, 
mainly in the faeces and urine (Vudathala et ai., 1994; Smith & Thakur, 1996). 
Even though fumonisins are poorly absorbed orally and then rapidly excreted, some studies have 
concluded that fumonisins are retained in the tissues. Prelusky et at. (1994) concluded that, in 
swine, a fraction of orally administered FBI was absorbed, distributed and remained in the 
tissues for an extended period implying that FBI may accumulate in the tissues if consumed 
over a period of time. 
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Smith & Thakur (1996) after feeding Holstein steers feed containing FBI found that although it 
was excreted mainly in the faeces, small amounts were retained in the liver, kidneys and muscle. 
Working with primates (vervet monkeys), Shephard et al., (l994A, 1994C) found that after oral 
administration of labelled FBI, in addition to being found in the faeces and urine, fumonisin was 
found in the contents of the intestine, liver, skeletal muscle, plasma, bile, kidney, heart, 
erythrocytes and brain (Chapter 2, Table 2.15). So it may be possible to detect fumonisins in the 
blood. 
Minimal studies have been done on natural excretion of fumonisins by humans and nothing is 
known about routes and rates of elimination. Recently, naturally occurring levels of FBI in 
human faeces was measured using HPLC. Concentrations ranged from 790 to 19560 ng/g of 
freeze-dried faecal sample (Chelule et al., 2000). 
For humans in Southern Africa, maize and maize products are a major component of their daily 
diet (Rava et al., 1996). However, consumption of maize contaminated with FBI is associated 
with the risk of OC. This was shown in the work done by the PROMEC, Medical Research 
Council (MRC) group studying low and high risk areas in the Transkei, South Africa (Burrell, 
1957; Marasas et al., 1988B; Rheeder et aI., 1992; Sydenham et al., 1990B). 
6.1.1 Objectives 
1. To investigate aqueous extraction methods so that the CI-ELISA method (Chapter 5) 
could be used to analyse blood and urine samples for fumonisins. 
2. To analyse blood and urine samples from control patients, patients with OC and patients 
with other types of cancer for fumonisins. 
3. To analyse some of the same samples by HPLC to confirm the ELISA results. 
4. To analyse serum samples from control patients, patients with OC and patients with 
other types of cancer for calcium and magnesium. 
6.1.2 Ethical Approval 
Ethical approval for use of human blood and urine samples was granted by the Ethics 




Calcium and Magnesium kits were purchased from Boehringer Mannheim, Germany. 
Levell and Level 2 control sera were purchased from Randox, United Kingdom. 
For all other chemicals refer to Chapter 3, section 3.2.1 and Chapter 5, section 5.2.1. 
6.2.2 Buffers/Solutions 
The following buffers were used in analysis of plasma and urine samples: 
Phosphate buffered saline (PBS) (PH 7.2) (Appendix 2, 2.2) 
0.15M Citrate-phosphate buffer (pH 5.0) (Appendix 2, 2.6) 
Stopping buffer: 0.1 % sodium azide in citrate-phosphate buffer (Appendix 2, 2.7) 
1M Sodium phosphate buffer (pH 3.35) (Appendix 2, 2.11) 
6.3 METHODS 
6.3.1 Competitive Indirect ELISA 
1. The wells of the microtitre plate (Nunc 96 well Maxisorb, AEC Amersham) were coated 
directly with FBI, 200 nglml in PBS, 100 III per well. The plate was covered and 
incubated for 18 hr at 4°C. 
2. The wells were blocked with 1.0% casein (m/v) in PBS, 250 III per well and incubated 
for 1 hr at 37°C. 
3. The plate was washed three times with 0.05% (v/v) Tween 20 in PBS. 
4. FBI standards (0, 1,2, 3,5,8, 10,20 ng/ml in PBS) were pipetted in triplicate into 
relevant wells, 50 III per well. 
5. The primary antibody (Ab l ) was added to relevant wells, 300 Ilglml in 0.5% BSA in 
PBS, 50 III per well. 
6. The plate was mixed by gentle tapping and incubated for 1 hr at 37°C. 
7. The plate was washed three times with 0.05% (v/v) Tween 20 in PBS. 
8. The second antibody (Abl), anti-chicken IgG conjugated with HRPO was added, 
1:4000, 120 III per well and incubated for 1 hr at 37°C. 
9. The plate was washed three tir.les with 0.05% (v/v) Tween 20 in PBS. 
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10. 150 III of substrate, 7.5 mg ABTS plus 7.5 III H202 in 15 ml citrate-phosphate buffer (pH 
5.0) was added to each well. The colour was allowed to develop for 15 min in the dark at 
RT. 
11. 50 III of stopping buffer was added to each well. 
12. The absorbance of each well was read at 405 nm (Bio-Rad Model 550 Plate Reader). 
6.3.1.1 Extraction Methods for Fumonisins in Plasma and Urine 
All recovery experiments for CI-ELISA included a positive control (serum/plasma/urine from a 
non maize eater spiked with FB t to give concentrations of 5 or 10 ng/ml, later 4 or 8 ng/ml); 
a buffer control (PBS spiked with FB t at the same concentration as the positive controls); 
and a negative control (serum/plasma/urine from a non maize eater with a volume of PBS added 
equivalent to the added volume ofFB t ). The extraction procedure was done on all controls. The 
buffer control indicated any loss ofFB t due to the extraction process without the complication 
of matrix interferences. 
Four or more positive controls were done for each experiment. All CI-ELISA analyses were 
done in triplicate; a standard curve and method controls were included on every plate and 
fumonisin concentrations were calculated as described in Chapter 5. 
Recovery results were calculated by first subtracting the result for the negative control from that 
of the spiked sample and then expressing it as a percentage of the buffer control. 
The samples used were plasma obtained using lithium heparin or EDT A as anticoagulant, serum 
and urine. Criteria for an acceptable extraction method were a low value for the negative 
control, recovery> 80 %, and ease of use. 
Pipetting serum/urine directly or simply diluted in buffer did not give good recoveries so various 
simple methods of clean-up (mainly to remove proteins) were tried. 
Initial extraction experiments used organic solvents viz. methanol (1 :5) or acetonitrile (1 :3 .3). 
After mixing, samples were centrifuged, the supernatant dried under N2 at 60°C and re-dissolved 
in 500 III PBS. Other experiments used addition of 10%, 20% or 50% methanol followed by 
centrifugation and analysis of the supernatant. 
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As an alternative, precipitation with 30% PEG 6 000 using a 1: 1 dilution of serum was 
attempted. Prior experiments using a 7.5% solution of BSA in PBS were done to ascertain the 
concentration of PEG 6 000 to use to precipitate all the protein. Suitable weights of PEG were 
added to duplicate 500 III volumes of the BSA solution to give a range of 18% to 30% PEG 
solutions. These were mixed for 1 min, centrifuged for 10 min (Hettich Mikroliter centrifuge) 
and the supernatant was analysed for protein by the biuret method (Chapter 3, section 3.3.5). 
(The average concentration of proteins in blood is 75 gil). 
Finally a simple boiling method using a 1: 1 dilution of the sample in PBS gave excellent 
recovery results. 200 III EDTA plasma / urine and 200 III PBS were pipetted into Eppendorf 
micro test tubes (AEC Amersham), sealed, mixed and allowed to stand for 10 min. 
The tubes were heated in a boiling water bath for 15 min, removed and cooled at RT for 5 min 
and then for 15 min at -20°e. Finally, they were centrifuged for 10 min at 15 624 g (Hettich 
Mikroliter centrifuge). Triplicate 50 III volumes of the supernatant were used in the ELISA 
method. 
6.3.1.2 Samples 
Blood and urine samples for CI-ELISA were collected from hospital and clinic patients in 
hospitals in the Durban Metropolitan area. Unfortunately it was not possible to get both types of 
samples on all patients. There were three groups of samples viz. patients with OC, controls (no 
cancer) and patients with other types of cancer (Le. not oesophageal). Since this was only a 
preliminary study, patients were not matched for age or sex. 
In the OC group there were 40 blood and 17 urine samples; in the control group 21 blood and 12 
urine samples. The 20 blood samples from the group of patients with other types of cancer were 
comprised of9 with breast cancer, 4 with cervical cancer, 2 each with cancer of the stomach and 
rectum, and 1 each with cancer of the pancreas, thyroid and prostate. The 10 urine samples were 
from 6 patients with breast cancer, 2 with cervical cancer and 1 each with cancer of the stomach 
and the larynx. 
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Blood was collected into EDT A tubes (Vacutainer, Becton Dickinson) to give plasma for 
fumonisin analysis; serum was used for calcium and magnesium measurements. Random (not 
24 hr) urine samples were collected into suitable containers. Separated plasma/serum and urine 
samples were given laboratory numbers and stored at -20°C until analysed. 
Extractions were done in duplicate and ELISA assays in triplicate. Every run included a 
standard curve, wells for non-specific binding (no Abl), low and high FBI method controls (in 
buffer) and serum/urine negative controls (no FBI) and serum/urine positive controls (spiked 
with FBI at 4 ng/ml). 
The mean of the triplicate absorbance values (minus the average absorbance for non-specific 
binding) was used to calculate fumonisin concentrations as described in Chapter 5, section 
5.4.3). 
Runs were only accepted if method controls were within their acceptable limits (mean ± 2SD). 
The mean value for the relevant negative serum/urine control was subtracted from sample 
results. The final fumonisin result was the average of the results for the two extractions 
multiplied by 2 (for the initial 1: 1 dilution). 
If the extraction concentrations differed by more than 1 ng/ml, the sample was repeated. 
Total plasma fumonisins were calculated using a blood volume of3.5 litres (Kleinman & 
Lorenz, 1996). 
Statistical evaluation was done by one-way analysis of variance (ANOVA) using 
Corel Quattro Pro 8. 
6.3.2 High Performance Liquid Chromatography 
6.3.2.1 Extraction of Fumonisin Bl from Plasma and Urine Samples 
For extraction of plasma samples, 3 ml methanol was added to 500 III plasma, mixed and 
centrifuged at 10°C for 10 min at 1 200 g. 
For extraction of urine samples, 1 ml urine plus 7.5 ml methanol was used. 
Strong anion exchange (SAX) columns (Varian Bond-Elut, 500 mg, SMM Instruments, South 
Africa) were pre-conditioned with 5 ml methanol followed by 5 ml methanol:water (3: 1). The 
supernatant from the methanol extraction of plasma/l.rine was applied to the column, washed 
with 5 ml methanol:water (3:1) and then 5 ml methanol. Elution was with 10 m15% acetic acid 
in methanol. Flow rate was 1 mllmin and columns were not allowed to run dry. 
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The eluted extracts were dried' under nitrogen at 60°C and stored sealed at 4°C until HPLC 
analysis. Each sample was extracted in duplicate (Shephard et al., 1992B; Thiel et al., 1993; 
Duncan et al., 1998). 
6.3.2.2 Analysis of Plasma and Urine Samples for Fumonisin Bl 
The mobile phase was composed ofO.lM sodium phosphate buffer (PH 3.35):methanol (27:73). 
The buffer was filtered before use through a 0.45 11m nylon filter (Lida, Chrom Tech Inc.). 
The mobile phase was degassed by sonication for 15 min/300 ml at 20°C and 200V (UMC 10 
waterbath, Ultrasonic Manufacturing Co.) 
The HPLC system consisted of a Spectra SYSTEM P2 000 binary pump, a Spectra SYSTEM 
AS3 000 autosampler equipped with a 100 III injection loop and a Spectra SYSTEM FL2 000 
fluorescence detector (Thermo Separation Products, SMM Instruments, South Africa). The CIS 
analytical column (Waters Nova-Pak stainless steel column, 3.9 x 150 mm, 4 11m packing 
material, MicroSep, South Africa) was preceded by a HIRPB-l OC guard column (Hichrom Ltd., 
SMM Instruments, South Africa). The guard column was replaced daily. 
A stock FBI standard (1 mg/ml in 1: 1 acetonitrile:water) was stored at 4°C. 
Working standards were prepared daily by dilution of the stock standard to give concentrations 
of 50 and 20 Ilg/ml, and 500, 400, 200, 100, 50, 20 and 10 ng/m!. 
Dried plasma/urine samples were re-dissolved in 100 III acetonitrile:water (1: 1). 
For derivatisation, 40 III sample or standard was added to 80 III OPA solution (Appendix 2, 
2.13) and mixed for exactly 10 sec before loading into the autosampler. The injection volume 
was 50 III . Each sample/standard was derivatised and injected in duplicate. The time from 
derivatisation to loading on to the column was 2 min. The run time was 6 min. Analyses were 
done over three days. 
The flow rate was 1 ml/min, the pressure 2 425 psi and temperature 23°C. For fluorometric 
detection the excitation wavelength was 230 nm and emission 440 nm. To avoid interference 
from impurities that gave high peaks beyond the limit of the photomultiplier tube, the emission 
wavelength was set at 600 nm for the first 2.5 min and switched automatically to 440 nm from 
2.5 to 6.0 min. Calculations of peak area were done using Spectra SYSTEM PC-lOOO software 
(Thermo Separation Products, SMM Instruments, South Africa). 
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Detection limits were calculated as a signal to noise ratio of 3: 1. 
Four serum and four urine samples were spiked at 16 ng/ml FBI. These were extracted and 
analysed as for patient samples. Recoveries were calculated as the percentage of the measured 
result divided by 16. 
6.3.2.3 Samples for High Performance Liquid Chromatography 
Nine plasma and eight urine samples with high fumonisin concentrations as measured by CI-
ELISA were selected for HPLC analysis. (Due to cost constraints it was not possible to analyse 
all the ELISA samples by HPLC). 
Sample results (mean of duplicate injection peak areas) were calculated from the equation for 
the straight line standard curve for that day and corrected for dilution to give values in ng/ml of 
plasma or urine. The final result was the average of the results for the two extractions for each 
sample. 
6.3.2.4 Statistics 
A comparison ofresults from CI-ELISA and HPLC was done using a one-way ANOV A using 
Corel Quattro Pro 8. 
6.3.3 Calcium and Magnesium 
Calcium and magnesium levels were measured on all ELISA samples for which serum or 
heparinised plasma was available. (EDT A plasma is not suitable for calcium and magnesium 
analyses; results on random urine samples are meaningless). Analysis was done on a Cobas 
Mira Plus Selective Automated Analyser (Boehringer Mannheim) using kits. Calcium was 
analysed using o-cresolphthalein and magnesium using xylidyl blue. Precinorrn U was used as 
calibrator; Levell and Level 2 control sera were used as method controls and run every 30 
samples. Analyses were done in duplicate with an acceptable error < 0.1 nunol/l difference 
between duplicates. 
Statistical evaluation was done by one-way ANOVA using Corel Quattro Pro 8. 
130 
6.4 RESULTS 
6.4.1 Recoveries of Fumonisins from Blood and Urine (Competitive Indirect ELISA) 
6.4.1.1 Organic Solvents 
Undiluted and unextracted spiked serum and plasma samples gave low absorbance readings 
(0.194 to 0.399, lower than the 20 ng/ml standard 0.557) showing interference with the antigen-
antibody reaction. (In the CI- ELISA absorbance is inversely related to concentration). 
Results for urine were slightly better (0.907 to 0.989) indicating that the interference is probably 
from proteins in the sample. The only recovery result was for urine (44.9%, n = 1 at 5 ng/ml). 
Diluting samples 1:5 with PBS also gave low absorbance readings. The three recovery values 
that could be calculated were unacceptable; 277.2% for EDTA plasma (n = 2 at 5 ng/ml) and 
179.7% for urine (n = 1 at 5 ng/ml). 
Extraction into methanol 1:5 gave better results but some results could not be calculated because 
the absorbance values were lower than that for the 20 ng/ml standard. Thus, there was still some 






77.4% (n = 2 at 5 ng/ml) 54.3% (n = 2 at 10 ng/ml) 
104.3% (n = 2 at 5 ng/ml) 86.7% (n = 2 at 10 nglml) 
No result 19.8% (n= 1 at 10 nglml) 
184.5% (n = 2 at 5 ng/ml) No result 
Since EDTA plasma seemed to give better results, a buffer solution containing 0.18% EDT A in 
PBS (i.e. the same concentration as used in Vacutainer blood collection tubes as an anti-
coagulant) was tried as a diluent for samples. The pH had to be adjusted to 7 since the presence 
of the normally acidic (PH 4.82 in water, pH 5.98 in PBS before adjusting) EDTA disrupted the 
antigen-antibody reaction so that a flat standard curve was obtained. 
Diluting serum samples 1: 1 with PBS before extraction into methanol gave 64.8% recovery and 
using EDTAlPBS gave 59.8% (n = 1 at 10 ng/ml). These are no better than the results using 
undiluted serum. 
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Extraction with both methanol and acetonitrile gave unacceptably high values for the negative 
control i.e. the absorbance values (405 nm) were higher than those for the 10 ng/ml and 
sometimes the 20 ng/ml standard due to interference in the antigen-antibody reaction .. 
Even after dilution with PBS or PBSIEDTA , extraction with methanol left a fatty deposit in the 
tube which gave a turbid solution on reconstitution with PBS i.e. there was probably still some 
matrix related substance left which interfered with the antigen-antibody reaction giving poor 
recoveries. Extraction with acetonitrile (1 :3.3) gave a smaller whiter pellet and clearer 
supernatant than with methanol but also poor recoveries, 79.4% for serum diluted with PBS 
(n = 1) and 33.4% if diluted with PBS/EDTA (n = 1). 
Adding 10% or 20% methanol to a diluted serum sample (1: 1 with PBS or EDT AlPBS) 
precipitated the proteins which were then removed by centrifugation; analysis was done on the 
supernatant. The presence of methanol affected the antigen-antibody reaction giving high 
recoveries (107 to 206%) but low values for the buffer control which should be 5 ng/ml. 
TABLE 6.1 EFFECT OF ADDITION OF METHANOL ON BUFFER CONTROL 
Diluent No methanol 10% methanol 20% methanol 
PBS 5.073 ng/ml 3.496 ng/mt 2.161 ng/m! 
PBS/EDTA 4.787 ng/ml 3.924 ng/m! 2.846 ng/m! 
Adding 50% methanol gave no results, i.e. , no reaction taking place. 
6.4.1.2 Polyethylene Glycol 6 000 
TABLE 6.2 DETERMINATION OF PEG 6 000 CONCENTRATION NEEDED TO 
PRECIPITATE PROTEINS IN SERUM 










Recovery results from serum were low; dilution with PBS gave only 19.5% recovery and 
dilution with PBSIEDTA gave 14.6% recovery (n = 1 at 5 ng/ml for both dilutions). These poor 
results were due to high values for the negative controls but the buffer controls were correct 
(5.329 ng/ml in PBS and 5.262 ng/ml in PBS/EDTA at 5 ng/ml). 
6.4.1.3 Boiling 
The best recovery results were obtained by using heat (boiling) to denature and precipitate the 
proteins (Table 6.3). This was also the quickest and easiest method of extraction; and gave 
acceptably low values for the negative controls. Boiling solutions of FBI in buffer had no effect 
on the fumonisin (unboiled standard 5.511 ng/ml, boiled standard 5.775 ng/ml). 
TABLE 6.3 RECOVERIES OF FUMONISINS FROM SERUMIPLASMA!URINE 
(COMPETITIVE INDIRECT ELISA) 
Level of FBl in Serum EDTAPlasma Heparin Plasma Urine 
spiked sample 
4 n2/ml 112.37 % 99.11 % 94.65 % 97.73 % 
N 5 7 5 6 
CV 15.1 % 6.1 % 14.7 % 19.8 % 
8 nglml 108.62 % 97.58 % 108.67 % 94.55 % 
N 5 7 5 8 
CV 6.8% 5.5 % 9.5 % 4.8% 
(Results in Table 6.3 were calculated as described in section 6.3.1.1). 
6.4.2 Results for Fumonisins on Patient and Control Samples (Competitive Indirect 
ELISA) 
6.4.2.1 Method Controls 
The mean value for the low FBI method control was 4.077 ng/ml, CV 7.4 % and acceptable 
range (mean ± 2SD) was 3.477 - 4.677 ng/m!. 
The mean value for the high FBI method control was 7.548 ng/ml, CV 7.4 % and acceptable 
range 6.340 - 8.576 ng/ml. These did not undergo the extraction procedure. 
The mean value for the positive plasma control was 4.378 ng/ml, CV 8.0 % and acceptable 
range 3.676 - 5.080 ng/m!. 
The mean value for the positive urine control was 4.440 ng/ml, CV 15.1 % and acceptable range 
3.100 - 5.780 ng/m!. 
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The latter two were treated like samples i.e. underwent the extraction process. 
6.4.2.2 Detection Limits 
The detection limit ofFB t in buffer was 0.2 ng/ml (Chapter 5, section 5.4.5.4) which would 
theoretically be 0.4 ng/ml in plasma/urine since samples were diluted 1: 1. 
The mean of the negative control was 0.637 ng/ml (n = 12) which confirms a detection limit of 
less than 1 ng/ml. 
6.4.2.3 Plasma and Urine Samples 
TABLE 6.4 COMPETITIVE INDIRECT ELISA RESULTS FOR CONTROL PATIENTS 
PLASMA URINE 
Patient Appearance Fumonisins Total fumonisins Colour Clarity Fumonisins 
Number (ng/ml) (ruD . (ng/ml) 
156 4.202 14.71 Y C 6.192 
158 ±H 3.043 10.65 
160 +H 5.429 19.00 
177 4.200 14.70 
178 9.226 32.29 
182 6.050 21.18 
183 4.272 14.95 
191 1.439 5.04 Y +T 10.936 
192 +H 2.188 7.66 
197 +H 1.120 3.92 
198 0.130 0.46 Y ++T 21.156 
203 +H 1.592 5.57 
205 ++++H 0.370 1.30 
206 ++++H 1.306 4.57 Y C 17.852 
210 ++H 1.032 3.61 Y +T 10.636 
222 5.949 20.82 PB ++T 36.212 
224 4.508 15.78 
226 2.606 9.12 
227 3.282 11.49 B C 24.926 
251 ++1 0.494 1.73 DB +++++1 22.552 
252 +H 0.000 0.00 y +T 12.499 
258 Y +T 43.232 
259 Y C 23.535 
261 Y C 8.835 
Key to Table 6.4 
H indicates degree of haemolysis of sample from slight (±) to grossly haemolysed (+++); 
I indicates icteric; T indicates degree of turbidity; Y - yellow; B - brown; PY - pale yellow; 
C - clear; W - watery. Results were calculated as explained in section 6.3 .1.2. 
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TABLE 6.5 COMPETITIVE INDIRECT ELISA RESULTS FOR PATIENTS WITH 
OESOPHAGEAL CANCER 
PLASMA URINE 
Patient Appearance Fumonisins Total fumonisins Colour Clarity Fumonisins 
Number (n!!/ml) fl.l!!) (n !!/m I) 
106 1.044 3.65 
108 0.000 0.00 y C 9.265 
110 0.924 3.23 
124 +1 4.778 16.72 
135 +H 0.602 2.11 
139 +H 3.378 11.82 
140 +H 5.892 20.62 
146 1.130 3.96 
148 7.190 25.17 
149 7.828 27.40 
152 +H 3.800 13.30 
155 19.115 66.90 
157 7.543 26.40 B +T 19.528 
159 +H 4.993 17.48 Y +T 28.076 
164 5.180 18.13 
165 5.884 20.59 
166 7.749 27.12 Y C 11.123 
168 9.491 33.22 
169 ±H 6.188 21.66 B +T 23.608 
170 3.928 13.75 
171 5.420 18.97 
172 3.626 12.69 
173 ++H 2.260 ' 7.91 
175 5.039 17.64 
176 py W 0.000 
179 ±H 3.044 10.65 
180 3.740 13.09 
184 7.070 24.75 
190 +H 0.947 3.31 
195 4.208 14.73 Y ++T 20.928 
202 3.614 12.65 B ++T 28.487 
215 ++H 0.962 3.37 
216 +H 4.125 14.44 B ++T 28.522 
217 2.751 9.63 
219 3.045 10.66 Y +T 20.079 
220 4.872 17.05 B ++T 17.268 
225 3.393 11.88 
237 2.728 9.55 
239 3.983 13.94 Y C 8.883 
240 3.951 13.83 Y ++T 26.183 
253 +H 0.000 0.00 y +T 15.362 
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TABLE 6.5 (CONTINUED) 
PLASMA URINE 
Patient Appearance Fumonisins Total fumonisins Colour Clarity Fumonisins 
Number (ng/mll (1l2:) 
260 y W 
262 B +T 
263 B +T 
Kev to Table 6. 5 
H indicates degree ofhaemolysis of sample from slight (±) to grossly haemolysed (+++); 
I indicates icteric; T indicates degree of turbidity; Y - yellow; B - brown; PY - pale yellow; 






TABLE 6.6. COMPETITIVE INDIRECT ELISA RESULTS FOR PATIENTS WITH OTHER 
TYPES OF CANCER 
PLASMA URINE 
Patient Appearance Fumonisins Total fumonisins Colour Clarity Fumonisins 
Number & (ne:/ml) ( lie:) (nf/ml) 
Cancer Type 
Breast 
136 +H 1.068 3.74 B +T 21.370 
150 +H 8.874 31.06 
154 +H 8.644 30.25 
181 9.883 34.59 
204 0.936 3.28 
207 0.298 1.04 B ++T 23 .312 
208 +H 0.380 1.33 
211 2.860 10.01 Y +T 18.178 
228 3.307 11.57 Y +T 16.335 
244 Y +T 9.496 
264 B +T 37.320 
Cervix 
151 +H 6.249 21.87 
162 6.126 21.44 
193 ±H 1.328 4.65 Y C 6.655 
236 4.605 16.12 
265 py C 8.289 
Larynx 
242 y +T 12.316 
Pancreas 
153 +++1 14.186 49.65 
Prostate 
134 +++H 0.510 1.79 
Rectum 
209 0.132 0.46 
223 7.180 24.13 
Stomach 
137 2.011 7.04 
189 3.053 10.69 B +T 21.077 
Thvroid 
221 4.827 16.89 
Key to Table 66 
H indicates degree of haemolysis of sample from slight (±) to grossly haemolysed (+++); 
I indicates icteric; T indicates degree of turbidity; Y - yellow; B - brown; PY - pale yellow; 
C - clear; W - watery. Results were calculated as explained in section 6.3 .1.2. 
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TABLE 6.7 SUMMARY OF COMPETITIVE INDIRECT ELISA RESULTS FOR 
FUMONISINS IN PLASMA AND URINE 
Fumonisins (ng/ml) in EDTA Plasma Fumonisins JnJ Imll in Urine 
Oesophageal Cancer Controls Other Oesophageal Controls Other 
Cancers Cancer Cancers 
AveraKe 4.385 2.973 4.323 18.930 19.910 17.435 
1.044 5.420 4.202 1.068 9.265 6.l92 21.370 
0.000 3.626 3.043 8.874 19.528 10.936 23.312 
0.924 2.260 5.429 8.644 28 .076 21.516 18.l78 
4.778 5.039 4.200 9.883 11.123 17.852 16.335 
0.602 3.044 9.226 0.936 23.608 10.636 9.496 
3.378 3.740 6.050 0.298 0.000 36.212 37.320 
5.892 7.070 4.272 0.380 20.928 24.926 6.655 
1.130 0.947 l.439 2.860 28.487 22.552 8.289 
7.190 4.208 2.188 3.307 28.522 12.499 12.316 
7.828 3.614 1.120 6.249 20.079 43.232 21.077 
3.800 0.962 0.130 6.126 17.268 23 .535 
19.115 4.l25 1.592 l.328 8.883 8.835 
7.543 2.751 0.370 4.605 26.l83 
4.993 3.045 l.306 14.186 15.362 
5.180 4.872 1.032 0.510 0.000 
5.884 3.393 5.949 0.132 46.624 
7.749 2.728 4.508 7.180 17.879 
9.491 3.983 2.606 2.011 
6.188 3.951 3.282 3.053 
3.928 0.000 0.494 4.827 
0.000 
Table 6.7 is a summary of results in Tables 6.4, 6.5 and 6.6. 
6.4.2.4 Statistical Evaluation 
The one-way ANOVA showed a highly significant difference between plasma results for OC 
and controls (p<O.OOOI). Even if the one high result of19.1l5 nglml was omitted the difference 
was still highly significant (p<O.OOOl). There was no significant difference between the urine 
results. 
Comparison of other cancers and control samples showed no significant differences for either 
the plasma or the urine samples. 
138 
However, there was again a highly significant difference between the plasma results for OC and 
other cancers (p<0.005), which was maintained even ifthe high oesophageal cancer result of 
19.115 ng/ml was excluded (p<0.05); and also if both this high result and the high result of 
14.186 ng/ml for other cancers was excluded (p<O.OOI). 
Interestingly the urine results also showed a significant difference between these two groups 
(p<0.05). 
6.4.3 High Performance Liquid Chromatography 
The usual injection volume was 20 III but was increased to 50 III to improve sensitivity. 
For the three days on which analyses were done, the average retention times were 4.364 ± 0.071 
min (CV 1.63%); 3.879 ± 0.053 min (CV 1.37%) and 4.379 ± 0.054 min (CV 1.23%). 
Peaks at high concentrations of FB ((chiefly higher standards) had a good shape but lower 
concentrations gave peaks with a shoulder. 
TABLE 6.8 RESULTS FOR STANDARDS FOR HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
Dav 1 Dav2 Dav3 
Standard FBI Peak Area Standard FBI Peak Area Standard FBI Peak Area 
(n!!/ml) (De/ml) (ne/ml) 
10 6116 
20 21775 20 10327 
50 44133 50 22090 
100 72215 100 51109 
200 127334 200 98452 
The equations for the standard curves on the three days of analysis were:-
Day 1 y = 577.01x + 12991 Regression 0.9974 
Day 2 
Day 3 
y = 492.47x + 191.14 
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FIGURE 6.1 CHROMATOGRAM OF 50 NGIML FUMONISIN B\ STANDARD 
(HIGH PERFORMANCE LIQUID CHROMATOGRAPHy) 
Retention time for 50 nglml FBI standard (Figure 6.1) was 4.424 min. 
6.4.3.1 Detection Limits 
TABLE 6.9 DETECTION LIMITS FOR HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
FBI Standard (ne/ml) Sienal:noise Averaee 
20 5.6 4.2 
20 3.3 
20 3.6 
10 3.1 3.3 
10 3.4 
The detection limit was taken as 10 ng/ml FBI standard in a.;etonitrile/water which translates 
into 1 ng/ml for urine samples and 2 ng/ml for serum sample. 
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6.4.3.2 Recoveries 
TABLE 6.10 RECOVERIES FOR FUMONISIN B t FROM PLASMAJURINE (HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY) 











Results (Table 6.10) were calculated as described in section 6.3 .2.2. 
6.4.3.3 Plasma and Urine Samples (High Performance Liquid Chromatography) 
After re-dissolving in acetonitrile:water (1: 1), the serum samples were mostly colourless but 
the urine samples were highly coloured (yellow, dark yellow, orange-brown, light yellow). 
These gave high fluorescence readings with a high interfering peak at 1-2 min which was 
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FIGURE 6.2 CHROMATOGRAM OF PLASMA SAMPLE 163 
(HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) 
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FIGURE 6.3 CHROMATOGRAM OF URINE SAMPLE 219 
(HIGH PERFORMANCE LIQUID CHROMATOGRAPHy) 


















FIGURE 6.4 CHROMATOGRAM OF URINE SAMPLE 222 
(HIGH PERFORMANCE LIQUID CHROMATOGRAPHy) 
Retention time for urine sample 222 (Figure 6.4) was 4.666 min . 
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Comparison of the plasma (Figure 6.2) and urine chromatograms (Figures 6.3 and 6.4) shows 
more clearly defined peaks and better results for plasma samples. In some samples FBI appeared 
as a shoulder on a larger peak (Figure 6.3); in others the presence of a peak with a retention time 
of about 5 min was clearly seen (Figure 6.4). 
TABLE 6.11 COMPARISON OF PLASMA AND URINE RESULTS ANALYSED BY 
COMPETITIVE INDIRECT ELISA AND HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
Plasma concentration ofFB t (nelml) Urine concentration ofFBt (n2/mll 
Sample ELISA HPLC Sample ELISA HPLC 
Number Number 
149 7.828 6.50 157 19.528 0.97 
157 7.543 12.38 202 28.487 9.01 
162 6.126 14.34 206 17.852 4.17 
165 5.884 16.45 219 20.079 2.30 
168 9.491 3.46 222 36.212 1.76 
169 6.188 12.55 258 43.232 2.20 
181 9.883 8.31 262 46.624 10.28 
184 7.070 3.74 264 37.320 2.06 
223 7.180 7.98 
AverQ/!e 7.466 9.523 31.167 4.09 
6.4.3.4 Statistical evaluation 
A one-way ANOV A showed no statistically significant differences between the two methods for 
plasma samples. Correlation and regression were r = 0.656, y = 25.44 - 2.13x (p<0.005). 
However, there was a highly significant difference between the two methods for urine results 
(p<0.001). 
6.4.4 Calcium and Magnesium 
The method controls (Levell, Lot. No. 128UN and Level2, Lot No. 062UE) were always 
within their limits. 
Calcium Levell Target value 2.26 mmolll Range 1.92 - 2.60 mmolll 
Calcium Level 2 Target value 3.20 mmolll Range 2.88 - 3.52 mmol/l 
Magnesium Levell Target value 0.89 mmol/l Range 0.80 - 0.98 mmolll 
Magnesium Level 2 Target value 1.23 mmolll Range 1.06 - 1.40 mmolll 
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TABLE 6.12 SUMMARY OF CALCIUM AND MAGNESIUM RESULTS ON SERUM 
SAMPLES 
Calcium (mmolll) Ma2nesium (mmolll) 
Oesophageal Cancer Controls Other Oesophageal Cancer Controls Other 
Cancers Cancers 
2.40 2.85 2.53 2.49 0.76 1.00 0.88 1.06 
2.43 2.85 2.34 2.96 0.82 1.18 0.85 0.99 
2.02 2.61 2.56 2.78 0.76 1.02 0.92 1.08 
2.81 2.47 2.48 2.50 1.09 1.00 0.89 0.92 
1.55 3.13 2.11 2.63 1.08 0.96 0.80 0.93 
2.73 2.42 2.57 2.38 1.10 0.79 0.92 
I 
0.85 
2.68 2.68 2.55 2.16 1.07 0.94 0.97 0.81 
2.66 2.85 2.62 2.64 0.95 0.94 0.98 0.93 
2.34 2.77 2.52 2.38 0.94 0.96 0.94 0.91 
2.75 2.72 2.41 2.77 0.95 0.91 0.99 0.92 
2.47 2.74 2.61 2.68 0.95 1.05 1.04 0.95 
2.55 2.31 2 .59 2.71 l.03 l.12 0.98 1.08 
2.65 2.49 2.19 2.33 0.91 0.88 l.23 l.05 
2.79 3.22 2.73 2.44 0.96 1.03 0.94 0.97 
2.41 2.81 2.80 2.65 0.87 0.94 0.91 l.00 
2.59 2.34 2.72 2.65 0.84 0.88 0.95 0.96 
2.57 2.42 2.61 2.83 0.88 00.93 0.97 0.97 
2.62 2.64 2.56 1.03 1.00 0.91 
2.33 2.63 0.84 0.96 
Results (Table 6.12) are the means of duplicates; the difference between duplicates < 0.1 mmolll. 
For further details of serum samples analysed for calcium and magnesium refer to Appendix 1, 
Tables 6.13, 6.14 and 6.15. 
6.4.4.1 Statistical Evaluation 
The one-way ANOV A showed a highly significant difference in calcium results between OC 
patients and controls (p<O.OOOI) which was maintained even if the lowest and highest values 
(a statistically acceptable approach) were excluded (p<O.OOOI). There was also a highly 
significant difference in magnesium results (p<O.OOOI) between these groups. 
Comparison of other types of cancer and control patients showed no significant differences for 
both the calcium and the magnesium results. 
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However, there was again a highly significant difference between calcium and magnesium 
results from patients with OC and those with other types of cancer (p<0.0001 for both). The 
significant difference was unchanged even ifthe lowest and highest calcium result from the OC 
patients were excluded. 
6.5 DISCUSSION 
6.5.1 Extraction and Recoveries of Fumonisins from Blood and Urine (Competitive 
Indirect ELISA) 
Recoveries from extraction of maize samples using organic solvents ranged from 59.7% to 
103% (Azcona-Olivera et at., 1992B; Maragos & Richard, 1994; Usleber et at., 1994; Abouzied 
et at., 1996; Yeung et at., 1996; Yu & Chu, 1996). Without doing any extraction, Scott et at. 
(1997) obtained recoveries of98.7 to 102.8% in beer samples. Scott & Lawrence (1994) in 
analysing maize-based foods concluded that control recoveries should be done for each type of 
food and different extraction methods are needed for different matrices. 
Protein is an interferent in many analyses in physiological fluids, hence in this study the 
extraction methods were aimed at removal of protein. Dilution in buffer and extraction with 
organic solvents were not effective extraction techniques. Even though 30% PEG 6 000 
precipitated the proteins in the sample, recoveries were low. 
Boiling diluted samples proved to be a quick and easy method of extraction. Fumonisins are 
thermostable (Dupuy et at., 1993; Maragos & Richard, 1994 ; Jackson et al., 1997) but proteins 
are denatured by heat and can be removed by centrifugation. 
Small differences in recoveries at two levels of FBI (Table 6.3) were found between blood 
samples collected without anticoagulant (112.4% and 108.6%) or using heparin (94.7% and 
108.7%) or EDTA (99.1 % and 97.6%). Urine samples also gave good recoveries (97.7% and 
94.6%). Comparison of the coefficients of variation for the recoveries showed they were slightly 
better at the level of 8 nglml than 4 nglml. 
The most consistent recovery results (CV 6.1 % at 4 ng/ml and 5.5% at 8 nglml) were from 
plasma using EDTA as anticoagulant; hence, all further samples analysed by CI-ELISA were 
collected in EDTA tubes. Blood collected with EDTA was also used by Shephard et al. (1992B) 
in their HPLC experiments. 
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6.5.2 Plasma and Urine Samples analysed for Fumonisins (Competitive Indirect ELISA) 
The patients in this study eat maize as a staple food. Studies of white and yellow maize in South 
Africa found the levels offumonisins to range from 0 to12 963 Ilg FB]/kg, 0 to 5 690 j.lg FB2/kg 
and 0 to 3 110 Ilg FB3/kg (Rava et at., 1996; Rava, 1996). Thus, South Africans consuming 
maize daily are exposed to fumonisins and it might be expected to find them in their blood and 
urine. In this study, detectable levels offumonisins (> 0.4 ng/ml) were found in both blood and 
urine of 86.9% and 94.9% of the samples, respectively. 
This CI-ELISA method is not specific for FBI as there was cross-reactivity with FB2 (97.7%) 
and FB3 (33.1 %) and possibly with hydrolysed fumonisins (Chapter 5, Table 5.20). Yet 
F. moniliforme produces predominantly FBI (Gelderblom et at., 1988) so any person consuming 
contaminated maize or food will be ingesting mainly FBI and hence the major fumonisin 
expected to be found in physiological fluids (e.g. blood and urine) would be FBI. 
Excreted fumonisins in humans may be unmetabolised or partially or fully hydrolysed. 
Haemolysis did not appear to affect results as similar values were found for unhaemolysed 
samples i.e. fumonisin was not sequestered inside the red blood cells. 
The two watery urines had no detectable fumonisins (possibly a dilution effect) but for accurate 
quantitative analysis a 24 hr urine collection would be necessary. (This study used random urine 
samples). 
Fumonisin levels in plasma samples from patients diagnosed with OC ranged from 0 to 19.115 
ng/ml, average 4.385 ng/ml (Table 6.5). In contrast, in the control patients, the highest level of 
fumonisin was 9.226 ng/ml, average 2.973 ng/ml (Table 6.4). Since both patients and controls 
consume a maize-based diet, it was not unexpected to find fumonisins in the plasma (and urine) 
of controls. There was a highly significant difference in fumonisin concentrations between 
patients with OC and controls; even excluding the one high OC result, the difference was still 
highly significant indicating a possible relationship between raised levels of fumonisins in the 
blood and OC (Table 6.7). 
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In the group with other types of cancer, the highest plasma value (14.186 ng/ml) was from a 
patient with pancreatic cancer (Table 6.6). There was no significant difference between the 
plasma results of this group and the controls but again there was a highly significant difference 
between patients with other types of cancer and those with OC (Table 6.7). This may show that 
fumonisins are associated specifically with OC and not other forms of cancer. 
Total fumonisins in plasma ranged from 0.00 to 32.29 ~g in control patients and from 0.46 to 
49.65 Ilg in patients with other types of cancer. For patients with OC the range was from 0.00 to 
33.22 ~g but one sample had 66.90 ~g (Tables 6.4, 6.5 and 6.6). These results only reflect 
circulating fumonisins in the blood; total body levels may well be higher if fumonisin is 
sequestered in the tissues. 
Levels offumonisins in urine were higher than in plasma, ranging from 0 to 46.624 ng/ml in OC 
patients (Table 6.5); from 6.192 to 43.232 ng/ml in controls (Table 6.4) and from 6.655 to 
37.320 ng/ml in patients with other types of cancer (Table 6.6). The higher levels offumonisins 
in urine are to be expected since ingested fumonisins are rapidly excreted. There was no 
significant difference in urine results between patients with OC and controls suggesting that 
higher levels in the blood of OC patients are not due to poorer excretion. Yet there was a 
difference between OC patients and those with other types of cancer (Table 6.7) which 
reinforces the suggestion that fumonisins are associated only with OC. 
6.5.3 High Performance Liquid Chromatography 
Recoveries ofFB t in serum and urine samples by HPLC averaged 69.6% and 48.1 % 
respectively. Shephard et al. (1992B) obtained recoveries of 86% and 87% for FBI in plasma 
and 91% and 94% in urine. However, their samples contained much higher levels offumonisins, 
viz. 1.4 ~g/ml and 6.2 ~g/ml in spiked plasma samples; and 1.0 ~g/ml and 12 J.Lg/ml in spiked 
urine samples i.e. about 1 000 times more FB t than in the present study where samples were 
spiked with 16 ng/ml FBI. Shephard's HPLC method gave detection limits of about 50 ng/ml 
with a signal to noise ratio 4: 1; this study gave lower detection limits for HPLC viz. 10 ng/ml at 
a signal to noise ratio of 3: 1. 
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Better recoveries and more clearly defined peaks were found in plasma samples (Figure 6.2) 
compared to urine samples (Figures 6.3 and 6.4). In some of the urine samples there was an 
interfering peak which co-eluted with FBI or otherwise the FBI peak appeared as a shoulder on 
a larger peak (Figures 6.3 and 6.4). It was also noted that many of the urine samples showed 
another peak at a retention time of 5 min - eluting after FBI (which had average retention times 
of 3.879,4.363 and 4.379 min for analyses done on three different days). The significance of 
this peak is not known. Maragos (1995) in analysing horse serum spiked with 100 ng/ml FBI 
also found interference by a component in the unspiked serum which had a similar migration 
time to FBI . 
There was also a problem in obtaining reliable results at such low levels of FB I - better peaks 
were obtained for standards at levels> 50 ng/ml but this would be below the level of naturally 
occurring FBI concentrations. To improve sensitivity and remove interfering solutes in human 
urine samples, Shetty & Bhat (1998) used an Amberlite XAD-2 non-ionic polymeric resin 
column prior to the SAX column and obtained recoveries of 93.6% to 94.4% (CV < 5%) with a 
detection limit of < 8 ng/ml. However, they were working with 100 ml of sample spiked at 10 to 
500 ng/ml FBI - in contrast to 1ml spiked at 16 ng/ml in this study. Also, for routine analysis, 
use of an additional column would add to the cost. 
6.5.4 Comparison of Results by High Performance Liquid Chromatography and 
Competitive Indirect ELISA on the Same Samples 
There was no significant difference in plasma results by the two methods but urine results were 
significantly different. Statistically this comparison would have been improved by analysis of 
more samples. The correlation coefficient for plasma results was 0.656 (p<0.005). 
Overall, plasma results were lower than urine results by CI-ELISA, whereas HPLC analysis 
gave lower urine than plasma results. Of the nine plasma samples, five gave higher results by 
HPLC than by ELISA and four gave lower results; all eight urine samples gave lower results by 
HPLC. The large interfering peak and inability to get a decent base-line contributed to the 
lower urine results. 
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The ELISA method was more sensitive with detection limits of 0.4 ng/ml for both plasma and 
urine samples in contrast with the HPLC method which had detection limits of 1ng/ml for urine 
and 2 ng/m1 for plasma samples. 
Recoveries for the ELISA method (99.11 % and 97.58% for plasma, 97.73% and 94.55% for 
urine samples) were much better than for HPLC (69.62% for plasma and 48.13% for urine). 
Furthermore, the recovery experiments in CI-ELISA were done at lower spiked concentrations 
of FBI (4 and 8 ng/ml) than for HPLC (16 ng/ml). 
No other workers have compared results between immunoassay and liquid chromatography for 
plasma or urine samples. However, in analysis of maize samples, ELISA methods usually 
showed higher values than HPLC but generally good correlation, r = 0.967, p<O.OOI (Sydenham 
et a!., 1996B); r = 0.955, p<O.OOI (Yu & Chu, 1996) and r = 0.512, p<0.05 (Pestka et at., 1994). 
But these comparisons were at higher concentrations of FBI than those in physiological fluids 
viz. 0.05 to 5.44 Ilg/g (50 to 5 440 ng/g), <10 to 49800 ng/g and 0.17 to 6.32 llg/g (170 to 6 320 
ng/g) respectively, as measured by HPLC. 
In contrast, using an in-house immunoaffinity column prior to analysis of maize samples by 
both immunoassay and HPLC, Maragos (1997) found good agreement between immunoassay 
and HPLC results at low levels of fumonisins « 2 llg/g) but at higher levels the HPLC results 
were lower. For beer samples, Scott et al. (1997) also found ELISA results were lower than 
HPLC results. 
Several possible explanations for differences between HPLC and ELISA results have been 
proposed including differences in extraction procedures and lower recoveries from samples 
prepared for HPLC; interference (inhibition) by components in the sample (matrix differences, 
possibly lipid based); completely different methodology principles; and precursors or 
metabolites produced by F moniliforme that cross-react with the antibodies or interfere in the 
immunoassay (Pestka et at., 1994; Shelby et al., 1994; Tejada-Simon et a!., 1995; Abouzied et 
aI., 1996; Sydenham et al., 1996B). Usleber et al. (1994) suggested that differences in the ratio 
of the open chain and cyclic forms of the TCA side chains may affect results as this ratio is pH 
dependent and different extraction procedures give different pH values of the extracts. The TCA 
groups are believed to be important for antibody binding (Azcona-Olivera et al., 1992A, 
1992B). 
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That the higher results for urine samples analysed by CI-ELISA compared to plasma samples 
are due to the measurement of other associated metabolites similar in structure to FB I seems 
likely since even taking differences in extraction recoveries into account, the concentrations of 
fumonisins in urine are lower by HPLC (measuring only FBI) than by ELISA. Shephard et ai. 
(1994A, 1994C) found that other primates excreted fully and partially hydrolysed fumonisins in 
unne. 
The plasma samples probably contained lower concentrations of metabolites explaining the 
paradox that some samples gave higher results by HPLC and others lower results compared to 
HPLC. The cross-reactivity experiments (Chapter 5, section 5.4.6) reinforces the probability that 
the ELISA method is detecting other unmetabolised fumonisins and probably metabolic 
products. 
6.5.5 Calcium and Magnesium 
Since FB I is believed to have chelating characteristics (Beier et aI., 1995; Beier & Stanker, 
1997) and is predominantly negatively charged at pH 7, it was decided to investigate calcium 
and magnesium levels in the blood samples of the three groups of patients used for this study. 
The reference range for calcium in serum is 2.1 to 2.6 mmolll and for magnesium is 0.65 to 
1.05 mmol/l (Farrell, 1984). Only two calcium results, both on patients with OC, were below the 
reference range; however, 37 results were above the reference range (20 from the OC group, 6 
from the control group and 11 from the group with other types of cancer - 4 with breast cancer, 
3 cervical, 1 each for prostate, rectal, stomach and thyroid cancer). None of the magnesium 
results were below the reference range but six OC, one control and three patients with other 
types of cancer (2 with breast and 1 with cervical cancer) had results above the reference range 
(Table 6.12). 
Highly significant differences for both calcium and magnesium results were found between OC 
patients cancer and controls with higher values for the OC patients. There were also highly 
significant differences between OC patients and those with other types of cancer but no 
significant differences between this latter group and control patients (section 6.4.4). 
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This raises the possibility that increased concentrations of divalent cations are involved in the 
mechanism of increased fumonisin levels in OC patients. 
A possible hypothesis is that these divalent cations aid in the attachment of fumonisin to cell 
membranes by forming a link between negatively charged carboxyl groups on the fumonisin 
molecule and negatively charged proteins on the cell surface. Alternatively, the fumonisin may 
be chelating the cations, changing shape and so being retained in the blood longer. 
6.6 CONCLUSIONS 
A simple but effective method for extracting fumonisins from plasma and urine samples was 
developed. Fumonisins are thermostable and boiling to remove interfering proteins was found to 
be quick, cheap and easy. The method gave good and reproducible recoveries in serum, EDT A 
and heparinised plasma and urine in the CI-ELISA method. 
The good agreement between plasma results for the CI-ELISA and HPLC methods confirmed 
the validity of the CI-ELISA method. The lack of correlation between the two methods for urine 
results was satisfactorily explained by the probable presence offumonisin metabolites in the 
urine which are measured by CI-ELISA but not by HPLC. The extraction methods for plasma 
and urine samples for HPLC need to be optimised to improve the recoveries and to remove 
interfering substances, particularly in urine samples. 
In analysis of fumonisins in plasma and urine, samples from three groups of patients viz. those 
with ~C, controls (no cancer) and those with other types of cancer, a significant difference was 
found between the OC group and the other two. This implies an association between fumonisin 
levels in the blood and OC but it must be remembered that other factors may also be causative 
agents in the development of OC e.g. nitrosamines, tobacco, air pollutants (Burrell, 1957; Rose, 
1982; van Rensburg, 1985). The significant differences in calcium and magnesium levels 
between the OC group and the other two indicated that these divalent cations could playa role 




Polyclonal antibodies against fumonisins were successfully raised in chickens and rabbits 
using a FBI-KLH conjugate as immunogen. This study was the first record ofpAb against 
fumonisin being produced in chickens. Using PEG 6 000, IgY was extracted from the egg 
yolks and IgG was extracted from rabbit serum. (Chapter 3, sections 3.3.3 and 3.3.4). 
Adaptation and optimisation of an existing method for estimating titre was done 
successfully. This study was the first record of coating microtitre plates directly with FBI i.e. 
it was not necessary to first prepare a FB I- protein conjugate (Chapter 3, sections 3.3.7 and 
3.4.3). Antibody titre was measured on all batches ofIgY and IgG extracts from all four 
animals (Chapter 3, section 3.3.8). Both chickens produced antibodies every week from 
week 2 to week 14 when collection of eggs ceased. Antibodies were found for every bleed of 
the rabbits viz. weeks 4,8, 12 and 14. The highest titres for each animal (in order from 
highest to lowest) were from week 8 for chicken 2, then chicken 1 at week 8, rabbit 1 at 
week 14 and rabbit 2 also at week 8 (Chapter 3, Figure 3.13). 
Both the chicken and the rabbit antibodies showed cross-reactivity mainly with FB2 but also 
with FB3; there was no cross-reactivity with So (Chapter 5, sections 5.3.5 and 5.4.6). 
Attempts to develop a CD-ELISA were not successful. Possibly the conjugation of FBI to 
HRPO using sodium periodate was not successful (Chapter 4, section 4.3.1) or the HRPO 
did bind to the FBI but caused steric hindrance so that the labelled FBI could not bind to 
Ab l . 
A CI-ELISA method was successfully developed and optimised using chicken antibodies. It 
was relatively inexpensive, rapid and easy to perform but could do with further refinements 
to reduce incubation times (Chapter 5, sections 5.3.2 and 5.4.2). The method also worked 
with the rabbit antibodies. 
The method has good reproducibility (low intra-plate and inter-plate CV) and good 
sensitivity (range from 0 to 20 ng/ml). Internal quality control was done by running low 
and high method controls and non-specific binding blanks on every plate and checking they 
remained within acceptable limits (Chapter 5, sections 5.3.4 and 5.4.5). 
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A comprehensive check on various methods of quantitative calculation was done. The one 
finally selected was plotting absorbance (at 405 nm) against FBI concentration and using a 
2nd order polynomial curve fitting equation (Chapter 5, sections 5.3.3 and 5.4.3). 
Confirmation of the correctness of the results by this method of calculation was supplied by 
using the programme on the plate reader at NBTS (Chapter 5, Table 5.11) and a dedicated 
programme on a different model of plate reader to the one normally used (Chapter 5, Table 
5.12). 
For adaptation of the CI - ELISA to analyse blood and urine samples there was no 
information in the literature as how to proceed, as no other group had used an imm.unoassay 
method for physiological fluids or tissues. 
Initial experiments indicated that the main interferent was protein as slightly better results 
were obtained with urine (lower protein content) compared with plasma/serum. After 
attempting several methods, heating by boiling to denature the proteins (which were then 
removed by centrifugation) proved to be a quick, cheap and easy method (Chapter 6, 
sections 6.3.1.1 and 6.4.1). Good recoveries were obtained with serum, EDTA plasma, 
heparinised plasma and urine (Chapter 6, Table 6.3). As a further part of the quality control, 
a positive and a negative plasma/urine control were included in every further run; these 
underwent the extraction process (Chapter 6, section 6.4.2.1). 
The PROMEC group found a definite association between fumonisins and OC but no one 
had as yet shown the presence of fumonisins in the physiological fluids of patients with OC; 
possibly because the only readily available method to date has been HPLC which is less 
sensitive than ELISA (Chapter 6, section 6.1). 
For the first time, this study found measurable levels offumonisins in OC patients (Chapter 
6, Tables 6.4 and 6.7). There was a significant difference in fumonisin levels in the blood 
and urine of patients with OC compared to controls and to patients with other types of 
cancer. Even though fumonisins were also found in the control group, this was not surprising 
since they too consume a maize-based diet. The fumonisins seemed to be associated 
specifically with OC and not with other types of cancer but larger numbers of samples need 
to be analysed to confirm these preliminary findings (Chapter 6, sections 6.3.1.2, 6.4.2.3 and 
6.4.2.4). 
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To check the validity of the CI-ELISA results, samples with high levels of fumonisins were 
analysed by HPLC. The extraction step for HPLC was more time consuming and more 
expensive than the boiling method; also the sensitivity and recoveries were not as good as 
for the CI-ELISA (Chapter 6, sections 6.3.2.1,6.4.2.2,6.4.3.1 and 6.4.3.2). 
Adaptation of the actual HPLC analysis to cope with interferents gave improved sensitivity 
over previously published methods (Chapter 6, section 6.3 .2.2 and 6.4.3.3). There was good 
correlation between results for plasma but not for urine samples (Chapter 6, Table 6.11 and 
section 6.4.3.4). This was explained by the fact that the ELISA method was probably 
measuring fumonisins plus metabolites which are more likely to be found in urine than in 
blood; also better peaks were obtained for plasma samples. 
It was found that OC patients had significantly more calcium and magnesium in their 'serum 
compared to the control group and to patients with other types of cancer (Chapter 6, Table 
6.12 and section 6.4.4.1). It was hypothesised that these cations might aid in the attachment 
ofFB\ to cell walls or may cause a delay in its excretion. 
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APPENDIXl 
TABLE 2.5 ANALYSIS OF FUMONISINS BY ALTERNATIVE METHODS 
Method Sample Recovery Detection Limits Reference 
Fluorometry Corn 83% 0.25 Ilg/g Duncan et al., 
Range 0 - 10 llg/g 1998 
HPLC-ESI-MS- Corn grit and corn no data 0.8 ng/g Lukacs et al., 
MS meal 1996 
LC-ESI-MS Rodent feed 68.9% (FBI) 1.1 ppb (ng/g) Churchwell et 
60.4% (FB2) al.,1997 
74.3% (FB3 ) 
TLC Corn & corn-based >80% 0.1 ppm (Ilg/g) Rottinghaus et 
feedstuffs al. 1992 
HPTLC Rice 81% 0.25 Ilg/g Dawlatana et 
Range 0 - 5 llg/g al. 1995 
SFEIHPLC Corn dust no data 150 ppb Selim et al., 
1996 
CZE Spiked horse serum 76% 100 ng/ml Maragos 1995 
Key to Table 2.5 







liquid chromatography electron spray-ionisation mass spectrometry 
thin layer chromatography 
high performance thin layer chromatography 
supercritical fluid extraction/high performance liquid chromatography 
capillary zone electrophoresis 
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TABLE 2.13 EFFECTS OF FUMONISIN B1 IN CELL CULTURE 
Type of cells: 
FB1 Concentration 
Rat hepatocytes: 
1 I.lM (1 hr) 
Primary rat hepatocytes: 
10 mM (2 hr) 
1 IlM (4 d) 
Pig kidney epithelial 
cells LLC-PK1: 
10,35 11M (4 d) 




neurons: 25 11M (1 d) 
Swiss 3T3 fibroblasts: 
10 - 50 nM (1 d) 
Chicken peritoneal 
macrophages: 
6 - 18 Ilg/ml 
Primary rat hepatocytes: 







25 50 100,2001lM 
Primary rat hepatocytes: 
100, 150 JlM 
African green monkey 
kidney cells CV -1 : 
1,2 5 IlM (3 hr) 
Pig kidney epithelial 
cells LLC-PKl: 
70 J.l.M (3 d) 
Swiss 3T3 fibroblasts: 
10, 20, 50 flM 
Key to Table 2.13 
[ ] 
Sa 
Effect of fumonisin Reference 
Inhibition of incorporation of 14C-serine into So Wang et al., 
Increased ffree Sal 1991 
Inhibition of incorporation of 14C-serine into So Norred et al., 
(IC so 0.1 flM) 1992 
Increased ffree Sal 
Inhibition of incorporation of 14C-serine into So Norred et al., 
(ICso 35 )lM) 1992 
Decreased cell proliferation and cell death 
Increased ffree Sal 
Inhibition of proliferation (measured as increase in Y 00 et al., 1992 
protein content) and cell death 
Decrease in incorporation of 3H-serine into So 
Increased rfree Sal (lCso 20 J.l.M) 
Inhibition ofsr,hingolipid formation from 14C-serine, Merrill et al., 
3H-galactose, H-sphinganine (ICso 0.7 JlM) 1993B 
Increased [free Sa] 
Stimulated DNA synthesis Schroeder et al., 
Increased [free Sal 1994 
Dose-dependent nuclear disintegration Chatterjee et al. , 
1995 
Inhibition of epidermal growth factor induced DNA Gelderblom et 
synthesis measured as incorporation of 3H-thymidine al., 1995 
Increased rfree Sal at fFB1l 1 ~lM 
Inhibition of incorporation of 3H-serine into Merrill et al., 
sphingomyelin and ceramide 1995A 
Inhibition of cell growth Wu et al., 1995 
Inhibition of ceramide synthase 
Decrease in synthesis of various lipids 
Increased ffree Sa] and [phytosphingosinel 
Inhibition of incorporation of 14C-palmitic acid into Gelderblom et 
lipids al., 1996B 
Increased [free Sa]; Decreased [cholesterol] 
Increased r polyunsaturated f~tty acids 1 
Induction of apoptosis Wang etal., 
Cell cycle arrest at G1 phase 1996 
Increased [free Sa] Yoo et al., 
Decreased [complex sphingolipids] 1996A 
Inhibition of cell growth; cell death 
Decreased synthesis of sphingomyelin and Meivar-Levy et 
ganglioside GM3 al.,1997 
Inhibited cell proliferation and DNA synthesis 
So sphingosine indicates concentration 
sphinganine ICso concentration causing 50% inhibition 
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TABLE 3.9 DATA TO CHECK DILUTION OF SECOND ENZYME-LABELLED 
ANTffiODY (SIGMA) TO USE FOR ANTffiODY TITRE OF RABBIT 
IMMUNOGLOBULIN G USING BATCH RlI14 
Ab1 (Jlg/ml) Log [IgG} 1:1000 1:2000 1:5000 1:10000 
1000 3.0 0.613 0.719 0.472 0.313 
500 2.7 0.412 0.512 0.325 0.283 
100 2.0 0.170 0.237 0.149 0.176 
25 1.4 0.000 0.008 0.007 0.011 
Key to Table 3.9 
Results are means of duplicate (except for the 25 Jlg/ml) absorbance values at 405 nm after subtraction of 
the mean of the relevant pre-immune absorbance value (RlIP) and the absorbance value for the no Ab l 
blank. 
TABLE 3.10 DATA FOR SUMMARY OF RESULTS OF EXPERIMENTS TO DETERMINE 
OPTIMUM BLOCKING AGENT, DILUENT AND DILUTION OF SECOND 
ENZYME-LABELLED ANTIBODY FOR TITRE OF CmCKEN 
IMMUNOGLOBULIN Y USING BATCH C2/8 
Ab1 Log B/Ab2C B/Ab2S/5 B/Ab2S/20 C/Ab2C/O.5 C/Ab2S/20 BC/Ab2C BC/Ab2S/20 C/Ab2C/l 
(Ilg/ml) IrIgYl 
1000 3 1.465 1.257 1.031 0.884 0.387 1.613 1.414 
100 2 1.072 0.287 0.297 0.313 0.081 1.336 0.579 
10 1 0.211 0.000 0.000 0.000 0.000 0.473 0.032 
K~ll. to [able 3.11 
.c&® Diluent Blocking Agent Ah2E 
B/Ab2C 0.5% BSA 0.5% BSA Dr. Coetzer 1:350 
BI Ab2S/5 0.5%BSA 0.5% BSA Sigma 1:500 
BI Ab2S/20 0.5% BSA 0.5% BSA Sigma 1: 2 000 
C/ Ab2CIO.5 0.5% casein 0.5% casein Dr. Coetzer 1: 3 50 
CI Ab2S120 1% casein 1% casein Sigma 1: 2 000 
BCI Ab2C 0.5%BSA 1% casein Dr. Coetzer 1: 350 
BCI Ab2S/20 0.5%BSA 1% casein Sigma 1: 2 000 
CI Ab2CIl 1% casein 1% casein Dr. Coetzer 1: 350 
Results are means of duplicate absorbance values at 405 nm after subtraction of the mean of the relevant 
pre-immune absorbance value (CliP) and the absorbance value for the no Ab l blank. 
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TABLE 3.14 DATA TO CHECK ANTffiODY TITRE FOR CmCKEN 1 
Batch 1000 500 Jlg/ml 250 Jlg/ml 100 Jlg/ml 25 Jlg/ml NoAb! NoAb l 
number l12:/ml 
Log fI2:Yl 3.0 2.7 2.4 2.0 1.4 
EVEN WEEKS 0.078 0.085 
ClIP 0.497 0.341 0.240 0.147 0.099 
CliO 0.000 0.000 0.000 0.000 0.000 
C1/2 0.187 0.081 0.022 0.000 0.000 
C1I4 1.003 0.939 0.774 0.590 0.253 
C1/6 0.700 0.553 0.440 0.254 0.003 
C1I8 1.081 0.947 0.709 0.464 0.110 
ClII0 0.746 0.664 0.493 0.269 0.045 
ClI12 0.801 0.673 0.561 0.354 0.039 
ClI14 0.841 0.603 0.550 0.355 0.019 
ODD WEEKS 0.089 0.088 
ClIP 0.394 0.243 0.177 0.134 0.129 
Clll 0.000 0.000 0.000 0.000 0.000 
ClI3 0.580 0.526 0.422 0.322 0.077 
C1I5 0.630 0.566 0.451 0.279 0.060 
CII7 0.789 0.635 0.472 0.269 0.031 
C1I9 0.881 0.825 0.617 0.344 0.072 
ClIIl 0.603 0.599 0.488 0.282 0.007 
ClI13 0.709 0.625 0.541 0.245 0.044 
Kev to Table 3.14 
Except for CliP, no Ab t and no Ab2, results are the means of duplicate absorbance readings at 
405 nm after subtracting the mean of the relevant pre-immune absorbance value (C21P) and the mean of 
the absorbance value for non-specific binding (no Ab l ). Duplicates differed by <5%. 
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TABLE 3.15 DATA TO CHECK ANTIBODY TITRE FOR CHICKEN 2 
Batch 1000 500 J.1g/ml 250 J.1g/ml 100 J.1g/ml 25 J.1g/ml NoAb l NoAb2 
number J.lg/ml 
Log rIgYl 3.0 2.7 2.4 2.0 1.4 
EVEN WEEKS 0.083 0.089 
C2/P OJ11 0.232 0.154 0.119 0.092 
C2/0 0.092 0.067 0.000 0.000 0.000 
C2/2 0.255 0.114 0.078 0.000 0.000 
C2/4 1.569 1.053 0.643 0.342 0.083 
C2/6 1.484 1.070 0.689 OJ04 0.041 
C2/8 1.698 1.330 1.034 0.648 0.168 
C2110 1.129 0.876 0.616 0.330 0.030 
C2112 1.487 1.284 0.961 0.616 0.080 
C2/14 1.471 1.180 0.723 0.340 0.023 
ODD WEEKS 0.079 0.072 
C21P 0.323 0.233 0.172 0.122 0.093 
C2/1 0.037 0.000 0.000 0.000 0.000 
C2/3 1.017 0.581 0.359 0.108 0.000 
C2/5 1.096 0.732 0.459 0.179 0.000 
C217 1.305 1.104 0.932 0.616 0.239 
C2/9 1.006 0.956 0.755 0.466 0.129 
C2111 0.855 0.836 0.642 OJ68 0.058 
C2/13 1.011 0.852 0.668 0.481 0.108 
Kev to Table 3.15 
Except for C2/P, no Abt and no Ab2, results are the means of duplicate absorbance readings at 405 nm 
after subtracting the mean of the relevant pre-immune absorbance value (C21P) and the mean of the 
absorbance value for non-specific binding (no Abt). Duplicates differed by <5%. 
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TABLE 3.16 DATA TO CHECK ANTIBODY TITRE FOR RABBITS 1 AND 2 
Batch 1000 500 flg/ml 250 flg/ml 100 flg/ml 25 flg/ml NoAb! NoAb 1 
number ut!/ml 
Lot! fI2:Yl 3.0 2.7 2.4 2.0 1.4 
RABBIT 1 0.095 0.088 
R1fP 0.417 0.295 0.221 0.159 0.118 
R1I4 0.227 0.118 0.071 0.000 0.000 
RU8 0.177 0.102 0.039 0.000 0.000 
R1/12 0.784 0.697 0.549 0.291 0.042 
RlI14 0.785 0.739 0.535 0.277 0.041 
RABBIT 2 0.116 0.095 
R2/P 0.516 0.394 0.296 0.211 0.147 
R2/4 0.349 0.249 0.192 0.1 17 0.000 
R2/8 0.772 0.635 0.443 0.l58 0.000 
R2/12 0.569 0.387 0.237 0.090 0.000 
R2/14 0.413 0.297 0.227 0.042 0.000 
Kev to Table 3.16 
Except for RlIP and R2/P, no Ab J and no Ab2, results are the means of duplicate absorbance readings at 
405 nm after subtracting the mean of the relevant pre-immune absorbance value (C21P) and the mean of 
the absorbance value for non-specific binding (no Ab J). Duplicates differed by <5%. 
TABLE 4.1 DATA FOR PROTEIN STANDARD CURVE 
Protein Concentration Absorbance Absorbance Mean 
(J12fml) 
50 0.061 0.068 0.065 
100 0.122 0.117 0.120 
200 0.241 0.238 0.240 
400 0.442 0.445 0.444 
600 0.619 0.626 0.623 
800 0.762 0.777 0.770 
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FIGURE 5.1 STANDARD CURVES AT DIFFERENT COATING CONCENTRATIONS OF 
FUMONISIN Bl 
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TABLE 5.4 DATA TO SELECT OPTIMUM CONCENTRATION OF PRIMARY ANTIBODY 
(CHICKEN ANTmODIES) 
Ab~ 100 llg!ml 
FBI Absorbance at 405 nm Mean SD CV -No Ab l %BlBo Log[FBd 
(n~/ml) n~/ml 
0 0.475 0.474 0.475 0.001 0.15 0.377 100.00 
1 0.377 0.382 0.380 0.004 0.93 0.282 74.77 0.0 
2 0.324 0.319 0.322 0.004 1.10 0.224 59.36 0.3 
5 0.244 0.247 0.246 0.002 0.86 0.148 39.18 0.7 
8 0.219 0.227 0.223 0.006 2.54 0.125 33.20 0.9 
10 0.211 0.216 0.214 0.004 1.66 0.116 30.68 1.0 
20 0.198 0.203 0.201 0.004 1.76 0.103 27.22 1.3 
50 0.198 0.199 0.199 0.001 0.36 0.101 26 .69 1.7 
Ab1 200 1l1!/mi 
0 0.642 0.651 0.647 0.006 0.98 0.549 100.00 
1 0.551 0.571 0.561 0.014 2.52 0.463 84.41 0.0 
2 0.519 0.525 0.522 0.004 0.81 0.424 77.30 0.3 
5 0.391 0.389 0.390 0.001 0.36 0.292 53.24 0.7 
8 0.333 0.337 0.335 0.003 0.84 0.237 43 .21 0.9 
10 0.306 0.317 0.312 0.008 2.50 0.214 38.92 1.0 
20 0.281 0.286 0.284 0.004 1.25 0.186 33 .82 1.3 
50 0.255 0.265 0.260 0.007 2.72 0.162 29.54 1.7 
Ab1 300 1l1!/mi 
0 0.761 0.766 0.764 0.004 0.46 0.666 100.00 
1 0.710 0.679 0.695 0.022 3.16 0.597 89.63 0.0 
2 0.670 0.672 0.671 0.001 0.21 0.573 86.10 0.3 
5 0.530 0.527 0.529 0.002 0.40 0.431 64.69 0.7 
8 0.452 0.446 0.449 0.004 0.94 0.351 52.74 0.9 
10 0.403 0.400 0.402 0.002 0.53 0.304 45 .60 1.0 
20 0.336 0.338 0.337 0.001 0.42 0.239 35.91 iJ 
50 0.315 0.319 0.317 0.003 0.89 0.219 32.91 1.7 
Ab l 400 111!/ml 
0 0.832 0.811 0.822 0.015 1.81 0.724 100.00 
1 0.784 0.781 0.783 0.002 0.27 0.685 94.61 0.0 
2 0.756 0.766 0.761 0.007 0.93 0.663 91.64 0.3 
5 0.660 0.657 0.659 0.002 OJ2 0.561 77.47 0.7 
8 0.579 0.575 0.577 0.003 0.49 0.479 66.21 0.9 
10 0.518 0.516 0.517 0.001 0.27 0.419 57.91 1.0 
20 0.422 0.428 0.425 0.004 1.00 0.327 45 .20 1.3 
50 OJ74 0.377 0.376 0.002 0.56 0.278 38.36 1.7 
Ab1 500 ll~/ml 
0 0.948 0.979 0.964 0.022 2.28 0.866 100.00 
1 0.879 0.92 0.900 0.029 3.22 0.802 92.61 0.0 
2 0.854 0.887 0.871 0.023 2.68 0.773 89.25 OJ 
5 0.756 0.776 0.766 0.014 1.85 0.668 77.18 0.7 
8 0.679 0.676 0.678 0.002 0.31 0.580 66.96 0.9 
10 0.627 0.614 0.621 0.009 1.48 0.523 60.37 1.0 
20 0.490 0.491 0.491 0.001 0.14 0.393 45.35 1.3 
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FIGURE 5. 3 OPTIMUM CONCENTR\TION OF PRIMARY ANTIBODY (RABBIT 
ANTIBODIES) 
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TABLE 5.5 DATA TO SELECT OPTIMUM CONCENTRATION OF PRIMARY ANTIBODY 
(RABBIT ANTmODIES) 
Ab, 100 Jig/ml 
FBI Absorbance at 405 nm Mean SD CV -No Ab l %BlBo Log [FBd 
(ng/ml) ng/ml 
0 0.429 0.497 0.463 0.048 10.39 0.273 100.00 
1 0.348 0.355 0.352 0.005 1.41 0.162 59.16 0.0 
2 0.322 0.319 0.321 0.002 0.66 0.131 47.80 0.3 
5 0.261 0.265 0.263 0.003 1.08 0.073 26.74 0.7 
8 0.253 nd 0.253 0.000 0.00 0.063 23.08 0.9 
10 0.248 0.232 0.240 0.011 4.71 0.050 18.32 1.0 
20 0.218 0.232 0.225 0.010 4.40 0.035 12.82 1.3 
SO 0.285 nd 0.285 0.000 0.00 0.095 34.80 1.7 
Ab1 200 Jig/mI 
0 0.563 0.608 0.586 0.032 5.43 0.396 100.00 
1 0.457 0.534 0.496 0.054 10.99 0.306 77.24 0.0 
2 0.447 0.450 0.449 0.002 0.47 0.259 65.36 0.3 
5 0.361 0.360 0.361 0.001 0.20 0.171 43.11 0.7 
8 0.339 0.331 0.335 0.006 1.69 0.145 36.66 0.9 
10 0.323 0.324 0.324 0.001 0.22 0.134 33.75 1.0 
20 0.312 0.314 0.3 13 0.001 0.45 0.123 31.10 1.3 
SO 0.418 0.415 0.417 0.002 0.51 0.227 57 .27 1.7 
Ab 1 300 Jig/ml 
0 0.705 0.699 0.702 0.004 0.60 0.512 100.00 
1 0.585 0.583 0.584 0.001 0.24 0.394 76.95 0.0 
2 0.543 0.518 0.531 0.018 3.33 0.341 66.50 0.3 
5 0.453 0.465 0.459 0.008 1.85 0.269 52.54 0.7 
8 0.403 0.402 0.403 0.001 0.18 0.213 41.50 0.9 
10 0.391 0.375 0.383 0.011 2.95 0.193 37.70 1.0 
20 0.365 0.355 0.360 0.007 1.96 0.170 33.20 1.3 
50 0.467 0.443 0.455 0.017 3.73 0.265 51.76 1.7 
Ab. 400 "e/ml 
0 0.778 0.789 0.784 0.008 0.99 0.594 100.00 
1 0.666 0.685 0.676 0.013 1.99 0.486 81.80 0.0 
2 0.591 0.625 0.608 0.024 3.95 0.418 70.43 0.3 
5 0.515 0.534 0.525 0.013 2.56 0.335 56.36 0.7 
8 0.486 0.487 0.487 0.001 0.15 0.297 49.96 0.9 
10 0.451 0.458 0.455 0.005 1.09 0.265 44.57 1.0 
20 0.429 0.425 0.427 0.003 0.66 0.237 39.93 1.3 
50 0.507 0.495 0.501 0.008 1.69 0.311 52.40 1.7 
Ab l 500 Jig/ml 
0 0.809 0.824 0.817 0.011 1.30 0.627 100.00 
1 0.717 0.719 0.718 0.001 0.20 0.528 84.28 0.0 
2 0.656 0.664 0.660 0.006 0.86 0.470 75.02 0.3 
5 0.581 0.601 0.591 0.014 2.39 0.401 64.01 0.7 
8 0.545 0.539 0.542 0.004 0.78 0.352 56.19 0.9 
10 0.513 0.482 0.498 0.022 4.41 0.308 49.08 1.0 
20 nd 0.450 0.450 0.000 0.00 0.260 41.50 1.3 
50 0.507 0.471 0.489 0.025 5.21 0.299 47.73 1.7 
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TABLE 5.6 DATA TO COMPARE INCUBATION TIMES FOR COMPETITION STEP IN 
COMPETITIVE INDIRECT ELISA METHOD 
HRl Mean SD CV -No Ab1 %BlBo Log[FBtJ 
wml 
FBI (ne/mn 
0 0.526 0.493 0.510 0.023 4.58 0.422 100.00 
1 0.462 0.446 0.454 0.011 2.49 OJ66 89.11 0.0 
2 0.446 0.428 0.437 0.0l3 2.91 OJ49 85.77 OJ 
5 0.397 0.393 0.395 0.003 0.72 0.307 77.53 0.7 
10 0.288 0.327 0.308 0.028 8.97 0.220 60J5 1.0 
20 0.251 0.263 0.257 0.008 3JO 0.169 50.44 1.3 
HR2 
FBI (ne/mn 
0 0.626 0.587 0.607 0.028 4.55 4.449 100.00 
1 0.497 0.452 0.475 0.032 6.71 6.608 78.24 0.0 
2 0.458 0.406 0.432 0.037 8.51 8.413 71.23 OJ 
5 0.374 0.361 0.368 0.009 2.50 2.403 60.59 0.7 
10 0.326 0.306 0.316 0.014 4.48 4.377 52.10 1.0 
20 0.254 0.261 0.258 0.005 1.92 1.824 42.46 1.3 
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TABLE 5.7 DATA TO SELECT OPTIMUM DILUTION OF SECOND ENZYME-
LABELLED ANTIBODY (CHICKEN ANTIBODIES) 
Dilution of Ab E I 1:2000 
FBI (ng/ml) Absorbance at 405 nm Mean SD CV -No Ab l %BlBo 
0 1.871 1.828 1.827 1.842 0.025 1.36 1.734 100.00 
1 1.743 1.811 nd 1.777 0.048 2.71 1.669 96.25 
2 1.700 1.589 nd 1.645 0.078 4.77 1.537 82.44 
3 1.549 1.527 1.405 1.494 0.078 5.19 1.386 79.91 
5 1.322 1.231 1.226 1.260 0.054 4.29 1.152 66.42 
8 0.928 0.869 0.897 0.898 0.030 3.29 0.790 45.56 
10 0.867 0.77 0.844 0.827 0.051 6.13 0.719 41.46 
20 0.625 0.61 0.645 0.627 0.018 2.80 0.519 29.91 
Dilution of Ab E I 1:3000 
0 1.711 1.603 1.555 1.623 0.080 4.92 1.525 100.00 
1 1.581 1.489 1.462 1.511 0.062 4.13 1.413 92.63 
2 1.428 1.401 1.417 1.415 0.014 0.96 1.317 86.38 
3 1.382 1.348 1.293 1.341 0.045 3.35 1.243 81.51 
5 1.185 1.169 1.169 1.174 0.009 0.79 1.076 70.58 
8 0.843 0.821 0.915 0.860 0.049 5.72 0.762 49.97 
10 0.845 0.840 nd 0.843 0.004 0.42 0.745 48.85 
20 0.601 0.608 0.581 0.597 0.014 2.35 0.499 32.70 
Dilution of Ab E I 1:4000 
0 1.650 1.565 1.614 1.610 0.043 2.65 1.515 100.00 
1 1.518 1.491 1.525 1.511 0.018 1.19 1.416 93.51 
2 1.455 1.375 1.420 1.417 0.040 2.83 1.322 87.26 
3 1.307 1.346 1.312 1.322 0.021 1.61 1.227 80.99 
5 1.219 1.116 1.145 1.160 0.053 4.58 1.065 70.31 
8 0.846 0.865 nd 0.856 0.013 1.57 0.761 50.21 
10 nd 0.771 0.785 0.778 0.010 1.27 0.683 45.09 
20 0.608 0.587 nd 0.598 0.015 2.49 0.503 33.18 
Dilution of Ab E I 1:5000 
0 1.263 1.059 1.114 1.145 0.106 9.22 1.057 100.00 
1 1.191 1.159 1.089 1.146 0.052 4.55 1.058 100.09 
2 1.114 1.079 nd 1.097 0.025 2.26 1.009 95.38 
3 1.059 1.010 0.999 1.023 0.032 3.12 0.935 88.40 
5 0.841 0.848 0.791 0.827 0.031 3.76 0.739 69.86 
8 0.651 0.592 0.599 0.614 0.032 5.25 0.526 49.75 
10 0.565 0.542 0.570 0.559 0.015 2.67 0.471 44.55 
20 0.414 0.44 0.431 0.428 0.013 3.08 0.340 32.19 
































TABLE 5.8 DATA TO SELECT VOLUME AND DILUTION OF SECOND ENZYME-
LABELLED ANTIDODY (CHICKEN ANTIDODIES) 
Dilution and volume of Ab2
E I 100 JlI 1:2 000 
FBI (ng/ml) Absorbance at 405 nm Mean SD CV -No Abl %BlBo Log[FBll 
n~/ml 
0 nd 1.041 1.031 1.036 0.007 0.68 0.850 100.00 
1 1.018 0.861 0.883 0.921 0.085 9.23 0.735 86.47 0.0 
2 nd 0.831 0.876 0.854 0.032 3.73 0.668 78.53 0.3 
5 0.763 0.698 0.722 0.728 0.033 4.52 0.542 63.73 0.7 
10 nd 0.485 0.533 0.509 0.034 6.67 0.323 38.00 1.0 
20 nd 0.450 0.453 0.452 0.002 0.47 0.266 31.24 1.3 
Dilution and volume of Ab2 E I 120 ad, 1:2 000 
0 1.074 0.973 1.072 1.040 0.058 5.55 0.839 100.00 
1 0.899 0.893 0.917 0.903 0.012 1.38 0.702 83.70 0.0 
2 0.820 nd 0.799 0.810 0.015 1.83 0.609 72.56 0.3 
5 0.739 0.729 0.658 0.709 0.044 6.23 0.508 60.53 0.7 
10 0.544 0.576 0.557 0.559 0.016 2.88 0.358 42.69 1.0 
20 0.514 0.471 0.526 0.504 0.029 5.74 0.303 36.09 1.3 
Dilution and volume of AblE 1 100 JlI 1:4000 
0 0.838 0.816 0.804 0.819 0.017 2.10 0.708 100.00 
1 0.725 0.732 0.751 0.736 0.0l3 1.83 0.625 88.24 0.0 
2 0.715 0.675 0.741 0.710 0.033 4.68 0.599 84.61 0.3 
5 0.597 0.576 0.565 0.579 0.016 2.81 0.468 66.12 0.7 
10 0.453 0.433 0.432 0.439 0.012 2.70 0.328 46.35 1.0 
20 0.366 0.349 0.354 0.356 0.009 2.45 0.245 34.64 1.3 
Dilution and volume of Ab2
E I 120 ad, 1:4 000 
0 0.790 0.767 0.816 0.791 0.025 3.10 0.682 100.00 
1 0.736 0.705 0.740 0.727 0.019 2.64 0.618 90.62 0.0 
2 0.670 0.673 0.674 0.672 0.002 0.31 0.563 82.60 0.3 
5 0.571 0.523 0.568 0.554 0.027 4.85 0.445 65.25 0.7 
10 0.406 nd 0.412 0.409 0.004 1.04 0.300 43 .99 1.0 
20 0.364 0.347 0.365 0.359 0.010 2.82 0.250 36.61 1.3 
nd-no data 
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TABLE 5.9 DATA TO SELECT OPTIMUM DILUTION OF SECOND ENZYME-
LABELLED ANTIBODY (RABBIT ANTIBODIES) 
Dilution of Ab E I 1:2000 
FBI (ng/ml) Absorbance at 405 nm Mean SD CV -No AbI %BlBo 
0 1.322 1.399 1.344 1.355 0.040 2.93 1.193 100.00 
1 1.133 1.185 1.294 1.204 0.082 6.82 1.042 87.34 
2 nd 1.175 1.114 1.145 0.043 3.77 0.983 82.36 
3 0.942 0.971 1.006 0.973 0.032 3.29 0.811 67.98 
5 0.930 0.924 0.859 0.904 0.039 4.35 0.742 62.22 
8 0.853 0.753 0.830 0.812 0.052 6.45 0.650 54.48 
10 0.683 0.617 0.700 0.667 0.044 6.58 0.505 42.30 
20 0.629 0.548 0.560 0.579 0.044 7.55 0.417 34.95 
Dilution of Ab E I 1:3000 
0 1.229 1.293 1.271 1.264 0.033 2.57 1.155 100.00 
1 1.064 1.104 1.044 1.071 0.031 2.85 0.962 83.24 
2 0.965 0.990 0.954 0.970 0.018 1.90 0.861 74.50 
3 nd 0.847 0.808 0.828 0.028 3.33 0.719 62.19 
5 nd 0.765 0.729 0.747 0.025 3.41 0.638 55 .22 
8 0.635 0.654 0.610 0.633 0.022 3.49 0.524 45.35 
10 0.535 0.548 0.557 0.547 0.011 2.02 0.438 37.88 
20 0.549 0.556 0.520 0.542 0.019 3.52 0.433 37.45 
Dilution of Ab E I 1:4000 
0 1.223 1.146 1.195 1.188 0.039 3.28 1.052 100.00 
1 1.011 0.976 0.988 0.992 0.018 1.79 0.856 81.34 
2 0.919 0.859 0.875 0.884 0.031 3 .51 0.748 71.13 
3 0.780 nd 0.815 0.798 0.025 3.10 0.662 62 .88 
5 0.690 0.650 0.692 0.677 0.024 3.50 0.541 51.46 
8 0.580 0.541 0.557 0.559 0.020 3.50 0.423 40.24 
10 0.533 0.512 0.563 0.536 0.026 4.78 0.400 38.02 
20 0.471 0.428 0.453 0.451 0.022 4.79 0.315 29.91 
Dilution of Ab E I 1:5000 
0 0.966 nd 0.988 0.977 0.016 1.59 0.860 100.00 
1 0.823 0.806 0.809 0.813 0.009 1.12 0.696 80.89 
2 0.767 0.728 0.754 0.750 0.020 2.65 0.633 73.57 
3 0.721 0.701 0.705 0.709 0.011 1.49 0.592 68 .84 
5 0.590 0.619 0.602 0.604 0.015 2.41 0.487 56.59 
8 0.537 0.537 0.538 0.537 0.001 0.11 0.420 48 .88 
10 0.450 0.451 0.441 0.447 0.006 1.23 0.330 38.41 
20 0.408 0.394 0.381 0.394 0.014 3.42 0.277 32.25 
































TABLE 5.14 DATA FOR STANDARD CURVE (CHICKEN ANTIBODIES) 
Absorbance at 405 nm Mean SD CV -NoAb! 
NoAb! 0.129 0.128 0.129 0.129 0.001 0.78 
FBI (ng/ml) 
0 1.473 1.518 1.649 1.547 0.091 5.91 1.418 
1 1.498 1.444 1.445 1.462 0.031 2.11 1.333 
2 1.380 1.354 1.323 1.352 0.029 2.11 1.223 
3 1.269 1.272 1.263 1.268 0.005 0.36 1.139 
5 1.132 1.166 1.118 1.139 0.025 2.17 1.010 
8 0.933 0.868 0.934 0.912 0.038 4.15 0.783 
10 0.730 0.764 0.780 0.758 0.026 3.37 0.629 
20 0.616 0.610 0.609 0.612 0.004 0.62 0.483 
TABLE 5.15 DATA FOR STANDARD CURVE (RABBIT ANTIBODIES) 
Absorbance at 405 nm Mean SD CV -No Ab1 
NoAb~ 0.107 0.110 0.099 0.105 0.006 5.40 
FBI (ng/ml) 
0 1.223 1.146 1.195 1.188 0.039 3.28 1.083 
1 1.011 0.976 0.988 0.992 0.018 1.79 0.887 
2 0.919 0.859 0.875 0.884 0.031 3.51 0.779 
3 0.780 nd 0.815 0.798 0.025 3.10 0.693 
5 0.690 0.650 0.692 0.677 0.024 3.50 0.572 
8 0.580 0.541 0.557 0.559 0.020 3.50 0.454 
10 0.533 0.512 0.563 0.536 0.026 4.78 0.431 
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FIGURE 5.9 STANDARD CURVE FOR FUMONISIN B1 (RABBIT ANTmODIES) 
TABLE 5.16 DATA FOR RANGE OF STANDARD CURVE 
Absorbance at 405 nm Mean SD CV -NoAbt 
NoAb1 0.110 0.105 nd 0.108 0.004 3.29 
FB1 (n2lml) 
0 nd 1.373 1.437 1.405 0.045 3.22 1.297 
1 1.294 1.236 1.267 1.266 0.029 2.29 1.158 
2 1.146 1.150 1.144 1.147 0.003 0.27 1.039 
3 1.074 1.118 1.041 1.078 0.039 3.58 0.970 
5 0.951 0.987 0.995 0.978 0.023 2.40 0.870 
8 0.783 0.795 0.792 0.790 0.006 0.79 0.682 
10 0.594 0.584 0.579 0.586 0.008 1.30 0.478 
20 0.460 0.456 0.461 0.459 0.003 0.58 0.351 
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TABLE 5.18 DATA FOR COMPETITIVE INDIRECT ELISA STANDARD CURVES 
FOR CROSS-REACTIVITY (CmCKEN ANTmODIES) 
%BlBo 
Concentration Log of FBI FB2 FB3 So 
(n!!/ml) Concentration 
2 0.30 79.11 93.76 88.03 98.41 
3 0.48 75 .68 78.80 83.35 102.70 
5 0.70 67.20 71.81 77 .61 98.37 
8 0.90 57.00 58.80 72.82 94.31 
10 1.00 46 .84 47.10 63.22 92.82 
20 1.30 39.84 38.72 53.14 92.75 
40 1.60 nd 37.55 46.17 95 .22 
nd - no data 
TABLE 5.19 DATA FOR COMPETITIVE INDIRECT ELISA STANDARD CURVES 
FOR CROSS-REACTIVITY (RABBIT ANTmODIES) 
%BlBo 
Concentration Log of FBI FB2 FB3 So 
(n!!/ml) Concentration 
2 0.30 85.02 88.46 89.60 99.80 
3 0.48 81.21 79.17 86.58 99.95 
5 0.70 72.46 74.21 79.62 97.96 
8 0.90 61.43 65 .09 76.87 98.97 
10 1.00 55.61 58.88 70.42 100.88 
20 1.30 42.08 44.65 56.74 92.08 
40 1.60 nd 37.65 48.37 91.30 
nd -no data 
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TABLE 6.13 CALCIUM AND MAGNESIUM RESULTS ON PATIENTS WITH 
OESOPHAGEAL CANCER 
Patient Ca Mg Appearance Type Patient Ca Mg Appearance 
No. (mmol/I) (mmolll) No. (mmol/l) (mmolll) 
106 2.40 0.76 P 170 2.85 1.00 +H 
108 2.43 0.82 P 171 2.85 1.18 
110 2.02 0.76 S 172 2.61 1.02 
124 2.81 1.09 +1 S 173 2.47 1.00 +H 
135 1.55 1.08 ++++H S 175 3.l3 0.96 
139 2.73 1.10 +++H P 179 2.42 0.79 +H 
140 2.68 1.07 +H P 180 2.68 0.94 
146 2.66 0.95 S 184 2.85 0.94 
148 2.34 0.94 +H S 190 2.77 0.96 +H 
149 2.75 0.95 P 195 2.72 0.91 
152 2.47 0.95 S 202 2.74 1.05 
155 2.55 1.03 P 215 2.31 1.12 +++H 
157 2.65 0.91 ±H S 216 2.49 0.88 ++H 
159 2.79 0.96 S 217 3.22 1.03 
164 2.41 0.87 P 219 2 .81 0.94 ±H 
165 2.59 0.84 P 220 2.34 0.88 
166 2.57 0.88 P 225 2.42 0.93 +H 
168 2.62 1.03 P 237 2.64 1.00 
169 2.33 0.84 ±H S 
Key to Table 6.13 
1 - icteric; H - haemolysed; S - serum; P - heparin plasma 
TABLE 6.14 CALCIUM AND MAGNESIUM RESULTS ON CONTROL PATIENTS 
Patient Ca Mg Appearance Type Patient Ca Mg Appearance 
No. (mmol/I) (mmol/l) No. (mmol/l) (mmol/l) 
156 2.53 0.88 S 197 2.41 0.99 + H 
158 2.34 0.85 +H S 203 2 .61 1.04 +H 
160 2.56 0.92 ±H S 205 2.59 0.98 +H 
177 2.48 0.89 S 206 2.19 1.23 +++H 
178 2.11 0.80 S 210 2.73 0.94 +H 
182 2.57 0.92 ±H S 224 2.80 0.91 
183 2.55 0.97 S 226 2.72 0.95 
191 2.62 0.98 ±H S 227 2 .61 0.97 +H 
192 2.52 0.94 +H S 
Key to Table 6.14 






























TABLE 6.15 CALCIUM AND MAGNESIUM RESULTS ON PATIENTS WITH OTHER 
TYPES OF CANCER 
Patient Ca Mg Appearance Type Patient Ca Mg Appearance 
No. (mmol/I) (mmolll) No. (mmolll) (mmolll) 
Breast Cervix 
136 2.49 1.06 +H S 151 2.38 0.91 ±H 
150 2.96 0.99 S 162 2.77 0.92 
154 2.78 1.08 ++H S 193 2.68 0.95 +H 
181 2.50 0.92 S 236 2.71 1.08 
204 2.63 0.93 S 
207 2.38 0.85 +H S 
208 2.16 0.81 +H S 
211 2.64 0.93 P 
Pancreas Prostate 
153 2.33 1.05 +++ I P 134 2.83 0.97 +H 
Rectum Stomach 
209 2.44 0.97 +I S 137 2.56 0.91 +H 
223 2.65 1.00 P 189 2.63 0.96 
Thyroid 
221 2.65 0.96 S 
Key to Table 6.15 












2.1 O.lM Sodium carbonate buffer. pH 8.5 
1.06 g anhydrous sodium carbonate (Na2C03) was dissolved in 100 ml distilled water and 
0.84 g anhydrous sodium hydrogen carbonate (NaHC03) was dissolved in 100 ml distilled 
water. The buffer was freshly prepared by mixing 10 ml Na2C03 and 85 ml NaHC03. The pH 
was adjusted using O.lM HCI and the volume was made up to 100 ml. 
2.2 Phosphate buffered saline (PBS), pH 7.2 (lOx) 
80 g NaCl, 2 g KCI, 11.5 g disodium hydrogen phosphate (Na2HP04) and 2 g potassium 
dihydrogen phosphate (KH2P04) were dissolved in 1 000 ml distilled water and stored at 4°C 
for maximum of three weeks. Daily a 1:10 dilution was made and adjusted to the correct pH 
using O.lM HCI or O.IM NaOH. 
2.3 O.1M (lOOmM) Sodium phosphate buffer, pH 7.6, with 0.02% sodium azide 
15.6 g sodium dihydrogen phosphate (Na2HP04.2H20) and 0.2 g sodium azide (NaN3) was 
dissolved in ± 850 ml distilled water, the pH adjusted using 2M NaOH and made up to 1 000 
ml and stored at 4°C. 
2.4 Borate buffered saline, pH 8.6 
0.54 g boric acid, 0.548 g NaCI, 0.175 g NaOH and 0.155 m137% HCI were dissolved in 200 
ml distilled water, the pH adjusted using O. 1M HCI or O. 1M NaOH, the volume made up to 
250 ml and stored at 4°C. 
2.5 O. 1M Carbonate buffer, pH 9.6 
1.06 g sodium bicarbonate (Na2C03) was dissolved in 100 ml disti1led water and 0.84 g 
sodium hydrogen carbonate (NaHC03) was dissolved in 100 ml distilled water. The buffer 
was freshly prepared by adding NaHC03 to 29.3 ml Na2C03 until the volume was 
approximately 95 ml, adjusted to the correct pH using O.IM HCI and made lip to 100 m!. 
2.6 O.l5M Citrate-phosphate buffer, pH 5.0 
2.1 g citric acid. H20 was dissolved in 100 ml distilled water; 3.56 g disodium hydrogen 
phosphate (Na2HP04.2H20) was dissolved in 100 ml distilled water. The citric acid was 
titrated with the sodium phosphate to pH 5.0 and stored at 4°C for a maximum of2 weeks . 
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2.7 Stopping buffer: 0.1 % sodium azide in citrate-phosphate buffer 
0.1 g NaN3 dissolved in 100 ml citrate phosphate buffer and stored at 4°C. 
Sodium azide is a toxic chemical and must be handles with care. 
2.8 1 mM Sodium acetate buffer, pH 4.4 
1 ml glacial acetic acid was added to about 900 ml distilled water and adjusted to the correct 
pH using O.lM NaOH (0.4 g in 100 ml distilled water). The solution was made up to 1 litre 
and stored at room temperature. 
2.9 200mM Sodium carbonate buffer, pH 9.5 
1.68 g sodium hydrogen carbonate (NaHC03) was dissolved in 100 ml distilled water and 
18.6 ml was pipetted into a beaker. 2.12 g Sodium carbonate (Na2C03) was dissolved in 100 
ml distilled water and was gradually added to the first solution until the pH was 9.5. 
2.10 O.lM Carbonate/bicarbonate buffer, pH 9.6 
0.795 g sodium carbonate (Na2C03) was dissolved in 500 ml distilled water; 1.465 g sodium 
bicarbonate (NaHC03) was dissolved in 500 ml distilled water. The two solutions were 
combined and the pH checked and adjusted if necessary. The buffer was stored at 4°C. 
2.11 O.lM Sodium phoshate buffer. pH 3.35 
1.56g sodium dihydrogen phosphate (NaH2P04.2H20) was dissolved in 100 ml deionised 
water, the pH was adjusted to 3.35 with o-phosphoric acid (about 2 drops) and the buffer was 
filtered under vacuum (Millipore system) through a 0.45j.tm, 47 mm nylon filter (Lida, Chrom 
Tech Inc.). 
2.12 O.1M Borate buffer, pH 10.5 
3.8 g sodium borate (Na2B407.1 OH20) was dissolved in 80 ml deionised water, the pH 
adjusted using 1 M KOH and made up to 100 m\. 
2.13 o-Phthaldialdehyde (OPA) 
21.2 mg OPA were dissolved in 600 j.tl methanol to which was added 20 j.tl mercaptoethanol 
and 15 ml O.lM borate buffer (pH 10.5) . The reagent was stored for a maximum of a week in 
the dark at 4°C. Immediately before use the OPA was filtered through a 22 j.tm filter (Lida, 
Chrom Tech Inc.). 
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